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ABSTRACT 
Several studies have identified Rho family GTPases (i. . Rho, Rac, Cdc42) as 
mediators of diverse critical cellular processes, such as actin cytoskeleton remodeling, 
gene transcription, cell-cell adhesion, and cell cycle progression.  However, more recent 
data highlight an essential role for Rho GTPases as regulators of neuronal morphology 
and neuronal survival. In particular, Rac GTPase generally induces neurite outgrowth and 
promotes neuronal survival while Rho GTPase typically provokes neurite retraction and 
induces neuronal apoptosis.  However, the precise signaling pathways that regulate 
neuronal survival downstream of Rho GTPases and the pot ntial involvement of 
dysregulated activity of Rho GTPases as a causative factor in the progression of 
neurodegenerative diseases remains to be elucidated.  
Consistent with a pro-survival function for Rac in neurons, inhibition of Rac with 
Clostridium difficle toxin B (ToxB) or expression of a dominant negative Rac1 mutant 
significantly induces activation of the “death executioner” caspase-3 and subsequent 
apoptosis in primary cerebellar granule neuron (CGN) cultures.  We have previously 
shown that Rac inhibition evokes apoptosis via inact v tion of a pro-survival mitogen 
activated protein kinase kinase (MEK)1/2/ extracellular signal regulated-kinase (ERK)1/2 
cascade which functions in healthy CGNs to promote the degradation of the pro-apoptotic 
Bcl-2 homology-3 domain (BH3)-only protein Bim while also repressing a pro-apoptotic 
Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) signaling 
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cascade.  Here, we reveal that ToxB induces the JAK-dependent phosphorylation 
(activation) of STAT5, which is sufficient to induce apoptosis through transcriptional 
repression of pro-survival Bcl-xL. Collectively, these data implicate Rac GTPase as a 
critical mediator of CGN survival.  
Given that ToxB inhibits Rho, Rac, and Cdc42, we aimed to elucidate the effects 
of more targeted Rac inhibition in CGNs.  NSC23766 specifically inhibits Rac GTPase 
activation by the Rac-specific GEFs Tiam1 and Trio. Targeted inhibition of Rac GTPase 
via NSC23766 treatment in CGNs evoked apoptosis via repression of unique 
MEK5/ERK5, p90Rsk, and Akt-dependent pro-survival pathways.  Furthermore, 
selective inactivation of Rac induced the activation and translocation of the pro-apoptotic 
BH3-only protein Bad to the mitochondria, where it has been demonstrated to induce 
apoptosis. Intriguingly, adenoviral expression of a constitutively active MEK5 protected 
CGNs from apoptosis induced by NSC23766, but not ToxB. These data demonstrate that 
selective inhibition of Rac GTPase with NSC23766 versus global inhibition of Rho 
GTPases with ToxB induces cell death via repression of distinct MAP kinase signaling 
pathways.  
We also report that treatment with either ToxB or Clostridium sordelli lethal 
toxin, which also inhibits Rac GTPase, induces caspase-dependent downregulation of the 
pro-survival transcriptional corepressor, C-terminal binding proteins (CtBPs), in CGNs.  
Interestingly, we demonstrate that downregulation of CtBPs undergoing apoptosis does 
not appear to occur via enhanced degradation or reduced transcription. Instead, our data 
suggest that caspases indirectly regulate the expression of CtBPs in CGNs undergoing 
apoptosis in a manner that occurs post-transcriptionally and is dependent on intact 
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miRNA machinery. Finally, inhibition of CtBPs with 4-methylthio-2-oxobutyric acid 
(MTOB) provoked CGN apoptosis that was associated with induction of the CtBP target 
Noxa.  These data indicate a novel function for CtBPs in regulating survival of primary 
CGNs.  
Finally, we examined the involvement of Rho GTPases in regulating the survival 
of motor neurons derived from embryonic stem cells (ESCs) as selective degeneration of 
motor neurons in the spinal cord and motor cortex underlies the pathology of 
amyotrophic lateral sclerosis (ALS). Consistent with our previous findings in CGNs, 
inhibition of Rac GTPase via NSC23766 treatment result d in apoptotic cell death of 
ESC-derived motor neurons that was coincident with deactivation of pro-survival ERK5 
and Akt signaling pathways. Surprisingly, we report that the BH3-only protein Bad 
localized exclusively to the nucleus in ESC-derived motor neurons treated with the Rac 
inhibitor.  In agreement with an antagonistic relationship exerted between Rac GTPase 
and Rho GTPase as a determinant of neuronal survival, we also report that constitutive 
activation of Rho GTPase via CN03 treatment induced Rho kinase (ROCK)-dependent 
apoptosis of ESC-derived motor neurons. Next, we inv stigated Rac and Rho GTPase 
activitity and localization in motor neurons in vivo. In the G93A mutant Cu, Zn 
superoxide dismutase (mSOD1) transgenic mouse model of ALS, we demonstrate that 
active Rac1-GTP is reduced within spinal cord motor neurons when compared to age-
matched wild type (WT) littermates. Furthermore, we report that total RhoB is expressed 
in the soma and nucleus of WT motor neurons; however, RhoB shows a marked 
redistribution to neuronal processes in end-stage mice harboring the G93A SOD1 
mutation. These data underscore the importance of Rh  family GTPases in maintaining 
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motor neuronal survival and suggest that diminished Rac GTPase activity or enhanced 
Rho GTPase activity may each contribute to selectiv loss of motor neurons during the 
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CHAPTER ONE: INTRODUCTION 
 Rho family GTPases (i.e. RhoA, Rac1, Cdc42) are best known for their role in 
regulating actin cytoskeleton dynamics.  In neurons, Rho GTPases have an important and 
conserved function in guiding dendritic arborization, growth cone development, and axon 
guidance.  In addition, more recent efforts have underscored an important function for 
Rho GTPases in regulating neuronal survival and death. In the regulation of both 
neuronal cytoskeletal dynamics and neuronal survival, Rho GTPase and Rac GTPase 
typically exhibit antagonistic functions. For example, Rho GTPase generally stimulates 
axonal retraction and neuronal death while Rac GTPase typically promotes axonal 
growth and neuronal survival. In addition to in vitro and in vivo animal models of 
neurodegenerative disease, recent studies in humans i plicate that dysregulation of Rho 
family GTPases may potentially underscore the etiology of some forms of 
neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Nonetheless, the 
precise signaling pathways that are disrupted in neurons exposed to dysregulated Rho 
family GTPase activity remain incompletely understood.  Thus, given the potential role 
of Rho GTPases in regulating neuronal development and survival, a major focus of this 
thesis is to elucidate the pro-survival and pro-apoptotic signals transmitted by members 




1.1 Apoptosis as a mechanism of neuronal death 
 Although neuronal cell death can occur through many diverse mechanisms, 
accumulating evidence suggests that neuronal apoptosis appears to be a major 
contributing factor common to several devastating neurodegenerative diseases and acute 
neuronal injury. Apoptosis is a conserved process of pr grammed cell death that is 
crucial to the proper development of organisms. While inadequate apoptosis within an 
organism can lead to cancer, excessive apoptosis can underlie the progression of 
neurodegenerative diseases. In healthy cells, members of the B cell lymphoma (Bcl)-2 
family of proteins tightly regulate the two principal pathways that transmit apoptotic 
signals in neuronal cells, the intrinsic (mitochondrial) pathway and the extrinsic (death 
receptor) pathway (Fig. 1.2).  
1.1.1 Overview of the Bcl-2 family members as regulators of apoptosis 
Abundant evidence demonstrates that signals of cell survival and cell death are 
critically regulated by the Bcl-2 family of proteins (Fig. 1.1). This family is classified 
into three functionally and structurally distinct categories. The first subfamily includes 
the pro-survival family members, most notable Bcl-2, Bcl-xL, and Mcl-1. These proteins 
are critical constituents of the cell, functioning to negatively regulate pro-apoptotic 
proteins. The second subfamily includes multi-domain pro-apoptotic Bax and Bak which, 
when activated, act at the mitochondria to induce permeabilization of the outer 
mitochondrial membrane and release of apoptogenic molecules (e.g. cytochrome C). The 
final subgroup of the Bcl-2 family comprises the Bcl-2 homology-3 domain (BH3)-only 
pro-apoptotic proteins. This family includes Bid, Bim, Bad, and Puma, amongst several 
others.  Numerous reports have demonstrated that the balance between pro-survival and 
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pro-apoptotic Bcl-2 family members represents a vitl checkpoint in whether or not a cell 
commits to apoptosis (Danial and Korsmeyer, 2004; Youle and Strasser, 2008).  
1.1.2 Extrinsic apoptotic pathway 
 The extrinsic apoptotic pathway is aptly named as it requires an extracellular 
signal to induce apoptosis (Fig. 1.2). This cascade is activated when a death ligand (e.g. 
Fas ligand) binds to a transmembrane death receptor (e.g. Fas) and leads to receptor 
oligomerization and recruitment of the Fas-associated death domain (FADD) adaptor 
protein. The death domain of the adaptor protein recruits pro-caspase-8 and forms the 
death inducing signaling complex (DISC). DISC formation triggers proteolysis of pro-
caspase-8 to its active form, caspase-8, which thencl aves and activates two critical 
executioners of apoptosis, pro-caspase-3 and pro-caspase-7. An alternate function of 
caspase-8 is cleavage of the BH3-only protein Bid to an active form termed truncated Bid 
(tBid). Truncated Bid translocates to the mitochondria and initiates the intrinsic apoptotic 
pathway by inducing the oligomerization of Bax and Bak, discussed below. Thus, tBid is 
an important link between the extrinsic and intrinsic apoptotic cascades (Li et al., 1998; 
Yin, 2006).  
1.1.3 Intrinsic apoptotic cascade 
 Central to the intrinsic apoptotic pathway is the mitochondria whose outer 
membrane’s permeabilization is a critical determinant in executing the death program 
(Fig. 1.2). The permeability of the mitochondria is tightly regulated by the balance of 
pro-survival and pro-apoptotic Bcl-2 family members. Under normal conditions, pro-
survival proteins such as Bcl-2 and Bcl-xL function t  neutralize the inherent pro-death 
activity of multi-domain pro-apoptotic family members. Intrinsic apoptosis is provoked 
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by apoptotic signals that originate within the cell, such as DNA damage or oxidative 
stress. Following apoptotic stimulation, BH3-only proteins respond by either inactivating 
pro-survival Bcl-2 members or by directly activating Bax and Bak to form homo- or 
hetero-oligomeric pores in the outer mitochondrial membrane (Kuwana et al., 2005; Kim 
et al., 2006).  This allows subsequent release of ap ptogenic factors such as cytochrome 
C (cytC) and Smac/Diablo. CytC binds monomeric apoptotic protease-activating factor-1 
(APAF-1), inducing a conformational change that permits heptamerization and 
recruitment of pro-caspase-9 into a large complex known as the apoptosome (Zou et al., 
1999). Once activated, pro-caspase-9 activates the death executioners caspase-3 and 
caspase-7 (Hakem et al., 1998).  
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1.1.4 Evidence supporting a role for apoptosis as a contributing factor to the etiology of 
human neurodegenerative disorders 
 Although neuronal cell death can occur through many diverse mechanisms, 
accumulating evidence suggests that neuronal apoptosis appears to be a major 
contributing factor common to several devastating neurodegenerative diseases. For 
example, Alzheimer’s disease (AD) is the most common f rm of dementia and is 
characterized by extensive loss of neurons in the hippocampus. Although the involvement 
of apoptosis in the progression of AD remains controve sial, increased DNA 
fragmentation consistent with apoptotic cell death has been reported in AD brain tissue 
samples when compared to aged control brains (Su et al., 1994; Troncoso et al., 1996). In 
further agreement with apoptotic cell death, Masliah et al. (1998) reported that AD 
patient brain samples demonstrated increased immunoreactivity of the death executioner 
of apoptosis, caspase-3.  
 In addition to AD, Huntington’s disease (HD) is a fatal autosomal dominant 
disorder characterized by loss of cells in the striatum and cortex, resulting in involuntary 
body movements (chorea). Early studies identified that DNA fragmentation consistent 
with apoptotic cell death may occur in HD striatal sections as Tdt-mediated dUTP–biotin 
nick end labeling (TUNEL) staining was increased when compared to neurologically 
normal postmortem brain tissue (Dragunow et al., 1995; Thomas et al., 1995; Butterworth 
et al., 1998). In addition, mitochondrial dysfunction has been reported in HD brains and 
studies examining lymphoblasts from HD patients revealed increased stress-induced 
apoptosis and enhanced activation of caspase-3 (Sawa et al., 1999). Furthermore, both 
8 
 
activation of caspase-1 and caspase-8 was observed in HD patient brain samples when 
compared to neurologically unaffected controls (Ona et l., 1999; Sánchez et al., 1999).  
 As a final example, amyotrophic lateral sclerosis (ALS) is a progressive and fatal 
neurodegenerative disorder characterized by loss of motor neurons from the motor cortex, 
brain stem, and upper and lower spinal cord, resulting in loss of motor function and 
eventually death due to respiratory failure. Increased DNA fragmentation consistent with 
apoptotic cell death has been reported in the motor cortex, brain stem, cervical cord, 
thoracic cord, and lumbar cord of ALS patients when compared to neurologically normal 
control samples (Ekegren et al., 1999; Martin, 1999).  Furthermore, an analysis of mRNA 
expression in spinal motor neurons from postmortem ALS tissue revealed decreased 
expression of pro-survival Bcl-2 mRNA and enhanced expression of pro-apoptotic Bax 
mRNA (Mu et al., 1996). In agreement with disruption f the balance of Bcl-2 family 
members as a causative factor underlying mitochondrial- ependent neuronal apoptosis, 
Bcl-2 protein expression is diminished and Bax and Bak expression is enhanced in 
mitochondrial fractions from ALS patients when compared to age-matched controls 
(Ekegren et al., 1999; Martin, 1999).  Collectively, these studies highlight the potential 
involvement of apoptotic cell death as a common factor underlying the etiology of 
several diverse neurodegenerative diseases.  
1.2 Introduction to C-terminal Binding Proteins (CtBPs) 
CtBPs were initially identified as binding partners for the E1A transforming 
proteins (Schaeper et al., 1995). Although the invertebrate genome encodes one CtBP 
protein, two CtBPs (CtBP1 and CtBP2) are encoded by the vertebrate genome and 
perform both unique and duplicative functions (Chinnadurai, 2002). CtBP1 and CtBP2 
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are closely related and act as transcriptional corepressors when activated by nicotinamide 
adenine dinucleotide (NADH) binding to their dehydrogenase domains (Kumar et al., 
2002).  Binding of NADH induces a conformational change within CtBPs that promotes 
association with DNA-binding transcriptional repressors, such as the E-box repressor 
ZEB (Postigo and Dean, 1999). Experimental evidence suggests that the majority of 
DNA-binding transcriptional repressors appear to recruit CtBPs through a PxDLS 
sequence (Chinnadurai, 2002). More recent studies have demonstrated that CtBPs exert 
transcriptional repression primarily via recruitment of a corepressor complex to DNA that 
consists of histone deactylases and histone methyltransferases (Shi et al., 2003). 
Nonetheless, CtBPs can also repress transcription through an HDAC-independent 
mechanism (Meloni et al., 1999; Koipally et al., 2000).  
More recent studies have demonstrated a critical function for CtBPs in the 
transcriptional repression of pro-apoptotic genes. For instance, murine embryonic 
fibroblasts (MEFs) deficient in CtBP1 and CtBP2 demonstrated enhanced sensitivity to 
apoptosis and showed increased expression of the pro-apoptotic proteins Bax, Puma, and 
Noxa (Grooteclaes et al., 2003; Bergman and Blaydes, 2006). Furthermore, human 
colorectal cancer HCT116 cells deficient in CtBP2 demonstrated increased expression of 
the BH3-only pro-apoptotic protein Bik (Kovi et al., 2010). In addition to a critical role 
for CtBPs in transcriptional co-repression of pro-apoptotic genes, a recent study by 
Paliwal et al. (2012) demonstrated that CtBP2 can also bind to the promoter region and 
enhance the transcriptional activation of Tiam1 to pr mote a pro-oncogenic function of 
CtBP2 in cancer cell migration. Nonetheless, while recent efforts have characterized the 
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involvement of CtBPs in promoting cellular survival in non-neuronal cell types, the 
involvement of CtBPs in regulation of neuronal survival remains to be elucidated.   
1.3 Introduction to Rho Family GTPases 
 The Rho family of GTPases belongs to the Ras superfamily of GTPases of low 
molecular weight (~21 kDa) guanine nucleotide binding proteins. Although the Rho 
GTPase family is further divided into seven subfamilies (Rho, Rac, Cdc42, Rnd, RhoD, 
RhoBTB, and RhoH), the most extensively studied members are RhoA, Rac1, and 
Cdc42. In the last few decades, studies have demonstrated that Rho family GTPases are 
important regulatory molecules that link surface receptors to the organization of the actin 
cytoskeleton. However, the involvement of Rho GTPases in maintaining other essential 
cellular functions has also been described, such as gene transcription (Hill et al., 1995), 
cell cycle progression (Olson et al., 1995), and regulation of cellular survival and death 
(Heasman and Ridley, 2008; Linseman and Loucks, 2008).  
Rho family GTPases are molecular switches that are activated by a variety of cell-
surface receptors, including tyrosine kinase and adhesion receptors, cytokine receptors, 
and G-protein coupled receptors (Kjoller and Hall, 1999; Sah et al., 2000). While the N-
terminal domain of Rho GTPases is highly conserved, the C-terminal domain contains 
more variation and may confer diverse functions for members of the Rho GTPase family 
(Didsbury et al., 1990).  Rho GTPases contain both nucleotide-and Mg2+-binding 
pockets. While nucleotide (GDP or GTP)-binding pockets within Rho GTPases regulate 
the conformation of the switch regions, Mg2+ is important for high-affinity binding of 
guanine nucleotides (Rossman et al., 2005). In addition, Rho family GTPases also contain 
a ~200 residue Dbl homology (DH) domain and an adjacent, C-terminal, Pleckstrin 
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homology (PH) domain. The DH domains of Rho GTPases facilitate the exchange of 
GDP for GTP while the PH domains bind phosphoinositides to localize Rho GTPases to 
plasma membranes (Rossman et al., 2005).  
Similar to Ras family GTPases, activation of Rho GTPases is regulated by cycling 
between an inactive GDP-bound state and an active GTP-bound state (Fig. 1.3). The 
binding of GTP elicits a conformational change within Rho GTPases which promotes 
their interaction with various downstream effectors. Rho family GTPase activation is 
facilitated by guanine nucleotide exchange factors (GEFs) that catalyze the conversion of 
GDP to GTP while inactivation of Rho GTPases is induced by GTPase activating 
proteins (GAPs) that stimulate the intrinsic ability of Rho GTPases to hydrolyze GTP to 
GDP.  The third class of molecules that regulate Rho GTPase activity, guanine 
dissociation inhibitors (GDIs), sequester Rho GTPases in a GDP-bound state in the 
cytosol and the dissociation of GDIs is required for membrane localization and 





Figure 1.3 Activation of Rho family GTPases.  Guanine nucleotide exchange factors 
(GEFs) catalyze the conversion of GDP to GTP to enhance Rho GTPase activation. 
GTPase activating proteins (GAPs) inactivate Rho GTPases by stimulating the ability of 
Rho GTPases to hydrolyze GTP to GDP. Finally, guanine dissociation inhibitors (GDI) 
regulate Rho GTPase activation by sequestering Rho GTPases in a GDP-bound state in 




1.4 Functions of Rho GTPases in regulating cytoskeletal dynamics 
1.4.1 Functions of Rho family GTPases in regulating he actin cytoskeleton 
Classic studies in serum-starved Swiss 3T3 fibroblasts underscored a crucial 
function for Rho family GTPases in regulating actin cytoskeletal dynamics (Hall, 1998).  
For example, addition of the Rho GTPase-activator lysophosphatidic acid (LPA) led to 
the formation of stress fibers and focal adhesion cmplexes while microinjection of a 
constitutively active mutant of Rac induced the formation of lamellipodia and the 
associated adhesion complexes.  Finally, microinjection of a GEF for Cdc42 enhanced 
the formation of filopodia and the associated adhesion complexes (Hall, 1998).  More 
recent efforts have identified the key signaling pathways that link Rho GTPases to 
modulation of the actin cytoskeleton (Fig. 1.4).  
The p21-activated kinase 1-6 (PAK1-6) family of serin /threonine kinases can be 
activated by both Rac and Cdc42 via the Cdc42/Rac-interactive binding (CRIB) motif. 
Although six isoforms of PAK have been identified, PAK1-3 are the most extensively 
characterized and it has been demonstrated that their kinase activity is stimulated upon 
interaction with Rac or Cdc42 (Wells and Jones, 2010). When the crystal structure of 
PAK1 was revealed by Lei et al. (2000), it became apparent that an autoinhibitory switch 
domain within the N-terminus of PAK1 prevents the activation of the C-terminal kinase 
domain. Binding of Rac or Cdc42 stimulates activation of PAK via an 
autophosphorylation event which disrupts the interaction between the autoinhibitory 
domain and the kinase domain (Buchwald et al., 2001).  Once activated, PAKs can 
directly phosphorylate and inhibit the activity of myosin light chain kinase (MLCK), 
effectively reducing the phosphorylation of the downstream effector myosin II regulatory 
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chain (MLC) and ultimately leading to the formation f lamellipodia while promoting the 
disassembly of stress fibers (Sanders et al., 1999; Bokoch, 2003; Watanabe et al., 2007). 
In addition to regulation of MLCK, PAK activity has also been shown to positively 
regulate LIM kinase via phosphorylation. Phosphorylation of LIM kinase stimulates its 
ability to phosphorylate and inhibit the actin capping protein, cofilin (Yang et al., 1998; 
Edwards and Gill, 1999; Dan et al., 2001).  Cofilin fu ctions as a destabilizing factor for 
actin filaments; therefore its inhibition enhances the actin polymerization that is 
necessary for the Rac-dependent formation of lamellipodia and membrane ruffles (Yang 
et al., 1998; Bamburg, 1999).  Finally, recent studies suggest that Rac and Cdc42 transmit 
signals to the actin cytoskeleton via Wiskott-Aldrich-syndrome (WASP) family of 
proteins. In particular, activated Cdc42 directly binds both WASP and neuronal WASP 
(NWASP), inducing the activation of actin related protein 2/3 (Arp2/3) to promote the 
formation of new actin filaments (Machesky and Gould, 1999; Kim et al., 2000). 
Conversely, Rac indirectly activates Arp2/3 via an interaction with additional members of 
the WASP family, WAVE1-3 (Eden et al. 2002; Kunda et al., 2003; Schenck et al., 
2003). Thus, Rac and Cdc42 signal through many diverse pathways to induce 
cytoskeletal rearrangements.  
Research has identified two major downstream effectors that are involved in Rho 
GTPase-mediated cytoskeletal rearrangements, Rho Kinase I and II (ROCKI/II) and the 
Diaphanous formin subfamily (Dia). Experimental evidence has established that 
Rho/ROCK signaling can directly oppose Rac/PAK signaling to influence cytoskeletal 
dynamics. For instance, while activation of Rac/PAK reduces the phosphorylation of 
MLC via inhibition of MLCK, activation of Rho/ROCK leads to the inhibition of myosin 
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light chain phosphatase (MLCPPase), increasing the phosphorylation and activation of 
MLC to induce the subsequent formation of actin stress fibers (Kimura et al., 1996). 
Nonetheless, Rho/ROCK signaling can also act in a manner parallel to Rac to induce 
cytoskeletal rearrangements. For example, Rho-dependent activation of ROCK can 
increase the phosphorylation and activation of LIMK, ultimately resulting in inhibition of 
the downstream effector cofilin to promote actin polymerization (Maekawa et al., 1999; 
Ohashi et al., 2000).  In addition to ROCK activation, Rho GTPase can also disrupt an 
autoinhibitory interaction between the N- and C-terminal domain of Dia proteins, 
stimulating their regulation of actin and microtubule cytoskeleton dynamics (Alberts, 
2001). Thus, Rho GTPase regulates the actin cytoskeleton through activation of ROCK or 
Dia.  
The antagonistic relationship established between Rac/Pak and Rho/ROCK 
signaling underscores the importance of maintaining a delicate balance between Rho 
family GTPase signaling in order to properly regulate actin cytoskeletal dynamics. 
Furthermore, the potential functions and importance of Rho GTPases in maintaining 







Figure 1.4 Rho GTPase signaling pathways regulating actin cytoskeletal dynamics.  
Rho activates its downstream effector ROCK to increase MLC and cofilin 
phosphorylation and induce the subsequent formation of actin stress fibers. Rac signals to 
PAK to decrease MLC phosphorylation, leading to the generation of lamellipodia. Rac 





1.4.2 Functions of Rho family GTPases in regulating of neuronal morphology 
In accordance with a conserved function in regulation of actin cytoskeleton 
dynamics, Rho family GTPases have been highlighted as key modulators of neuronal 
morphology. Similar to regulation of the actin cytoskeleton, Rho and Rac/Cdc42 exhibit 
an antagonistic relationship to determine neuronal morphology (Fig. 1.5). Indeed, an 
early study by Kozma et al. (1997) demonstrated that microinjection of Rac or Cdc42 in 
N1E-115 neuroblastoma cells enhanced growth cone dev lopment and neurite outgrowth, 
whereas the Rho inhibitory cytotoxin Clostridium botulinum C3 coenzyme abolished 
Rho-dependent growth cone collapse and neurite retraction. In the same cell line, axonal 
outgrowth induced by the guidance molecule netrin-1 required both Rac and Cdc42, 
while downregulation of either Rho or ROCK was sufficient to induce axonal outgrowth 
(Li et al., 2002). Further, both neurite retraction and F-actin disassembly induced by LPA 
in N1E-115 neuroblastoma cells were mimicked by constitutively activated RhoA and 
blocked by a dominant negative mutant of RhoA (Kranenburg et al., 1997).  Similarly, in 
PC12 cells, constitutive activation of Rho or micronjection of the downstream effector of 
Rho, Rho kinase (ROCK), induced neurite retraction while a kinase dead mutant of 
ROCK was unable to stimulate neurite retraction (Katoh et al., 1998a,b; Sebök et al., 
1999). Further illustrating the antagonistic relationship between Rac and Rho in 
determining neuronal morphology, PC12 cells exposed to nerve growth factor (NGF)-
induced neurite outgrowth in a Rac-dependent manner that was inhibited by activation of 
either RhoA or ROCK (Yamaguchi et al., 2001). Collectively, these studies highlight that 




A major downstream target of Rac and Cdc42, PAK, has been shown to mediate 
growth cone development and neurite outgrowth (Fig. 1.5). For instance, membrane 
targeting of PAK1 has been demonstrated to induce neurite outgrowth of PC12 cells 
while expression of dominant negative PAK1 construct inhibits this effect (Daniels et al., 
1998). Further highlighting the antagonistic signali g characteristic of Rac and Rho 
GTPases, PAK5-induced neurite outgrowth in PC12 cells occurred in a kinase-dependent 
mechanism and was abolished by expression of constitutively active RhoA (Dan et al., 
2002). Intriguingly, early evidence provided in cortical neurons suggests that Rac may 
regulate the length of PAK activation as Rac-dependent hyperphosphorylation of PAK1 
was shown to decrease its kinase activity (Nikolic et al., 1998). In addition to neurite 
outgrowth, Rac signaling to PAK has also been implicated in axonal guidance and 
pathfinding. For example, Rac and PAK have been demonstrated to interact with the 
SH2/SH3 adaptor protein DOCK to control the direction of axon extension in Drosophila 
photoreceptors and olfactory neurons (Hing et al., 1999; Newsome et al., 2000; Ang et 
al., 2003).  
In opposition to Rac/Cdc42 signaling to PAK, Rho kinase (ROCK) has been 
identified as a major downstream target of Rho-dependent neurite retraction (Fig. 1.5). In 
retinal ganglion cell cultures, expression of the repulsive guidance molecule ephrin-A5 
induced collapse in a mechanism consistent with activation ROCK as inhibition utilizing 
the putative ROCK inhibitor, Y-27632, diminished the collapse of growth cones (Wahl et 
al., 2000).  In N1E-115 neuroblastoma cells, expression of a constitutively active mutant 
of ROCK was sufficient to induce neurite retraction whereas expression of a dominant 
negative ROCK mutant attenuated LPA-induced neurite retraction concurrent with 
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enhanced phosphorylation of MLC and remodeling of intermediate filaments and 
microtubules (Amano et al., 1998, Hirose et al., 1998).  Interestingly, while activation of 
ROCK alone is sufficient to induce neurite retraction and cell rounding in N1E-115 cells, 
this effect is blocked by coexpression of dominant negative Rac or Cdc42, suggesting 
that ROCK-dependent neurite retraction may be mediat , in part, through deactivation 
of Rac and/or Cdc42 activity (Hirose et al., 1998).  
Many studies in neurons support the general model that Rac/Cdc42 elicit neurite 
outgrowth and growth cone development while Rho induces neurite retraction and 
growth cone collapse. However, it is important to note that Rho family GTPases can have 
opposing effects on neuronal morphology. For example, expression of a dominant 
negative mutant of Rac1 has been demonstrated to promote neurite outgrowth in dorsal 
root ganglion (DRG) cells (Fournier et al., 2003) and constitutively active Rac1 increases 
the proportion of collapsed growth cones in DRG neurons (Jin and Strittmatter, 1997; 
Vastrik et al., 1999). Similarly, constitutive activation of Rac1 was shown to decrease the 
length of the longest neurite in mouse cortical neurons (Kubo et al., 2002).  Furthermore, 
in some studies, Rho GTPase has been demonstrated to induce neurite formation. Indeed, 
expression of dominant negative RhoA inhibited axon growth in hippocampal neurons 
(Ahnert-Hilger et al, 2004). While these discrepancies in Rho family GTPase functions 
may reflect differences in either organism specific- or cell type-specific regulation of 
neuronal morphology, they also further underscore the importance of tight regulation of 




1.5 Rho family GTPases in regulation of neuronal survival and apoptosis 
The essential functions of Rho family GTPases in regulating neuronal growth 
cone formation, neurite outgrowth, and neuronal development suggest that Rho GTPases 
have an important and conserved function in mediating neuronal survival and death. 
Indeed, similar to the opposing functions exerted btween members of the Rho GTPase 
family in maintenance of neurite outgrowth and growth cone formation, Rac activation 
typically promotes neuronal survival while Rho activa on elicits neuronal death. In 
further support of an antagonistic relationship, recent efforts have identified a key 
signaling network that maintains neuronal survival downstream of Rho family GTPases, 
particularly between Rac GTPase and Rho GTPase (Fig. 1.5).  
1.5.1 Principal Rac-dependent pro-survival signaling pathways 
 In accordance with a conserved function in regulating neurite outgrowth and 
growth cone formation, previous studies have demonstrated an important role for Rac 
GTPase in transmitting pro-survival signals in neurons (Fig. 1.5). Rac GTPase signals to 
the downstream effector PAK1 to promote survival of cerebellar granule neurons (CGNs) 
(Johnson and D’Mello, 2005) and inhibition of Rac via the large cytotoxin Clostridium 
difficile Toxin B induces CGN apoptosis via deactivation of PAK (Le et al., 2005; 
Loucks et al., 2006). In neurons and other cells, PAK is known to promote cellular 
survival through activation of mitogen activated protein kinase (MAPK) pathways. In 
CGNs in particular, PAK activates a pro-survival MEK1/2/ERK1/2 signaling cascade 
which functions in healthy CGNs to enhance degradation of the pro-apoptotic BH3-only 
protein Bim, as well as, repress a pro-apoptotic JAK/STAT signaling cascade (Loucks et 
al., 2006). In addition to transmission of pro-survival signals, PAK can also promote 
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cellular survival through phosphorylation of the BH3-only protein Bad, which enhances 
the association of Bad with cytosolic 14-3-3 scaffolding proteins, effectively inactivating 
the BH3-only protein by targeting it away from the mitochondria where it functions to 
induce apoptosis (Zha et al., 1996; Schürmann et al., 2000). In addition to PAK, Rac 
often exerts pro-survival signaling through activation of the downstream effector 
phosphatidylinositol 3-kinase (PI3K). Once activated, PI3K promotes cellular survival by 
activating Akt or p90rsk to enhance the phosphorylation of Bad (Datta et al., 1997; del 
Peso et al., 1997; Tan et al., 1999).  
1.5.2 Principal Rho-dependent pro-apoptotic signalig pathway 
In further support of the antagonistic relationship between members of the Rho 
GTPase family, Rho GTPase signaling characteristically antagonizes Rac-dependent pro-
survival signaling pathways (Fig. 1.5). The major dwnstream effector of Rho, ROCK, 
activates phosphatase and tension homolog (PTEN) which can indirectly antagonize the 
activation of Akt by Rac. Indeed, siRNA against PTEN diminished the ability of 
constitutively active RhoA to reduce the phosphorylation (activation) of Akt in human 
embryonic kidney cells (Li et al., 2005). Consistent with a pro-survival function for Akt 
in phosphorylating the pro-apoptotic protein Bad, inhibition of ROCK prevented the 
dephosphorylation (activation) of Bad in the penumbra area of rats subjected to ischemia 
(Wu et al., 2012).  The inhibition of Akt by the Rho/ROCK/PTEN pathway occurs 
indirectly as PTEN dephosphorylates phosphatidylinositol (3, 4, 5)-triphosphate into 
phosphatidylinositol (4, 5)-biphosphate to terminate Akt activation (Lai et al., 2014).  
These previous studies have served to highlight that balanced signaling between Rho 
GTPase and Rac GTPase is a critical determinant of neuronal survival.     
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Figure 1.5 Rho GTPase signaling pathways regulating neuronal survival.  Rho 
activates a downstream ROCK/PTEN pathway that indirectly inactivates the pro-survival 
protein Akt to suppress neurite outgrowth and neuronal survival. Rac signals to PI3K to 
activate Akt to enhance neurite outgrowth and neuronal survival. Rac also activates 




1.6 Evidence of dysregulated Rho family GTPase activity underlying the selective 
motor neuron degeneration observed in ALS 
ALS is a devastating neurodegenerative disorder chaa terized by loss of motor 
neurons of the motor cortex, brain stem, and upper and lower spinal cord. Patients that 
receive a diagnosis of ALS typically succumb to thedisorder within 2-5 years due to 
respiratory failure. Approximately 10% of ALS cases appear to be caused by a genetic 
component, while the remaining 90% are considered sporadic in nature. In 1993, the 
glycine to alanine substitution at position 93 in Cu, Zn- superoxide dismutase (SOD1) 
was one of eleven mutations intially identified to be causative in familial ALS. Although 
the G93A SOD1 mutation remains the best characterized to date, mutations in additional 
genes such as Alsin (ALS2), TDP43, and FUS have also been linked to other familial 
forms of ALS. Currently, the only drug that is approved for the treatment of ALS, 
Riluzole, is an anti-glutamateric compound that extends the lifespan of patients a mere 3 
months (Miller et al., 2007). Thus, it is imperative that new molecular targets are 
identified for the treatment of ALS. Recent evidenc suggests that a loss of Rac GTPase 
activity or gain of Rho GTPase activity may underlie the disease progression in ALS.  
1.6.1 Loss of Rac and ALS 
Recessive mutations in a Rac guanine nucleotide exchange factor (GEF), alsin 
(ALS2), have been reported in juvenile forms of ALS, primary lateral sclerosis, and 
infantile-onset ascending hereditary spastic paralysis (Hadano et al., 2007).  When 
overexpressed in cultured human cells, alsin mutants re rapidly degraded, suggesting 
disease progression occurs through a mechanism consistent with alsin loss-of-function 
(Yamanaka et al., 2003).  Although alsin is a GEF for both Rab5 and Rac, alsin 
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colocalizes with Rac in the growth cones of neurons a d regulates Rac signaling and 
neurite outgrowth through its intrinsic GEF activity, hus suggesting a link between Rac 
disruption and neurodegenerative disease (Topp et al., 2004; Kanekura et al., 2005; Tudor 
et al., 2005).  In addition to juvenile onset ALS, a recent study identified a mutation in 
the PH domain of alsin that underlies the development of infantile-onset ascending 
hereditary spastic paraplegia (Wakil et al., 2014).  Given the specificity of the DH/PH 
tandem repeat for activation of Rac GTPase, but not Rab5, (Zheng, 2001; Topp et al., 
2004; Tudor et al., 2005), this study further highli ts that a loss of Rac activity may 
underlie the progression of early onset forms of ALS.  
The critical role of Rac in maintaining neuronal survival is evidenced by the fact 
that disruptions in Rac signaling have been shown to induce apoptosis in a variety of 
diverse neuronal cell types, including primary motor neurons (Kanekura et al., 2005; 
Jacquier et al., 2006; Loucks et al., 2006; Stankiewicz et al., 2012).  In spinal motor 
neurons isolated from embryonic rats, siRNA knockdown of alsin induces neurite 
retraction and cell death that is abrogated by expression of constitutively active Rac 
(Jacquier et al., 2006).  Furthermore, alsin antagonizes NSC34 motor neuronal death 
induced by the expression of ALS-causing SOD1 mutants (mSOD1) via activation of a 
pro-survival Rac/PI3K/Akt signaling cascade (Kanekura et al., 2005).  Intriguingly, 
accumulating evidence suggests that SOD1 may regulat  the activity of Rac GTPase. In 
particular, neuronal apoptosis induced via expression of either G93A or H80R mSOD1 in 
SH-SY5Y dopaminergic cells correlated with a decrease in Rac GTPase activity. Indeed, 
expression of a constitutively active Rac GTPase mutant abrogated mSOD1-induced 
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neuronal death while expression of dominant negative Rac GTPase alone induced 
apoptosis (Pesaresi et al., 2011).  
In addition to mutations that code for alsin and SOD1, recent evidence also 
suggests that ARHGEF16, a GEF for Rac GTPase, is hypermethylated and 
downregulated in postmortem sporadic ALS spinal cord samples when compared to 
samples from neurologically normal controls (Figueroa-Romero et al., 2012).  Thus, 
dysregulation of Rac GTPase may be a common factor underlying both familial and 
sporadic forms of ALS. While accumulating evidence has highlighted a critical function 
for Rac GTPase in maintaining neuronal survival, the involvement of Rac in the etiology 
of ALS has only been examined recently and the exact mechanism by which disruptions 
in Rac activity may induce neuronal apoptosis remains poorly understood.  Alterations in 
Rac activity in motor neurons and mouse models of ALS warrants further investigation as 
it has significant potential to elucidate insights into neurodegenerative disease and 
delineate novel therapeutic targets.   
1.6.2 Gain of Rho GTPase activity in ALS 
Although recent efforts are only beginning to elucidate a role for enhanced Rho 
GTPase activation in the disease progression of ALS, hyperactivation of Rho GTPase has 
been underscored as a contributing factor in many other models of neurodegenerative 
disease and neuronal trauma. For example, while total RhoA expression was unaltered 
following lateral fluid percussion brain injury in rats, RhoA activity was increased in both 
the cortex and hippocampus ipsilateral and contralateral to the injury (Dubreuil et al., 
2006).  Furthermore, in an i vitro model of Phenylketonuria brain injury, phenylalanine 
induced mitochondrial-dependent apoptosis of cortical neurons occurred via a mechanism 
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consistent with activation of RhoA (Zhang et al., 2010). A recent study has also 
suggested a role for RhoA in calcium-dependent excitotoxic cell death in rat neurons 
(Semenova et al., 2007). In addition to RhoA, RhoB as also been implicated in neuronal 
apoptosis following ischemia as increases in RhoB expression occur following ischemic 
injury and precede DNA fragmentation indicative of apoptosis (Trapp et al., 2001). 
Moreover, corticohippocampal neurons deficient in RhoB are resistant to staurosporine-
induced apoptosis and RhoB knockout mice display diminished basal levels of caspase-3 
activity in the adult brain (Barberan et al., 2011).  Collectively, these data implicate that 
aberrant activation of RhoA and/or RhoB may contribute to neuronal apoptosis in a 
variety of in vitro and in vivo models of neurodegenerative demise.  
In addition to the above studies demonstrating the involvement of Rho GTPase in 
various models of neurodegeneration, recent efforts have begun to highlight that aberrant 
Rho GTPase activity may also underlie the pathology of ALS.  For example, although the 
significance remains unknown, the Rho guanine nucleotid  exchange factor (RGNEF) 
displays enhanced cytoplasmic inclusions in spinal motor neurons from both sporadic and 
familial ALS patients (Keller et al., 2012; Droppelmann et al., 2013).  However, future 
studies will be required to identify the importance of RGNEF-positive spinal motor 
neuron cytoplasmic inclusions. Nonetheless, in accordance with enhanced Rho GTPase 
activity as a causative factor to motor neuronal deth in ALS disease progression, ROCK 
activity is increased in the G93A mSOD1 mouse model f ALS, as well as, sporadic ALS 
patients (Hu et al., 2003; Capitanio et al., 2012; Conti et al., 2014). While the above 
studies indicate that a gain of Rho GTPase activity ma  underlie the progression of ALS, 
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relatively few studies have examined the precise mechanism by which unopposed 
activation of Rho GTPase may contribute to the motor neuronal death observed in ALS. 
1.7 Models to study neuronal apoptosis 
1.7.1 Cerebellar granule neurons 
The relatively simple process of isolating rat cereb llar granule neurons has made 
their use in studies of neuronal apoptosis widespread. These primary neuronal cultures 
are extremely homogeneous and have been used extensively to examine the molecular 
mechanisms involved in neuronal apoptosis. Early studies conducted in CGNs exposed to 
low potassium determined that CGNs undergo apoptotic cell death as evidenced by DNA 
fragmentation (D’Mello et al., 1993).  Further, it was previously demonstrated that CGNs 
subjected to low potassium conditions undergo extrinsic apoptosis as evidenced by 
increased expression of Fas ligand and caspase-3 (Ginham et al., 2001; Fig. 1.6).  In 
addition, CGNs also appear to be sensitive to intrinsic (mitochondrial) apoptosis as CGNs 
derived from mice overexpressing the pro-apoptotic protein Bax or deficient in the pro-
survival protein Bcl-2 displayed enhanced sensitivity to apoptotic cell death when 
compared to CGNs isolated from wild type mice (Tanabe et al., 1997).  In addition to 
these prior studies demonstrating that CGNs undergo both intrinsic and extrinsic 
apoptosis, we have shown that inhibition of Rac GTPase utilizing large Clostridial 
cytotoxins or expression of a dominant negative Rac1 mutant induces mitochondrial-
dependent apoptosis of CGNs.  Cell death occurred in a mechanism consistent with DNA 
fragmentation and activation of the death executioner of apoptosis, caspase-3 (Linseman 
et al., 2001; Le et al., 2005; Loucks et al., 2006). Thus, primary CGN cultures provide an 
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excellent in vitro model that can be used to study the Rac-dependent signaling pathways 





Figure 1.6 CGNs undergo caspase-dependent apoptosis.  CGNs were incubated in 
either control medium or 25k- medium deprived of potassium for 24 h. Following 
incubation, CGNs were fixed with 4% paraformaldehyde and stained for DAPI (blue), β-
tubulin (green), and active caspase-3 (red). Note that CGNs deprived of trophic support 






1.7.2 Embryonic Stem Cell-Derived Motor Neurons 
Traditionally, ALS has been a difficult disease to m del in vitro due to the fact 
that it is characterized by the loss of upper and lower spinal motor neurons.  Motor 
neurons isolated from embryonic mice and rats do not yield high numbers, making it 
difficult to perform experiments that may require high cellular content. Furthermore, it is 
unknown if motor neurons isolated from embryonic rodents are mature enough to mimic 
those that are lost in aging-related disorders such as ALS. To overcome this issue, 
Wichterle and colleagues (2002) developed a protocol to terminally differentiate mouse 
ESCs into motor neurons which express GFP under cont ol of the motor neuron-specific 
HB9 homeobox promoter.  Following a one week differentiation protocol, approximately 
30% of the cultured cells are identified as GFP-expr ssing motor neurons (Fig. 1.7). 
ESC-derived motor neurons can populate the embryonic spinal cord, project axons, and 
form synapses with muscle cells (Wichterle et al., 2002). Thus, ESC-derived motor 
neurons represent a novel in vitro model that can be utilized to study the involvement of 





































Figure 1.7 Generation and differentiation of ESC-derived motor neurons. ESCs 
harboring an enhanced GFP (eGFP) transgene driven by the motor neuron-specific Hb9 
promoter were cultured on a layer of mouse embryonic fibroblasts. After detachment 
with trypsin, embryoid bodies (EBs) were cultured in suspension in differentiation 
medium containing retinoic acid to induce the formation of motor neuron progenitors. 
After 24 h, sonic hedgehog and glial cell line-deriv d neurotrophic factor were added to 
further promote the differentiation of neural precursor cells into spinal motor neurons. 
After a 48 h incubation, EBs were collected and digested with papain to produce a single 
cell suspension. Cells were then plated onto matrigel-coated culture dishes (top panel). 
After 24 h on matrigel, EGFP+ motor neurons appear healthy and extend long processes 
as well as multiple shorter neurites (bottom panel). Consistent with Wichterle et al. 
(2002), approximately 30% of cells terminally differentiated into spinal motor neurons.
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CHAPTER TWO: SIGNAL TRANSDUCER AND ACTIVATOR OF 
TRANSCRIPTION (STAT)-5 MEDIATES NEURONAL APOPTOSIS INDUCED 




 In several neuronal cell types, the small GTPase Rac is essential for survival. We 
have shown previously that the Rho family GTPase inhib tor Clostridium difficile toxin B 
(ToxB) induces apoptosis in primary rat cerebellar granule neurons (CGNs) principally 
via inhibition of Rac GTPase function. In the present study, incubation with ToxB 
activated a proapoptotic Janus kinase (JAK)/signal tr nsducer and activator of 
transcription (STAT) pathway, and a pan-JAK inhibitor protected CGNs from Rac 
inhibition. STAT1 expression was induced by ToxB; however, CGNs from STAT1 
knock-out mice succumbed to ToxB-induced apoptosis a  readily as wild-type CGNs. 
STAT3 displayed enhanced tyrosine phosphorylation following treatment with ToxB, and 
a reputed inhibitor of STAT3, cucurbitacin (JSI-124), reduced CGN apoptosis. 
Unexpectedly, JSI-124 failed to block STAT3 phosphorylation, and CGNs were not 
protected from ToxB by other known STAT3 inhibitors. In contrast, STAT5A tyrosine 
phosphorylation induced by ToxB was suppressed by JSI-124. In addition, roscovitine 
similarly inhibited STAT5A phosphorylation and protec ed CGNs from ToxB-induced 
apoptosis. Consistent with these results, adenoviral infection with a dominant negative 
STAT5 mutant, but not wild-type STAT5, significantly decreased ToxB-induced 
apoptosis of CGNs. Finally, chromatin immunoprecipitation with a STAT5 antibody 
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revealed increased STAT5 binding to the promoter region of prosurvival Bcl-xL. STAT5 
was recruited to the Bcl-xL promoter region in a ToxB-dependent manner, and this DNA 
binding preceded Bcl-xL down-regulation, suggesting transcriptional repression. These 
data indicate that a novel JAK/STAT5 proapoptotic pathway significantly contributes to 
neuronal apoptosis induced by the inhibition of Rac GTPase.  
2.2 Introduction 
 Rho family GTPases are important mediators of cellular development, survival, 
and death. The most well characterized members of the family are RhoA, Rac1, and 
Cdc42. Although best known for regulating actin cytoskeletal dynamics, Rho GTPases 
also play important roles in cell cycle progression (Olson et al., 1995), gene transcription 
(Hill et al., 1995), and cell-cell or cell-matrix adhesion (Clark et al., 1998; Fukata et al., 
1999). In recent years, the role of Rho GTPases in neuronal survival has begun to be 
investigated. For example, inhibitors of 3-HMG-CoA reductase (statins) decrease the 
localization of Rho GTPases to the plasma membrane and induce apoptosis in rat cortical 
neurons (Tanaka et al., 2000). We have shown previously that the function of Rac is 
essential for the survival of cerebellar granule neurons (CGNs) as the inhibition of Rac 
with either large Clostridial cytotoxins or overexpression of a dominant negative Rac 
mutant induces mitochondrially dependent apoptosis f these cells (Linseman et al., 
2001). In a similar manner, use of either dominant negative Rac or siRNA against the 
Rac guanine nucleotide exchange factor alsin (ALS2) results in apoptosis of primary 
cultured spinal motor neurons (Jacquier et al., 2006). The critical role of Rac in neuronal 
survival is further evidenced by the finding that ALS2 is mutated in juvenile onset 
amyotrophic lateral sclerosis. Although changes in Rac activity in patients harboring 
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disease-causing ALS2 mutations have not been directly valuated, disruption of Rac 
function as a possible underlying cause of neurodegen rative disease is suggested by the 
fact that alsin mediates Rac-dependent prosurvival signaling in primary motor neurons 
(Jacquier et al., 2006). Collectively, these findings implicate Rac as a crucial mediator of 
neuronal survival and suggest that disruption of Rac activity may contribute to the 
progression of neurodegenerative disorders.  
 We have reported previously that inhibition of Rho GTPases with Clostridium 
difficile toxin B (ToxB) and in particular inhibition of Rac lead to the derepression of an 
as yet undefined proapoptotic JAK/STAT pathway (Loucks et al., 2006). The JAK/STAT 
pathway has been shown to play a critical role in cytokine signaling, and JAK activation 
can turn on an array of downstream effects including cell proliferation, differentiation, 
and apoptosis (Igaz et al., 2001). An important feature of the JAK/STAT signaling 
cascade is that it can exert either a prosurvival or pr apoptotic effect depending upon the 
stimulus and cell type. For example, cytoprotective signals are transmitted from the 
gp130 receptor to a prosurvival JAK/STAT3 pathway in cardiac myocytes (Yamauchi-
Takihara and Kishimoto, 2000). Moreover, data implicate constitutive activation of 
STAT1 and STAT3 proteins in breast cancer cells (Watson and Miller, 1995). 
Conversely, more recent data have emerged to suggest that the JAK/STAT pathway may 
also induce apoptosis under certain cellular conditions. For instance, STAT1 has been 
shown to mediate IFN-γ induced apoptosis in liver cells treated with the hepatotoxic 
compound galactosamine (Kim et al., 2003). In addition, chromatin immunoprecipitation 
experiments performed in thymocytes suggest that glucocorticoids induce apoptosis 
through repression of prosurvival Bcl-xL in a STAT5-dependent manner (Rocha-Viegas 
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et al., 2006). Although it is clear that JAK/STAT activation can induce apoptosis in 
diverse non-neuronal cell types, the significant involvement of this signaling pathway in 
neuronal apoptosis has only recently been recognized.  
 In a previous study, we showed that inhibition of Rac induces CGN apoptosis by 
inactivating a prosurvival p21-activated kinase PAK/mitogen-activated protein kinase 
kinase (MEK)/extracellular signal-regulated kinase (ERK) cascade. Although we have 
demonstrated that disruption of this pathway results in the derepression of a proapoptotic 
JAK/STAT pathway, we have yet to identify which particular STAT family members 
mediate neuronal apoptosis in response to ToxB (Loucks et al., 2006). Thus, the current 
study focuses on identifying the STAT family members involved and the consequences 
of STAT activation downstream of Rac inhibition in CGNs. These primary neuronal 
cultures are extremely homogeneous and have been usd extensively to examine 
molecular mechanisms involved in neuronal apoptosis (Linseman et al., 2001; D’Mello et 
al., 1993; Contestabile, 2002; Vaudry et al., 2003). Although we show that Rac inhibition 
leads to the up-regulation of STAT1 expression and e hanced tyrosine phosphorylation 
of STAT3, we report that these transcription factors a e not responsible for inducing 
apoptosis in ToxB-treated CGNs. Instead, we demonstrate hat STAT5 is activated and 
subsequently translocates into the nucleus to transc iptionally repress prosurvival Bcl-xL 
in Rac-inhibited CGNs. To our knowledge, these results are the first to identify a 




2.3 Materials and Methods 
 
2.3.1 Reagents 
 C. difficile toxin B was isolated or prepared as a recombinant protein as described 
previously (Just et al., 1995). The polyclonal antibodies used for immunoblotting STAT1, 
STAT3, and phosphorylated STAT5 (pSTAT5) were from Cell Signaling Technology 
(Beverly, MA). Horseradish peroxidase-linked secondary antibodies and reagents for 
enhanced chemiluminescence detection were from Amersham Biosciences. The 
polyclonal antibody used to detect active caspase-3 by immunocytochemistry was from 
Promega (Madison, WI). For Western blotting, active caspase-3 was detected with a 
polyclonal antibody from Abcam (Cambridge, MA). 4, 6-Diamidino-2-phenylindole 
(DAPI), Hoechst dye 33258, and a monoclonal antibody against β-tubulin were from 
Sigma. Anti-rat and anti-mouse Cy3- or FITC-conjugated secondary antibodies for 
immunofluorescence were from Jackson ImmunoResearch Laboratories (West Grove, 
PA). The monoclonal antibody against LAP-2 and the polyclonal total STAT1 and total 
STAT5 antibodies used for Western blotting were from BD Biosciences. Purvalanol A, 
JSI-124, roscovitine, mifepristone, JAK3 inhibitor, and the small molecule JAK inhibitor 
I (2-(1, 1-dimethyl) 9-fluro-3, 6-dihydro-7H-benz[h]imidaz [4, 5,-f] isoquinolin-7-one; 
pan-JAK inhibitor (pan-JI)) were from Calbiochem. The specific JAK1/2 inhibitor 
ruxolitinib was purchased from ChemieTek (Indianapolis, IN), and the JAK3 inhibitor 
tofacitinib was from Selleck Chemicals (Houston, TX).  
2.3.2 CGN culture 
 Rat CGNs were isolated and cultured from 7-day-old Sprague-Dawley rat pups of 
both sexes (15–19 g) as described previously (Linseman et al., 2001). Briefly, CGNs 
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were plated on 35-mm-diameter plastic dishes coated with poly-l-lysine at a density of 
2.0 × 106cells/ml in basal modified Eagle's medium containing 10% fetal bovine serum, 
25 mm KCl, 2 mm l-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin 
(Invitrogen). Cytosine arabinoside (10 µm) was added to the culture medium 24 h after 
plating to limit the growth of non-neuronal cells. With this protocol, cultures were ~95% 
pure for granule neurons. In general, experiments were performed after 6–7 days in 
culture.  
2.3.3 CGN culture from STAT1 knock-out (KO) mice 
 STAT1 KO mice and their wild-type littermates were obtained commercially 
from Taconic (Hudson, NY). CGNs from these mice were isolated and cultured 
essentially as described above.  
2.3.4 Cell lysis and immunoblotting 
 After treatment as described under “Results,” CGN whole cell lysates or immune 
complexes of STAT5A or STAT5B were prepared for Western blotting essentially as 
described previously (Loucks et al., 2006). Protein co centrations were determined by a 
commercially available protein assay kit (BCA, Thermo Scientific), and SDS-
polyacrylamide gel electrophoresis was performed using equal amounts of protein 
followed by transfer to polyvinylidene difluoride (PVDF) membranes (Amersham 
Biosciences). Nonspecific binding sites were blocked in phosphate-buffered saline (PBS) 
(pH 7.4) containing 0.1% Tween 20 (PBS-T), 1% bovine serum albumin (BSA), and 
0.01% sodium azide for 1 h at room temperature (25 °C). Membranes were incubated for 
1 h in primary antibody diluted in blocking solution. Excess primary antibody was 
removed by washing the membranes with PBS-T five tim s over 25 min. The membranes 
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were then incubated for 1 h with the appropriate horseradish peroxidase-conjugated 
secondary antibodies diluted in PBS-T. Excess secondary antibody was removed by 
washing the membranes with PBS-T five times over 25 min. Immunoreactive proteins 
were detected by enhanced chemiluminescence. Blots shown are representative of a 
minimum of three independent experiments.  
2.3.5 Quantification of apoptosis 
 After induction of apoptosis, CGNs were fixed in 4% paraformaldehyde for 30 
min, and nuclei were stained with Hoechst dye (8 µg/ml final concentration) for 30 min. 
CGNs containing condensed and/or fragmented nuclei w re scored as apoptotic. 
Typically, 800 cells were quantified from each 35-mm well by randomly counting five 
40× fields. Final counts represent data obtained from at least three independent 
experiments performed in duplicate.  
2.3.6 Immunocytochemistry 
 CGNs were plated at a density of 2.0 × 106cells/ml in 35-mm wells. After ToxB 
treatment, CGNs were fixed in 4% paraformaldehyde, washed once in PBS, and then 
permeabilized and blocked in PBS containing 0.2% Triton X-100 and 5% BSA. Primary 
antibodies were diluted in 2% BSA and 0.2% Triton X-100 in PBS, and cells were 
incubated in primary antibody overnight at 4 °C. Cells were subsequently washed five 
times in PBS and then incubated for 1 h with DAPI and either Cy3- or FITC-conjugated 
secondary antibody diluted in 2% BSA and 0.2% Triton X-100. The cells were washed 
five additional times with PBS before the addition of an antiquench solution composed of 
0.1% p-phenylenediamine in 75% glycerol in PBS. Fluorescent images were captured 
using a 40× water oil immersion objective on a Zeiss Axioplan 2 microscope with a 
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Cooke Sensicam deep cooled charge-coupled device cam ra and a Slidebook software 
analysis program for digital deconvolution (Intelligent Imaging Innovations Inc., Denver, 
CO).  
2.3.7 Preparation of nuclear and cytosolic extracts from CGNs 
 Nuclear and cytosolic extracts were prepared as described by Li et al. (2001). 
Briefly, CGNs were detached from culture dishes by a cell scraper and centrifuged at 250 
× g for 5 min. The cell pellets were washed and homogenized with 15 strokes of a tightly 
fitting Dounce homogenizer to release nuclei. Next, the homogenate was centrifuged at 
14,000 × g for 15 s to pellet the nuclei. The supernatants (cytosolic fractions) were 
removed, the pellets were resuspended in a HEPES/glycerol buffer, and nuclear proteins 
were extracted at 4 °C for 45 min. Insoluble nuclei w re precipitated by centrifugation at 
14,000 × g for 15 min, and the supernatants were dialyzed against  Tris/glycerol buffer 
for 3 h at 4 °C.  
2.3.8 Adenovirus preparation and infection 
 Wild-type STAT5 and dominant negative STAT5 adenoviral constructs were 
prepared as described previously (Ahonen et al., 2003). CGNs were infected in vitro on 
day 6 with adenovirus carrying GFP, wild-type STAT5, or dominant negative STAT5 at 
a multiplicity of infection of 100. At 48 h of infection, cells were treated with 40 ng/ml 
ToxB. At 72 h of infection, cell lysates were prepared for immunoblot analysis, or cells 
were fixed for immunocytochemistry as described above.  
2.3.9 Chromatin immunoprecipitation (ChIP) 
 ChIP assays were performed according to the manufacturer's protocol using the 
ChIP assay kit from Active Motif (Carlsbad, CA). CGNs were treated with 40 ng/ml 
40 
 
ToxB for 0 and 8 h. Next, DNA-associated proteins were cross-linked with 
formaldehyde. Cross-linked chromatin was extracted, sheared enzymatically, and 
incubated with a ChIP grade STAT5 antibody overnight at 4 °C and protein G-agarose 
beads. After washing, immune complexes were eluted from the beads, heated to reverse 
the cross-links, and treated with proteinase K and RNase A to remove proteins and any 
contaminating RNA. DNA was analyzed by polymerase chain reaction (PCR) using the 
following primers provided by SABiosciences that generate a 114-bp product that 
corresponds to the promoter region of the rat Bcl-xL gene: forward primer, 5′-
GAAGCTGACACCAGTGAGTGTCCGAACGGTAAATGCCTACGAAGCTGACAC
AGTGAGTG-3′; and reverse primer, 5′-GTAGGCATTTACCGTTCGGA-3′. These 
primers were selected because they amplify a sequence of DNA that is near two predicted 
STAT5 binding sites on the promoter region of Bcl-xL variant 1 and variant 2. As a 
negative control, ChIP reactions were performed as escribed in the absence of STAT5 
antibody followed by PCR. PCR was performed using the following conditions: one 
cycle of 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s.  
2.3.10 Data analysis 
 Results represent the mean ± S.E. for the number (n) of independent experiments 
performed. Statistical differences between the means of unpaired sets of data were 
evaluated by one-way analysis of variance with a post hoc Tukey's test. A p value of 
<0.05 was considered statistically significant. Images and immunoblots are representative 
of at least three independent experiments. For the cycle threshold values reported in Fig. 
2.10A, results represent the mean for four independent experiments, and statistical 




2.4.1 STAT1 is up-regulated in JAK-dependent manner i  CGNs treated with Rho family 
GTPase inhibitor ToxB 
 To evaluate the involvement of Rac in CGN survival, cultures were incubated 
with C. difficile toxin B. This cytotoxin monoglucosylates a key threonine residue in the 
switch 1 region of Rho GTPases, thus preventing any interactions with downstream 
effectors (Just et al., 1995; Jank and Aktories, 2008). We have shown previously that 
inhibition of the Rho family member Rac with ToxB elicits the derepression of a 
proapoptotic JAK/STAT pathway in CGNs (Loucks et al., 2006). However, the specific 
STAT family protein involved in this pathway has not yet been elucidated. As STAT1 is 
the most extensively described family member in studies of apoptosis (Sahni et al., 2001; 
Stephanou and Latchman, 2003; Sironi and Ouchi, 2004), we examined its expression 
following Rac inhibition. CGNs incubated with ToxB for 24 h exhibited a marked 
increase in the expression of STAT1 (Fig. 2.1A). Moreover, co-incubation with a small 
molecule pan-JI (structure shown in Fig. 2.1B) was sufficient to prevent the induction of 
STAT1 by ToxB, confirming that the increase in STAT1 is dependent on JAK activation 
(Fig. 2.1A).  
 In addition to provoking apoptosis in a variety of diverse cell types (Thomas et 
al., 2004; Kaganoi et al., 2007; Soond et al., 2007), activated STAT1 has been shown to 
play a proapoptotic role in neuronal death induced during ischemic brain injury (Takagi 
et al., 2002). To determine whether derepression of a JAK/STAT1 pathway exerts a 
similar proapoptotic effect in Rac-inhibited neurons, we examined the neuroprotective 
effects of pan-JI in ToxB-treated CGNs. Examination of nuclei by Hoechst staining 
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revealed increased apoptotic cell death in ToxB-treated CGNs as evidenced by nuclear 
fragmentation and/or condensation. The effect of ToxB on the morphology of CGN 
nuclei was significantly attenuated by co-treatment with the pan-JI (Fig. 2.1D, lower 
panels). As an additional means of identifying apoptotic cells, we examined caspase-3 
activation as cleavage to its active proteolytic fragments is a hallmark of apoptosis and 
signifies commitment to cell death (Porter and Jänicke, 1999). CGNs treated with ToxB 
alone exhibited increased activation of caspase-3, and this effect was blocked by pan-JI 
(Fig. 2.1D, upper panels). Quantification of apoptosis in CGNs co-incubated with ToxB 
and pan-JI revealed that the pan-JI conferred significa t neuroprotection and effectively 
reduced apoptosis to control levels (Fig. 2.1C). Taken together, these data suggest that 
inhibition of Rac with ToxB results in the activation of a proapoptotic JAK/STAT1 
signaling pathway in CGNs.  
 To elucidate the specific JAK family member(s) that induces STAT activation 
downstream of Rac inhibition in CGNs, we evaluated he protective effects of more 
targeted JAK inhibitors against ToxB. We found that two specific JAK3 inhibitors (JAK3 
inhibitor and tofacitinib) did not confer significant neuroprotection in ToxB-treated 
CGNs (Fig. 2.1E). However, we found that the JAK1/2 inhibitor (ruxolitinib) modestly 
protected CGNs from ToxB-mediated apoptosis, althoug  this effect did not quite reach 
statistical significance. Based on the marked protectiv  effects of the pan-JI (which 
inhibits JAK1–3 and Tyk2 with similar potency) and our results showing that more 
targeted inhibition of specific JAK family members (JAK1–3) is not overtly protective, 
these data suggest a possible contribution of Tyk2 in mediating the apoptosis downstream 
of ToxB-mediated Rac inhibition in primary CGNs.  
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Figure 2.1 STAT1 is up-regulated in JAK-dependent manner during CGN apoptosis 
induced by Rho family GTPase inhibitor ToxB. A. CGNs were incubated for 24 h in 
complete medium containing 25 mm KCl and serum (control (Con) medium) ± ToxB (40 
ng/ml) or ToxB + pan-JI (1 µm). Cells were then lysed, and proteins were resolvd by 
SDS-PAGE and transferred to PVDF membranes. The membrane was probed with an 
antibody against STAT1. STAT1 expression was up-regulated when treated with ToxB, 
and this effect was blocked by pan-JI. B. Molecular structure of pan-JI. C. Quantification 
of apoptosis in CGNs incubated for 24 h as described n A. **, p < 0.01 compared with 
control (Con); ††, p < 0.01 compared with ToxB. D. CGNs were incubated for 24 h as 
described in A. For 4 independent experiments following incubation, cells were 
incubated with a polyclonal antibody against active caspase-3 (shown in red) and a 
monoclonal antibody against β-tubulin (shown in green), and nuclei were stained with 
DAPI (shown in blue). Lower panels show decolorized DAPI staining of nuclei for 
clarity. CGNs incubated with ToxB exhibited many condensed and/or fragmented nuclei 
and displayed increased immunoreactivity for active caspase-3. CGNs co-incubated with 
pan-JI were significantly protected from apoptosis and displayed nuclear morphology 
similar to that in controls. Scale bar, 10 µm. E. CGNs were incubated for 24 h in control 
medium ± ToxB (40 ng/ml) or ToxB + JAK3 inhibitor (JAK3 Inh; 100 µm), ruxolitinib 
(Rux; 10 µm), or tofacitinib (Tof; 10 µm). Following incubation, cells were fixed with 4% 
paraformaldehyde, and the nuclei were stained with Hoechst dye. Apoptotic cells were 
scored as those with condensed and/or fragmented nuclei. Values are mean ± S.E. for 6 
independent experiments. I acknowledge Alex Loucks for assistance with generating data 
for this figure. 
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2.4.2 STAT1 is not activated by tyrosine phosphorylation nor does it translocate into 
nucleus of ToxB-treated CGNs 
 Next, we examined the phosphorylation status and localization of STAT1 in 
CGNs exposed to ToxB. To translocate into the nucleus and influence gene expression, 
members of the STAT family must be activated via tyrosine phosphorylation (Rawlings 
et al., 2004). Whereas total STAT1 expression increased in CGNs treated for 24 h with 
ToxB, time course experiments performed for up to 24 h did not show significant 
activation of STAT1 as assessed by tyrosine phosphorylation (Fig. 2.2A). Furthermore, 
using immunostaining to examine STAT1 localization, we found that STAT1 remained 
cytosolic and perinuclear in CGNs following ToxB treatment (Fig. 2.2B). These 
observations are striking in that they suggest that t e observed up-regulation of STAT1 
expression may not be directly involved in apoptosis following ToxB-mediated inhibition 




Figure 2.2 STAT1 does not display increased tyrosine phosphorylation nor does it 
translocate into nucleus of ToxB-treated CGNs. A. A 24h time course of ToxB 
treatment (40 ng/ml) was performed in CGNs. Cell lysates were resolved by SDS-PAGE, 
and proteins were transferred to PVDF membranes. The blots were probed with 
antibodies against pSTAT1 (Tyr-701) and STAT1. Little to no increase in the tyrosine 
phosphorylation of STAT1 was observed in CGNs subjected to ToxB for up to 24 h. B. 
CGNs were incubated with control (Con) medium ± ToxB (40 ng/ml) for 8 h. Cells were 
fixed, and their nuclei were stained with DAPI. A primary antibody against pSTAT1 
(Tyr-701) and a Cy3-conjugated secondary antibody were used to visualize pSTAT1. 
Incubation of CGNs with ToxB did not result in translocation of pSTAT1 into the 
nucleus. Scale bar, 10 µm. I acknowledge Alex Loucks for assistance with generating 
data for this figure. 
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2.4.3 CGNs from STAT1 knock-out mice are susceptibl to ToxB-induced apoptosis 
 To definitively establish whether the up-regulation f total STAT1 expression in 
the absence of enhanced tyrosine phosphorylation or nuclear translocation is involved in 
ToxB-mediated apoptosis, we measured the effects of ToxB on primary cultures of CGNs 
isolated from STAT1 KO mice versus their wild-type (WT) littermates. CGNs from WT 
mice demonstrated a marked increase in STAT1 expression following ToxB treatment, 
whereas CGNs from STAT1 KO mice did not demonstrate any expression of STAT1 in 
either the absence or presence of ToxB (Fig. 2.3A), thus confirming effective knock-out 
of STAT1 expression in these mice. Unexpectedly, CGNs from both WT and STAT1 KO 
mice equally succumbed to apoptosis in response to ToxB treatment (Fig. 2.3B), whereas 
inclusion of the pan-JI was equally neuroprotective for both cell types (Fig. 2.3C). 
Collectively, these data indicate that although total STAT1 is up-regulated a different 
member of the STAT family mediates JAK-dependent apoptosis in Rac-inhibited CGNs.  
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Figure 2.3 CGNs from STAT1 knock-out and wild-type mice are equally susceptible 
to ToxB-induced apoptosis. A. CGNs from WT and STAT1 KO mice were treated for 
0, 24, or 48 h with ToxB (40 ng/ml). Cell lysates were resolved by SDS-PAGE, and 
proteins were transferred to PVDF membranes. The blot was probed with a primary 
antibody against STAT1. The Western blot shows induce  expression of STAT1 in WT 
CGNs after treatment with ToxB. B. WT and STAT1 KO CGNs were incubated for 48 h 
in control (Con) medium ± ToxB (40 ng/ml) or with ToxB + pan-JI (1µm). Cells were 
fixed, and nuclei were stained with Hoechst. Both WT and KO cells treated with ToxB 
displayed condensed and/or fragmented nuclear morphology. WT and KO CGNs co-
incubated with pan-JI exhibited nuclear morphologies similar to those of control cells. 
Scale bar, 10 µm. C. Quantification of apoptosis in CGNs incubated for 24 or 48 h with 
control medium ± ToxB (40 ng/ml) or ToxB + pan-JI (1 µm). STAT1 KO cells 
succumbed to apoptosis as readily as WT CGNs after treatment with ToxB. When co-
incubated with pan-JI, STAT1 KO and WT CGNs showed similar protection from ToxB. 
**, p < 0.01 compared with control; ††, p < 0.01 compared with ToxB. Inh, inhibitor. 
Values are mean ± S.E. for 3 independent experiments. I acknowledge Alex Loucks for 
assistance with generating data for this figure. 
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2.4.4 STAT3 is tyrosine phosphorylated in response to ToxB, and this effect is blocked by 
Pan-JI 
 As our data demonstrate that STAT1 up-regulation does not significantly 
contribute to apoptosis in Rac-inhibited CGNs, we next evaluated the involvement of 
additional members of the STAT family. Recent evidence suggests that STAT3 mediates 
β-amyloid-induced apoptosis in mouse cortical neurons (Wan et al., 2010). To determine 
whether ToxB-targeted inhibition of Rac acts to ultimately activate a similar proapoptotic 
JAK/STAT3 pathway, we analyzed the activation of STAT3 in response to ToxB 
treatment. Time course experiments demonstrated that STAT3 was tyrosine 
phosphorylated as early as 6 h after ToxB treatment (Fig. 2.4A), and inclusion of pan-JI 






Figure 2.4 STAT3 is tyrosine phosphorylated in response to ToxB in CGNs, and this 
effect is blocked by pan-JI. A. CGNs were incubated for various periods of time up to 8 
h with ToxB in control medium. Cells were lysed, and proteins were resolved by SDS-
PAGE and transferred to PVDF membranes. The blot was probed with antibodies against 
pSTAT3 (Tyr-705) or STAT3. The expression of pSTAT3 increased in response to 
ToxB. B. CGNs were incubated for 6 or 8 h in control (Con) medium ± ToxB (40 ng/ml) 
or ToxB + pan-JI (1 µm). Cell lysates were resolved by SDS-PAGE, and proteins were 
transferred to PVDF membranes. The blot was probed with antibodies against pSTAT3 
(Tyr-705) or STAT3. The pan-JI inhibitor blocked ToxB-induced STAT3 




2.4.5 The reputed STAT3 inhibitor JSI-124 protects CGNs from ToxB-induced apoptosis 
 To further define the potential role of STAT3 in the proapoptotic pathway 
activated downstream of Rac inhibition, we examined whether or not the reputed STAT3 
inhibitor JSI-124 (Blaskovich et al., 2003) exerted a protective effect in ToxB-treated 
CGNs (Fig. 2.5A). Following a 24-h incubation period with ToxB alone, many CGNs 
displayed condensed and/or fragmented nuclei consiste t with apoptosis. In contrast, 
CGNs co-incubated with JSI-124 were essentially completely protected from apoptosis, 
and their nuclei were morphologically similar to those in control cells (Fig. 2.5B). 
Inclusion of JSI-124 reduced CGN apoptosis in the pr sence of ToxB to ~10% (Fig. 
2.5C). These data support a model in which a proapoptotic JAK/STAT3 pathway 






Figure 2.5 The reputed STAT3 inhibitor, JSI-124, protects CGNs from ToxB-
induced apoptosis. A. Molecular structure of JSI-124. B. CGNs were incubated for 24 h 
in control (Con) medium ± ToxB (40 ng/ml) or ToxB + JSI-124 (JSI; 5 µm). Cells were 
fixed, and their nuclei were stained with Hoechst dye. CGNs treated with ToxB exhibited 
significantly more condensed and/or fragmented nuclei than control CGNs. CGNs co-
incubated with JSI-124 were significantly protected from apoptosis, and their nuclei were 
morphologically similar to those of control cells. Scale bar, 10 µm. C. Quantification of 
apoptosis in CGNs treated with ToxB or ±JSI-124. Values are mean ± S.E. JSI-124 
significantly protected CGNs from ToxB-induced apoptosis. **, p < 0.01 compared with 
control; ††, p < 0.01 compared with ToxB. Values are mean ± S.E. for 5 independent 




2.4.6 Phosphorylated STAT3 does not translocate into nucleus of CGNs following 
treatment with ToxB, and additional STAT3 inhibitors do not protect CGNs from 
apoptosis induced by ToxB 
 To further investigate the role of STAT3 in apoptosis, we examined whether or 
not pSTAT3 translocates into the nucleus following ToxB treatment. Nuclear 
fractionation experiments demonstrated that althoug STAT3 was tyrosine 
phosphorylated pSTAT3 remained cytosolic following ToxB targeted inhibition of Rac 
(Fig. 2.6A). Furthermore, two additional STAT3 inhibitors, STA-21 and a STAT3 
inhibitory peptide, did not protect CGNs from ToxB-induced apoptosis (Fig. 2.6, B and 
C). These results indicate that STAT3 does not directly regulate apoptosis downstream of 
Rac inhibition. This finding was particularly surprising as the selective STAT3 inhibitor 
JSI-124 exerted a neuroprotective effect in ToxB-treated CGNs. However, further 
evaluation of the effects of JSI-124 in CGNs revealed that this compound in fact had no 
significant inhibitory effect on ToxB-induced STAT3 phosphorylation (Fig. 2.6D). These 
data suggest that the mechanism by which JSI-124 protects CGNs from apoptosis is 
unrelated to attenuation of activated STAT3 and may involve a different member of the 




Figure 2.6 Phosphorylated STAT3 does not translocate into nucleus of CGNs 
following treatment with ToxB, and additional STAT3 inhibitors do not protect 
CGNs from apoptosis. A. CGNs were incubated in control (Con) medium ± ToxB (40 
ng/ml) for 8 h. Following incubation, the cells were fractionated into nuclear and 
cytosolic (cyto) fractions as described under “Experimental Procedur s.” A monoclonal 
antibody against pSTAT3 (Tyr-705) was used for Western blotting. pSTAT3 did not 
translocate into the nucleus following treatment wih ToxB. The purity of the nuclear 
fractions was verified by immunoblotting for LAP-2. B  CGNs were incubated for 24 h in 
control medium ± ToxB (40 ng/ml) or ToxB + STA-21 (20 µm). Cells were fixed, and 
nuclei were stained with Hoechst dye to quantify apoptosis. STA-21 did not protect 
CGNs from ToxB-induced apoptosis. Results shown are mean ± range (n = 2). C. CGNs 
were incubated for 24 h in control medium ± ToxB (40 ng/ml) or ToxB + STAT3 
inhibitory peptide (Inh Pep; 100 µm). Cells were fixed, and nuclei were stained with 
Hoechst dye to quantify apoptosis. STAT3 inhibitory peptide did not protect CGNs from 
ToxB-induced apoptosis. Results shown are mean ± range (n = 2). D. CGNs were 
incubated for 24 h in control medium ± ToxB (40 ng/ml), JSI-124 (JSI; 5 µm), or ToxB + 
JSI-124. The cells were lysed, and proteins were separated by SDS-PAGE and transferred 
to PVDF membranes. Blots were probed for pSTAT3 (Tyr-705). ToxB increased the 
expression of pSTAT3. This effect was not blocked by co-incubation with JSI-124. NS, 
nonspecific band shown to indicate equal protein loading. Values are mean ± range for 2 
independent experiments. I acknowledge Alex Loucks for assistance with generating data 
for this figure. 
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2.4.7 Tyrosine phosphorylation of STAT5 in response to ToxB in CGNs is blocked by JSI-
124 and putative STAT5 inhibitor roscovitine 
 Recent evidence demonstrates a necessary role for STAT5 in apoptosis induced 
by oncostatin M in osteosarcoma cells (Chipoy et al., 2007). In addition, both STAT5 
isoforms have been implicated in the down-regulation of the prosurvival Bcl-xL protein 
in thymocytes (Nelson et al., 2004). Therefore, we next examined STAT5 and found that 
STAT5 was tyrosine phosphorylated in ToxB-treated CGNs. Interestingly, although 
blotting for total STAT5 clearly showed the presenc of both STAT5A (94 kDa) and 
STAT5B (92 kDa) in CGNs (Fig. 2.7A, lower blot), Western blots for phospho-STAT5 
only indicated a single tyrosine phosphorylated isoform in response to ToxB (Fig. 2.7A, 
upper blot). Therefore, we next sought to determine whether STAT5A or STAT5B was 
phosphorylated in response to ToxB. To establish which STAT5 isoform was 
phosphorylated, we compared lysates that were immunoprecipitated for either STAT5A 
or STAT5B with whole cell lysates and Western blotted for total STAT5. Using this 
approach, we were able to determine where the STAT5A and STAT5B isoforms were 
detected by immunoblot (Fig. 2.7B, left panel). Despite efficient immunoprecipitation of 
each of the STAT5 isoforms from CGNs using isoform-specific antibodies, we were not 
able to observe tyrosine phosphorylation of either isoform in response to ToxB. However, 
in whole cell lysates obtained following 8 h of ToxB treatment, we observed a 
pronounced increase in the tyrosine phosphorylation of the higher molecular weight 
STAT5A isoform but not STAT5B using a phosphospecific antibody to STAT5 (Fig. 
2.7B, right panel). The inability to observe STAT5A tyrosine phosphorylation following 
immunoprecipitation may reflect the physical association of STAT5A with one or more 
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protein tyrosine phosphatases, any one of which maybe insensitive to the phosphatase 
inhibitors present in our lysis buffer, as described previously (Chughtai et al., 2002; 
Rigacci et al., 2003). Our data are consistent withseveral previous reports demonstrating 
that STAT5A and STAT5B can be individually activated in a stimulus- and cell type-
specific manner (Rosen et al., 1996; al-Shami et al., 1997; Storz et al., 1999; Grimley et 
al., 1999; Faderl et al., 2003).  
 In addition, co-treatment of CGNs with either JSI-124 or the putative STAT5 
inhibitor roscovitine (Mohapatra et al., 2003) was sufficient to block the tyrosine 
phosphorylation of STAT5A in response to ToxB (Fig. 2.7, A and B). To further 
substantiate the involvement of STAT5 in ToxB-treated CGNs, we examined STAT5 
phosphorylation and localization by immunocytochemistry. In control CGNs, the 
expression of pSTAT5 detected by immunofluorescence was negligible. In contrast, 
following incubation of CGNs with ToxB, there was a profound increase in the 
immunoreactivity for pSTAT5, and this transcription factor was principally localized to 
CGN nuclei (Fig. 2.7C). Collectively, these data indicate that STAT5 is tyrosine 
phosphorylated in response to ToxB and localizes to the nucleus under these conditions 
to modulate gene transcription. Moreover, the tyrosine phosphorylation of STAT5 
appears to be specific for the STAT5A isoform and is sensitive to inhibition by either 




Figure 2.7 STAT5A shows enhanced tyrosine phosphorylation in response to ToxB 
in CGNs that is blocked by JSI-124 and STAT5 inhibitor roscovitine. A. CGNs were 
incubated in control (Con) medium ± ToxB (40 ng/ml) or ToxB + JSI-124 (JSI; 5 µm) for 
24 h. Cells were lysed, and proteins were resolved by SDS-PAGE and transferred to 
PVDF membranes. Blots were probed for pSTAT5 (Tyr-694) and total STAT5. STAT5 
was phosphorylated in response to ToxB, and this effect was blocked by JSI-124. B. 
CGNs were incubated in control medium ± ToxB (40 ng/ml) or ToxB + roscovitine 
(Rosc; 30 µm) for 24 h. Following incubation, cells were lysed and immunoprecipitated 
(IP; right panel) for either total STAT5A or STAT5B. Immunoprecipitated proteins and a 
lane containing the whole cell lysate (WCL) were resolved by SDS-PAGE and transferred 
to PVDF membranes. Blots were probed for total STAT5. In the left panel, proteins were 
lysed following a 24-h incubation period and resolved by SDS-PAGE. Next, proteins 
were transferred to PVDF membranes. Blots were probed for pSTAT5 (Tyr-694) and 
total STAT5. STAT5 was phosphorylated in response to ToxB, and this effect was 
blocked by roscovitine. NS, nonspecific band shown to indicate equal protein loading; 
5A, STAT5A; 5B, STAT5B. C. CGNs were incubated in control medium ± ToxB (40 
ng/ml) for 24 h. Cells were fixed and incubated with a polyclonal antibody against 
pSTAT5 (Tyr-694; shown in green). Nuclei were stained with DAPI (shown in blue). 




2.4.8 Roscovitine significantly protects CGNs from ToxB-induced apoptosis 
 Consistent with STAT5 playing a key role in ToxB-induced apoptosis, CGNs co-
treated with ToxB and roscovitine displayed healthy, intact nuclei (Fig. 2.8A). 
Quantification of these results shows that roscovitine significantly protected CGNs from 
ToxB-induced apoptosis (Fig. 2.8B). In addition, ToxB treatment for 24 h resulted in the 
cleavage of procaspase-3 to its active fragments, an effect largely attenuated by 
roscovitine (Fig. 2.8C). Generally, roscovitine is u ed to suppress the cell cycle through 
inhibition of cyclin-dependent kinases (CDKs) (Edamatsu et al., 2000). To ensure that the 
protection conferred by roscovitine was not through CDK suppression but was a result of 
STAT5 inhibition, CGNs were also treated with ToxB ± purvalanol A, a closely related 
CDK inhibitor. Although remarkably similar in structure, purvalanol A did not protect 
CGNs from ToxB-induced apoptosis and in fact signifcantly enhanced cell death (Fig. 
2.8D). These results suggest that the neuroprotective effects of roscovitine are unrelated 





Figure 2.8 Roscovitine significantly protects CGNs from ToxB-induced apoptosis. A. 
CGNs were incubated for 24 h in control (Con) medium ± ToxB (40 ng/ml) or ToxB + 
Roscovitine (Rosc; 30 µm). Following incubation, cells were fixed, and the nuclei were 
stained with Hoechst dye. Scale bar, 10 µm. B. Quantification of apoptosis in CGNs 
treated with ToxB alone or co-treated with roscovitine. Values are mean ± S.E. (n = 6). 
Roscovitine significantly protected CGNs from ToxB-induced apoptosis. **, p < 0.01 
compared with control; ††, p < 0.01 compared with ToxB. C. CGNs were treated as 
described in A and lysed. Proteins were separated by SDS-PAGE and tr sferred to 
PVDF membranes. The membrane was immunoblotted (IB) for caspase-3. Roscovitine 
blocked the ToxB-induced processing of caspase-3 to its active fragments. fl, full length. 
D. CGNs were incubated for 24 h in control medium ± ToxB (40 ng/ml) or ToxB + 
purvalanol A (Purv; 30 µm). Following incubation, cells were fixed with 4% 
paraformaldehyde, and the nuclei were stained with Hoechst dye. Purvalanol A did not 
protect CGNs from ToxB-induced apoptosis. Values are mean ± S.E. for 3 independent 




2.4.9 Adenoviral dominant negative STAT5 protects CGNs from ToxB-induced apoptosis 
 As a more specific approach to definitively establish the proapoptotic role of 
STAT5 following disruption of Rac activity, we examined the neuroprotective effects of 
a dominant negative mutant of STAT5 containing a C-terminal truncation at residue 713 
that removes the entire transcriptional activation d main of STAT5 (Ad-DN STAT5; Ref. 
Wang et al., 1996). First, adenoviruses expressing either WT STAT5 or DN STAT5 were 
grown and overexpressed in HEK293AD cells, and these cells were compared with cells 
that were infected with the Ad-GFP control. Infection with Ad-WT STAT5 increased 
expression of full-length STAT5, and Ad-DN STAT5 appeared as a lower molecular 
weight form of STAT5 (Fig. 2.9A). Next, we infected CGNs with the Ad-GFP control, 
WT STAT5, and DN STAT5 and observed similar high level expression of the constructs 
(Fig. 2.9B). Importantly, none of the adenoviral constructs induced any significant 
increase in basal apoptosis of CGNs on their own (Fig. 2.9C). As we have consistently 
shown, ToxB treatment resulted in condensed and fragmented nuclei indicative of 
apoptosis. Not unexpectedly, preincubation of CGNs with WT STAT5 did not confer 
neuroprotection from ToxB treatment (Fig. 2.9E). However, CGNs preincubated with 
Ad-DN STAT5 and subsequently treated with ToxB displayed nuclear morphology 
strikingly more similar to that of control CGNs (Fig. 2.9E). Quantification of apoptosis 
revealed that inhibiting the transcriptional activity of endogenous STAT5 through 
overexpression of Ad-DN STAT5 significantly protectd CGNs from ToxB-induced 
apoptosis (Fig. 2.9D). The protective effect of Ad-DN STAT5 was not as complete as 
that with the chemical JAK/STAT inhibitors used previously. This was likely a reflection 
of the infection efficiency of CGNs, which we observ d to be 50–60% in cells infected 
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with Ad-GFP. These data highlight a novel proapoptotic function for STAT5 downstream 




Figure 2.9 Adenoviral dominant negative STAT5 protects CGNs from ToxB-
induced apoptosis. A. HEK293AD cells were infected for 48 h with an adenovirus 
carrying GFP (Ad-GFP), wild-type STAT5 (Ad-WT STAT5), or dominant negative 
STAT5 (Ad-DN STAT5). Cell lysates were separated by SDS-PAGE, transferred to 
PVDF membranes, and immunoblotted (IB) for STAT5 expression. There was a marked 
increase in STAT5 expression in HEK cells infected with either Ad-WT or Ad-DN 
STAT5. Endo, endogenous; trunc, truncated. B. CGNs were infected for 48 h with the
same adenoviruses as described in A, and cell lysates were probed for STAT5 expression. 
C. CGNs were incubated for 48 h with adenoviruses as described above. The cells were 
fixed, and the nuclei were stained with Hoechst. Apoptotic cells were scored as those 
with condensed and/or fragmented nuclei. There was no ignificant difference in basal 
apoptosis in CGNs infected with Ad-GFP, Ad-WT STAT5, or Ad-DN STAT5. D. CGNs 
were infected for 48 h with either Ad-WT STAT5 or Ad-DN STAT5. After the initial 24 
h of incubation, each experimental condition was treated ±ToxB (40 ng/ml) for 24 h. At 
the end of the incubation, cells were fixed, and nuclei were stained with DAPI. Apoptotic 
cells were scored as those with condensed and/or fragmented nuclei. The -fold change in 
apoptosis for ToxB-treated cells versus control (Con) cells was quantified. CGNs 
incubated with dominant negative STAT5 were protected from ToxB-induced apoptosis. 
Data shown represent the mean ± S.E. for n = 3 experiments. **, p < 0.01 versus WT 
STAT5. E. CGNs were incubated as describe in D. Cells were then fixed, and nuclei were 
stained with Hoechst dye. Images shown are representative of three independent 
experiments. Scale bar, 10 µm. Values are mean ± S.E. for 6 independent experiments. 
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2.4.10 STAT5 transcriptionally represses Bcl-xL during ToxB-induced apoptosis 
 Recent studies suggest that under certain conditios STAT5 transcriptionally 
represses prosurvival members of the Bcl-2 family (Chipoy et al., 2007; Nelson et al., 
2004; Moucadel and Constantinescu, 2005). Disturbances in the ratio of these proteins to 
their corresponding proapoptotic family members caninduce apoptosis. The prosurvival 
members of the Bcl-2 family have an important and well documented role in promoting 
cell survival through binding and inactivating the proapoptotic members of their same 
family (Korsmeyer et al., 1993). To evaluate whether STAT5 similarly represses Bcl-2 
family proteins in Rac-inhibited CGNs, we isolated and purified DNA with a ChIP grade 
antibody to STAT5 in control CGNs or those treated with ToxB for 8 h. There was no 
significant difference between STAT5 bound to the promoter region of Bcl-2 in control 
versus ToxB-treated CGNs (data not shown). In the case of Bcl-xL, the input levels of 
Bcl-xL promoter DNA amplified from the non-immunoprecipitated control and ToxB-
treated CGNs were not significantly different. However, the cycle threshold values 
obtained for amplification of the Bcl-xL promoter fom STAT5 ChIP samples were 
significantly lower for ToxB treatment compared with the control, indicating a significant 
increase in STAT5 binding to the Bcl-xL promoter in Rac-inhibited CGNs (Fig. 2.10A). 
Indeed, we report that there was an apparent although not statistically significant 9.5 ± 
4.1 (n = 4)-fold increase in STAT5 recruitment to the Bcl-xL promoter in response to 
ToxB treatment after 8 h (Fig. 2.10B). Consistent with these data, Bcl-xL expression was 
down-regulated at 16 h and more significantly at 24 h after ToxB treatment (Fig. 2.10C). 
In agreement with a relatively slow mechanism of death due to the transcriptional 
repression of Bcl-xL, we report that ToxB did not induce caspase-3 activation or 
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significant apoptotic morphology until 16 h of incubation after STAT5 is bound to the 




Figure 2.10 STAT5 transcriptionally represses Bcl-xL during ToxB-induced 
apoptosis. A. CGNs were incubated in control (Con) medium ± ToxB (40 ng/ml) for 8 h. 
As a control for ChIP experiments (“Input”), ChIP-quantitative PCR was performed as 
described under “Experimental Procedures” in the absence of the STAT5 antibody to 
determine the total concentration of input Bcl-xL promoter DNA. The graph shows the 
mean ± S.E. of the results of four independent experiments. The concentration of input 
DNA did not differ significantly between the control and ToxB samples. ChIP: STAT5, 
CGNs were incubated in control medium ± ToxB (40 ng/ml) for 8 h. The relative binding 
of STAT5 to the Bcl-xL promoter was assessed via ChIP-quantitative PCR analysis as 
described under “Experimental Procedures.” The graph shows the mean ± S.E. of the 
results for four independent experiments. STAT5 binding to the Bcl-xL promoter was 
significantly increased in response to ToxB treatment for 8 h. *, p < 0.05 versus control 
evaluated by a two-tailed Student's t test. B. The -fold enrichment of STAT5 recruitment 
to the Bcl-xL promoter was quantified from the cycle threshold (Ct) value. STAT5 
binding to the promoter region of Bcl-xL increased 9.5 ± 4.1-fold in response to 8-h 
ToxB treatment, although it was not statistically significant. C. CGNs were incubated for 
0, 16, and 24 h with ToxB (40 ng/ml). Cells were thn lysed, and proteins were resolved 
by SDS-PAGE and transferred to PVDF membranes. The membrane was probed with an 
antibody against Bcl-xL. Subsequently, the blot was stripped and reprobed for active 
caspase-3 and actin (loading control). Bcl-xL expression decreased in response to ToxB, 
and active caspase-3 expression increased. The valus above the Bcl-xL blot represent 
optical densities (O.D.) of the Bcl-xL expression. The normalized optical density for the 




 Several studies have demonstrated a critical role for Rho GTPases (i.e. Rac, Rho, 
and Cdc42) in promoting neuronal survival (Kobayashi et al., 2004; Kanekura et al., 
2005; Cheung et al., 2007). Consistent with these findings, we have shown previously 
that Rac activity is critical for the survival of primary CGNs (Linseman et al., 2001), and 
Rac signaling functions to repress a proapoptotic JAK/STAT pathway in these neurons 
(Loucks et al., 2006). Similarly, studies from other groups support a role for the 
activation of a prodeath JAK/STAT pathway in neurons (Colodner and Feany, 2010; 
Mäkelä et al., 2010). For instance, Takagi et al. (2002) reported that STAT1 was 
phosphorylated on activating tyrosine and serine residues and translocated into neuronal 
nuclei following ischemic brain injury in mice. Moreover, STAT1 KO mice displayed a 
decrease in the volume of ischemic brain injury and re uced TUNEL staining when 
compared with WT mice subjected to middle cerebral a tery occlusion. Thus, STAT1 can 
play a proapoptotic role in neurons exposed to ischemic stress. In a similar manner, 
cortical neurons cultured from STAT1 KO mice showed marked resistance to interferon 
γ-stimulated neurotoxicity of the human immunodeficincy virus type 1 proteins gp120 
and Tat (Giunta et al., 2006). A more recent study demonstrated that exposure of SH-
SY5Y neuroblastoma cells to interferon β induced STAT1 tyrosine phosphorylation and 
caspase-dependent apoptosis (Dedoni et al., 2010). Both STAT1 activation and caspase 
activation were prevented by a JAK inhibitor. Similar to STAT1, STAT3 also has the 
potential to have a proapoptotic effect in neurons u der certain conditions. Wan et al.
(2010) recently showed that a proapoptotic Tyk2/STAT3 pathway mediates β-amyloid 
peptide-induced neuronal death. Specifically, siRNA knockdown of STAT3 protected 
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PC12 cells from β-amyloid, and a STAT3 inhibitory peptide protected cultured cortical 
neurons. Finally, cortical neurons isolated from Tyk2-null mice were significantly less 
sensitive than WT neurons to β-amyloid-induced apoptosis. Collectively, these studies 
demonstrate that both STAT1 and STAT3 have the potential of acting as proapoptotic 
mediators in neurons under specific pathological conditions. In contrast to these previous 
reports, we found that although total STAT1 levels are up-regulated and STAT3 is 
activated via tyrosine phosphorylation in response to ToxB neither transcription factor is 
responsible for the neuronal apoptosis induced in CGNs by inhibition of Rac function.  
 Instead, we report that ToxB induces the enhanced tyrosine phosphorylation of 
STAT5, which subsequently translocates into the nucleus of CGNs. Interestingly, we 
found that the phosphorylation of STAT5 was prevented by the reputed STAT3 inhibitor 
JSI-124. This finding is perhaps not surprising given that JSI-124 has been reported to 
exert effects outside of STAT3 inhibition (Graness and Goppelt-Struebe, 2006). In fact, 
this compound was recently shown to inhibit the neuroprotective effects of growth 
hormone against glutamate-induced toxicity in hippocampal neurons, an effect that is 
dependent on STAT5 activity (Byts et al., 2008). In addition to the neuroprotective 
effects of JSI-124, we report that roscovitine similarly inhibits STAT5 phosphorylation 
induced by ToxB and protects CGNs against ToxB targeted Rac inhibition. The effects of 
roscovitine were dissociated from its effects as a CDK inhibitor because the similarly 
structured compound purvalanol A did not protect CGNs from ToxB. Our data with 
roscovitine are consistent with a previous study showing its ability to suppress STAT5 
activation in a leukemia cell line (Mohapatra et al., 2003). Finally, we show that 
adenoviral infection with a dominant negative mutant of STAT5, but not WT STAT5, 
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significantly protects CGNs from Rac inhibition with ToxB. To our knowledge, these 
findings are novel in that they are the first to identify a proapoptotic function for STAT5 
in neurons.  
 Our data indicate that of the two STAT5 isoforms only STAT5A is activated via 
phosphorylation in CGNs exposed to ToxB-mediated Rac blockage. Although the two 
isoforms are highly homologous, this is consistent with several previous reports that have 
revealed isoform-specific STAT5 activation. Similar to our results in CGNs, JAK/STAT 
signaling has been shown to induce caspase-dependent apoptosis in response to 
granulocyte-macrophage colony-stimulating factor (GM-CSF) in OCIM2 acute myeloid 
leukemia cells (Faderl et al., 2003). However, although GM-CSF has been shown to 
preferentially activate STAT5A in human monocytes (Rosen et al., 1996), this factor was 
shown to induce specific STAT5B signaling in human neutrophils (al-Shami et al., 1997). 
In a similar manner, insulin was demonstrated to aciv te STAT5B, but not STAT5A, in 
Kym-1 rhabdomyosarcoma cells (Storz et al., 1999). Furthermore, targeted gene 
disruptions of either STAT5A or STAT5B in mice have shown functional differences in
vivo. For example, deletion of STAT5A disrupts prolactin-derived mammary gland 
maturation, whereas disruption of STAT5B diminishes growth hormone effects on 
hepatic function and body mass in male mice (Grimley et al., 1999). Thus, our data are 
consistent with several previous reports highlighting isoform-specific activation and 
functions of STAT5.  
 STAT5 is activated by many diverse cytokines and growth factors, and it is well 
established that this transcription factor has an important role throughout the body. 
Although few studies have examined the role of STAT5 in the central nervous system, 
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the majority of reports are paradoxical to our present study and suggest that STAT5 
chiefly exerts a prosurvival effect in neurons. For example, STAT5 is required in 
conjunction with Akt to mediate the neurotrophic and europrotective effects of both 
growth hormone in hippocampal neurons (Byts et al., 2008) and erythropoietin in 
differentiated neuroblastoma cells (Um and Lodish, 2006). Furthermore, STAT5 was 
shown to elicit a prosurvival effect via induction f Bcl-2 and Bcl-xL in neural progenitor 
cells subjected to apoptotic stimulation (Choi et al., 2011). Thus, the relatively few 
studies conducted on STAT5 in neuronal models indicate that it mainly functions to 
transmit prosurvival signals. However, critical studies in non-neuronal cells suggest that 
the downstream effects of STAT5 are much more complex. STAT5 sensitizes 
osteosarcoma cells to apoptosis following treatment with oncostatin M (Chipoy et al., 
2007). Moreover, in a mouse model of familial amyotrophic lateral sclerosis, a JAK3 
inhibitor was shown to extend the lifespan of mutant mice when compared with those that 
did not receive the inhibitor. Although the effects of this inhibitor on the activation of 
specific STAT family members was not evaluated in th s particular study, JAK3 has been 
shown to activate STAT5 in various studies (Bingisser et al., 1998; Cavalcanti et al., 
2010; Martín et al., 2010). In evaluating various JAK isoform-selective inhibitors, we did 
not observe any significant inhibition of ToxB-induced apoptosis in CGNs except with a 
pan-JI. Thus, our data suggest a possible contribution of Tyk2 or multiple JAK isoforms 
in the apoptosis of neurons subjected to Rac inhibition. In conjunction with our present 
findings, these previous studies suggest that STAT5 functions in a cell type- and 
stimulus-specific manner, and the specific role of JAK/STAT5 in the central nervous 
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system and in particular with respect to neuronal survival is likely determined by many 
factors.  
 Although we have identified Rac as a repressor of a proapoptotic JAK/STAT5 
pathway, the mechanism of STAT5 activation following Rac inhibition remains 
incompletely understood. Suppressors of cytokine signal ng (SOCS) exist as endogenous 
STAT inhibitors (Krebs and Hilton, 2001; Cooney, 200 ), and previous evidence 
suggests that SOCS protein expression can be regulat d by ERK (Terstegen et al., 2000; 
Borland et al., 2009). This is consistent with our previous finding that a prosurvival 
MEK/ERK pathway functions downstream of Rac GTPase to actively repress 
proapoptotic JAK/STAT signaling in healthy CGNs (Loucks et al., 2006). Whether 
SOCS proteins are indeed mediators of the Rac-depennt repression of proapoptotic 
JAK/STAT signaling in neurons remains to be investigated.  
 In agreement with our work identifying a proapoptotic JAK/STAT5 pathway in 
CGNs, recent examination of the genetic targets of STAT5 demonstrates transcriptional 
regulation of prosurvival members of the Bcl-2 family. For example, STAT5 has been 
shown to negatively regulate the levels of Bcl-2 in osteosarcoma cells sensitized to 
undergo apoptosis (Chipoy et al., 2007). Similarly, both STAT5 isoforms were shown to 
bind to the promoter region of Bcl-x, a gene that is ranscribed into prosurvival Bcl-xL 
and proapoptotic Bcl-extra short (Bcl-xS) (Boise e al., 1993; Nelson et al., 2004; 
Moucadel and Constantinescu, 2005). Therefore, it was of interest to determine whether 
Bcl-2 and/or Bcl-xL were transcriptional targets of STAT5 in CGNs subjected to Rac 
inhibition with ToxB. Our ChIP data show that STAT5 is recruited to the Bcl-xL 
promoter in ToxB-treated CGNs. These results suggest that STAT5 may transcriptionally 
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repress Bcl-xL to tip the delicate balance between prosurvival and proapoptotic Bcl-2 
proteins toward apoptosis. Consistent with this interpretation, we observed caspase-3 
activation and classical apoptotic morphology subsequent to down-regulation of Bcl-xL 
protein levels. Although we show that STAT5 binding to the promoter region of Bcl-xL 
increases in response to Rac inhibition, an alternaive mechanism by which STAT5 may 
mediate transcriptional repression of Bcl-2 family proteins in the nucleus is through 
competitive binding to the transcriptional co-activa or p300/cAMP-response element-
binding protein (CREB)-binding protein (CBP) (Zhu et al., 1999; Zhang et al., 2008). At 
the present time, we cannot exclude this as a possible mechanism of STAT5-dependent 
transcriptional repression of Bcl-xL during Rac inhibition.  
 Another potential mechanism by which STAT5 has been proposed to repress Bcl-
xL transcription involves a cooperative interaction with the glucocorticoid receptor (GR). 
A recent report found that glucocorticoid treatment i  lymphoid cells inhibited the 
transcription of Bcl-xL and decreased the ratio of Bcl-xL to the proapoptotic Bcl-xS in a 
STAT5B-dependent manner to induce apoptosis (Rocha-Viegas et al., 2006). Conversely, 
another report found that the GR can interact with STAT5 to up-regulate Bcl-xL as part 
of a prosurvival pathway activated by the GR agonist methylprednisolone in 
oligodendrocytes (Xu et al., 2009). Given the evidence suggesting that the GR can act in 
a cooperative manner with STAT5 to regulate the transcription of Bcl-xL, we sought to 
determine whether or not the GR was involved in STAT5 -mediated apoptotic signaling 
in CGNs subjected to ToxB treatment. In CGNs exposed to ToxB, the GR antagonist 
mifepristone provided no significant protection, indicating that the STAT5-dependent 
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effects on Bcl-xL transcription are likely GR-independent in this cell system (data not 
shown).  
 In summary, we show that ToxB-induced inactivation of Rac GTPase results in 
the derepression of a novel proapoptotic JAK/STAT5 pathway. Although STAT1 was 
induced and STAT3 was phosphorylated following ToxB treatment, neither protein was 
responsible for inducing apoptosis of CGNs downstream of Rac inhibition. Rather, our 
data support a model in which ToxB-induced Rac inhibition in CGNs activates a novel 
proapoptotic JAK/STAT5 pathway that, following STAT5A phosphorylation and 
translocation to the nucleus, results in the transcriptional repression of prosurvival Bcl-xL 
and subsequent activation of caspase-3 and apoptosis. To our knowledge, our findings are 
novel in that they are the first to demonstrate a proa optotic function for a JAK/STAT5 
pathway in neurons.  
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CHAPTER THREE: NEURONAL APOPTOSIS INDUCED BY SELECTIVE 
INHIBITION OF RAC GTPASE VERSUS GLOBAL SUPRESSION OF RHO 
FAMILY GTPASES IS MEDIATED BY ALTERATIONS IN DISTINCT 
MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING CASCADES 
 
3.1 Abstract 
Rho family GTPases play integral roles in neuronal differentiation and survival. We 
have previously shown that Clostridium difficile toxin B (ToxB), an inhibitor of RhoA, 
Rac1, and Cdc42, induces apoptosis of cerebellar granule neurons (CGNs). In the current 
study, we compared the effects of ToxB to a selectiv  inhibitor of the Rac-specific 
guanine nucleotide exchange factors (GEFs), Tiam1 and Trio (NSC23766). In a manner 
similar to ToxB, selective inhibition of Rac induces CGN apoptosis that is associated 
with enhanced caspase-3 activation and reduced phosphorylation of the Rac effector, 
p21-activated kinase (PAK). In contrast to ToxB, caspase inhibitors do not protect CGNs 
from targeted inhibition of Rac. Also dissimilar toToxB, selective inhibition of Rac 
neither inhibits MEK1/2/ ERK1/2 nor activates JNK/c-Jun. Targeted inhibition of Rac 
instead suppresses distinct MEK5/ERK5, p90Rsk and Akt-dependent signaling cascades 
known to regulate the localization and expression of the Bcl-2 homology-3 domain 
(BH3)-only protein Bad. Adenoviral expression of a constitutively active mutant of 
MEK5 is sufficient to attenuate neuronal cell death induced by selective inhibition of Rac 
with NSC23766, but not apoptosis induced by global inhibition of Rho GTPases with 
ToxB. Collectively, these data demonstrate that global suppression of Rho family 
GTPases with ToxB causes a loss of MEK1/2/ERK1/2 signal ng and activation of JNK/c-
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Jun, resulting in diminished degradation and enhanced transcription of the BH3-only 
protein Bim. In contrast, selective inhibition of Rac induces CGN apoptosis by repressing 
unique MEK5/ERK5, p90Rsk, and Akt-dependent pro-survival pathways, ultimately 
leading to enhanced expression, dephosphorylation, and mitochondrial localization of 
pro-apoptotic Bad.  
3.2 Introduction 
Rho family GTPases belong to the Ras superfamily of m nomeric G-proteins and 
include the well described proteins Rac, Rho, and Cdc42.  While Rho GTPases are best 
recognized for their prominent roles in regulating actin cytoskeletal dynamics, more 
recent studies have demonstrated an important role for Rho GTPases in regulating 
neuronal survival (Linseman and Loucks, 2008).  Indeed, apoptosis induced by inhibitors 
of 3-HMG-CoA reductase (statins) was correlated with loss of plasma membrane-
associated Rho GTPase family members in rat cortical neurons (Tanaka et al., 2000), and 
downregulation of Rho family GTPases is closely associated with an increase in neuronal 
apoptosis (Desagher et al., 2005).  More recently, Rac has been highlighted as a specific 
member of the Rho GTPase family critical for maintai ing neuronal survival. For 
example, prior studies demonstrated that either dominant negative Rac expression or 
siRNA-mediated knockdown of the Rac GEF, Alsin (ALS2), induces apoptosis of 
cultured motor neurons (Topp et al., 2004; Jacquier et al., 2006).  The critical 
involvement of Rac in neurodegeneration is further evidenced by studies demonstrating 
that loss-of-function mutations in ALS2 are causative in juvenile onset ALS (Yamanaka 
et al., 2003). Collectively, these data highlight Rac as a crucial modulator of neuronal 
74 
 
survival and suggest that Rac dysregulation may underlie some forms of 
neurodegenerative disease. 
In previous studies, we have examined the neurotoxic effects of the large 
cytotoxin Clostridium difficle toxin B (ToxB) in CGNs.  ToxB monoglucosylates a key 
threonine residue in the switch 1 region of Rho GTPases, preventing Rho, Rac, and 
Cdc42 from interacting with their downstream effectors (Just et al., 1995). Global 
inhibition of Rho GTPases with ToxB induces CGN apoptosis through dysregulation of 
critical pro-survival and pro-apoptotic signaling cas ades (Loucks et al., 2006; 
Stankiewicz et al., 2012).  Specifically, ToxB induces downregulation of Rac1 GTPase, 
as well as elements of a Rac-dependent mitogen-activated protein (MAP) kinase 
pathway, including the p21-activated kinase (PAK), MAP kinase kinase (MEK)1/2, and 
extracellular signal-regulated kinase (ERK)1/2 signaling cascade. Inhibition of this 
pathway in CGNs induces apoptosis, in part, through reduced degradation of the pro-
apoptotic BH3-only protein Bim.  In addition to repssion of a pro-survival 
MEK1/2/ERK1/2 signaling cascade, we have previously reported that broad Rho GTPase 
inhibition with ToxB induces CGN death through activa on of a c-Jun N-terminal kinase 
(JNK)/c-Jun pathway that stimulates transcription of Bim (Le et al., 2005). Thus, ToxB 
globally suppresses Rho GTPase function and induces CGN apoptosis through 
dysregulation of specific MAP kinase signaling cascades, leading to enhanced expression 
and diminished degradation of the pro-apoptotic BH3-only protein Bim.   
The focus of the current study was to compare the effects of ToxB on neuronal 
survival to those of a more targeted inhibitor of Rac GTPase. While ToxB has been 
shown to inhibit Rac, Rho, and Cdc42, NSC23766 suppresses a more discrete pool of 
75 
 
Rho family GTPases through inhibition of the Rac-specific GEFs, Tiam1 and Trio, which 
are two of the most prominent regulators of Rac in the brain (Schmidt and Hall, 2002). 
The application of this targeted Rac inhibitor allows for a refined understanding of the 
Rho-family GTPase-regulated signaling pathways essential to neuronal survival. 
Contrary to our results with ToxB, we demonstrate that targeted inhibition of Rac with 
NSC23766 does not turn off pro-survival MEK1/2/ERK1/2 signaling in CGNs, nor does 
it activate the JNK/c-Jun cascade.  Instead, NSC23766 induces apoptosis via repression 
of the distinct MAP kinase pathway, MEK5/ERK5. Further establishing these findings, 
adenoviral expression of constitutively active MEK5 significantly protects CGNs from 
NSC23766-mediated Rac inhibition but is unable to protect CGNs from ToxB-mediated 
global Rho GTPase inhibition. We report that loss of MEK5/ERK5 signaling in 
NSC23766-treated CGNs results in deactivation of the downstream effectors p90Rsk and 
Akt, leading to induction, dephosphorylation, and mitochondrial localization of the BH3-
only, pro-apoptotic protein Bad. These findings arenovel in that they are the first to 
distinguish the precise MAP kinase signaling pathways that regulate neuronal apoptosis 
in response to selective inhibition of Rac versus global suppression of Rho family 
GTPases. 
3.3 Materials and Methods 
3.3.1 Reagents 
NSC23766, JNK inhibitor II (SP600125), caspase inhibitors BOC, LEHD, and QVD 
(Non-O-Methylated) were obtained from Calbiochem (San Diego, CA). Clostridium 
difficile Toxin B was prepared using a method published previously (Just et al., 1995). 
The monoclonal antibody for active Rac1 was procured from NewEast Biosciences 
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(Malvern, PA).  Hoechst dye 33258 and 4,5-di-amidino-2-phenylindole (DAPI) were 
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal antibody to 
active caspase-3 was from Promega (Madison, WI). Cy3- and FITC-conjugated 
secondary antibodies for immunoflourescence were from Jackson Immunoresearch 
Laboratories (West Grove, PA). The CellQuanti-MTT viability assay kit was obtained 
from Bioassay Systems (Hayward, CA). The monoclonal β-tubulin antibody conjugated 
to Alexa Fluor® 555, polyclonal antibodies for pPAK1 (Ser144)/pPAK2 (Ser 141), 
PAK1/2/3, pERK1/2 (Thr202/Tyr204), pMEK1/2 (Ser217/ 221), pERK5 
(Thr218/Tyr220), pAkt (Ser473), ERK5, and the monoclonal antibodies against Actin, c-
Jun, and pBad (Ser136), pP90Rsk (Ser380) were purchased from Cell Signaling 
Technology (Beverly, MA). Polyclonal antibodies for pMEK5 (S311/T315) and MAP2 
monoclonal were obtained from Abcam (Cambridge, MA).  The monoclonal antibody 
used to detect β-tubulin was purchased from Sigma (St. Louis, MO), The rabbit 
monoclonal antibody for Bad (N-term) was purchased from Millipore (Billerica, MA). 
Horseradish peroxidase-linked secondary anti-bodies and reagents for enhanced 
chemilumine-scence detection were from Amersham Bio-sc ences (Piscataway, NJ, 
USA).  
3.3.2 CGN culture 
CGNs were isolated from 7-day old Sprague-Dawley rat pups of both sexes (15-
19 g) as described previously (Linseman et al., 2001). Briefly, neurons were plated on 35-
mm diameter plastic dishes coated with poly-L-lysine at a density of approximately 2.0 x 
106 cells/mL in basal modified Eagle’s medium containing 10% fetal bovine serum, 
25mM KCl, 2mM L-glutamine, and penicillin (100 units/mL)/streptomycin (100 µg/mL) 
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(Life Technologies, Grand Island, NY).  At 24 h after plating the CGNs, cytosine 
arabinoside (10 µM) was added to the culture medium to limit the growth of non-
neuronal cells. In general, experiments were performed after 6-7 days in culture. 
3.3.3 Cell lysis and immunoblotting 
Following treatments as described in the Results section, cell lysates were 
prepared for Western blotting as previously described (Loucks et al., 2006). The protein 
concentration of the samples was determined using a protein assay kit (BCA, 
Thermoscientific, PA, USA) and SDS-polyacrylamide gel electrophoresis was performed 
using equal amounts of protein followed by transfer to polyvinylidene difluoride (PVDF) 
membranes (Amersham Biosciences).  The entire PVDF membranes, once processed, 
were blocked in PBS (pH 7.4) containing 0.1% Tween 20 (PBS-T) and 1% bovine serum 
albumin (BSA) for 1 h at room temperature (25°C).  Subsequently, membranes were 
incubated for 1 h with primary antibodies diluted in blocking solution. Excess primary 
antibody was removed by washing the membranes with PBS-T five times over 25 min. 
The corresponding horseradish peroxidase-conjugated secondary antibodies diluted in 
PBS-T were incubated with the membranes for 1 h following the washes. Excess 
secondary antibody was removed by washing with PBS-T five times over 25 min. 
Immunoreactive proteins were detected by enhanced ch miluminescence.  
3.3.4 Immunofluorescence microscopy 
 After treatment, CGNs were washed once with PBS (1 mL/well) and then fixed 
in 4% paraformaldehyde (1 mL/well) for 1 h at room temperature (25°C). Cells were 
washed once with PBS (1 mL/well) and then permeabilized and blocked in 0.2% Triton 
X-100 and 5% BSA in PBS (pH 7.4). Primary antibodies were diluted in 2% BSA and 
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0.2% Triton X-100 in PBS. Cells were incubated in the primary antibody for 1 h at room 
temperature or overnight at 4°C depending on the antibody. After incubation, cells were 
washed five times in PBS (5 minutes per wash) and then incubated for 1 h at 25°C with 
Cy3- or FITC-conjugated secondary antibodies and DAPI diluted in 2% BSA and 0.2% 
Triton X-100 in PBS. Following the second incubation, neurons were washed an 
additional five times with PBS (5 minutes per wash) before the addition of anti-quench 
(0.1% p-phenylenediamine in 75% glycerol) in PBS. Fluorescent images were captured 
by using a 63x oil immersion objective on a Zeiss Axioplan 2 microscope equipped with 
a Cooke Sensicam deep-cooled charge-coupled device (CCD) camera and a Slidebook 
software-analysis program for digital deconvolution (I telligent Imaging Innovations, 
Inc., Denver, CO).  
3.3.5 Quantification of apoptosis 
Following treatment, Hoechst dye (8µg/mL, final cone tration) was added 
directly to each well and incubated at 25°C for 30 minutes to stain CGN nuclei. Cells 
were then washed with PBS (1mL/well) and fixed by incubation in 4% paraformaldehyde 
(in PBS) for 30 minutes at 25°C. Cells were subsequently washed twice with PBS 
(1mL/well). To quantify apoptosis CGNs displaying condensed chromatin or nuclear 
fragmentation were scored as apoptotic. Approximately 300 neurons were counted in a 
minimum of three 63x fields of a 35-mm dish, and final counts represent data collected 
from a minimum of three independent experiments performed in duplicate.  
3.3.6 MTT viability assay 
Following treatment, 187.5 µL of CellQuanti-MTT assy reagent (calculated at 15 
µL per 80 µL of culture medium) was added directly to each well. CGNs were incubated 
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for 4 h at 37°C in 10% CO2.  Blanks, wells containing control media alone, were 
incubated with 187.5 µL of assay reagent along with samples. Subsequently, the media 
was aspirated and DMSO was added (2mL/well). Following solubilization 
(approximately 10 minutes at room temperature), 200 µL of each blank or sample was 
diluted and mixed in spectrophotometer cuvettes containi g 800 µL of sterile water. 
Samples and blanks were made up in triplicate. Absorbance readings were taken at a 
wavelength of 570 nm. Data represent five independent experiments performed in 
triplicate. 
3.3.7 Adenovirus preparation and infection 
Adenoviral constitutively active MEK5 was purchased from Cell BioLabs (San 
Diego, CA) and Adenoviral GFP was a kind gift from Marja T. Nevalainen (Thomas 
Jefferson University, PA, USA) and was prepared as previously described (Ahonen et al., 
2003). CGNs were infected on day 5 in vitro with 35 moi (multiplicity of infection) of 
adenovirus carrying GFP or constitutively active MEK5. At 48 h post-infection, some 
cells were treated with 175 µM NSC23766 for an additional 48 h. At 72 h post-infection, 
another group of cells were treated with 60 ng/mL ToxB for an additional 24 h. At 96 h 
post-infection, cells were fixed for fluorescent imaging and quantification of apoptosis, as 
described above.  
3.3.8 Data analysis 
In general, western blotting observations were based upon three ind pendent 
experiments. Graphical data represent the mean ± SEM for the number of independent 
experiments performed (n). Statistical differences between the means of unpaired sets of 
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data were assessed by one-way ANOVA, and further analyzed using a post hoc Tukey’s 
test. A p-value of <0.05 was considered statistically significant. 
3.4 Results 
3.4.1 The specific Rac inhibitor NSC23766 induces inactivtion of Rac-GTP resulting in 
CGN apoptosis 
The targeted Rac inhibitor, NSC23766, selectively and reversibly hinders 
GDP/GTP exchange carried out by the Rac-specific guanine nucleotide exchange factors 
(GEFs), Tiam1 and Trio. Specifically, this cell-permeable pyrimidine compound targets a 
tryptophan within the GEF binding site, prohibiting Tiam1 and Trio from binding and 
activating Rac (Fig. 3.1) (Gao et al., 2004). Consistent with this mechanism of inhibition, 
CGNs incubated for 48 h with NSC23766 (200 µM) exhibited significantly decreased 
immuno-reactivity for active Rac (Rac-GTP) compared to control CGNs (Fig. 3.2A). The 
maintenance of an intact microtubule network, visual zed by β-tubulin and MAP2 
immunoreactivity, confirmed that the relative lack of Rac-GTP staining observed in 
NSC23766-treated cells was not due to the global absence or disruption of cellular 
components (Fig. 3.2B, upper panels). Moreover, examin tion of nuclei by Hoechst 
staining revealed significantly increased apoptotic cell death in NSC23766-treated CGNs 
compared to untreated controls as evidenced by nuclear fragmentation and/or 
condensation (Fig. 3.2B, lower panels and 3.2C). Collectively, these data indicate that the 
targeted inhibition of a select pool of Rac GTPase ctivated by Tiam1 and Trio is 




Figure 3.1 NSC23766 acts by specifically inhibiting the activation of Rac by GEFs 
Tiam1 and Trio. A. Chemical structure of NSC23766. B. The cell-perm able pyrimidine 
compound selectively and reversibly hinders GDP/GTP exchange carried out by the Rac-
specific guanine nucleotide exchange factors (GEFs), Tiam 1 and Trio. Specifically, 
NSC23766 targets a key tryptophan residue within the GEF binding site, prohibiting 





Figure 3.2 The specific Rac inhibitor NSC23766 reduces activation of Rac1, 
resulting in CGN apoptosis.  CGNs were incubated for 48 h in either control medium 
alone (Con) or containing NSC23766 (200 µM; NSC).  A. Cells were then fixed and their 
nuclei stained with DAPI. Active Rac1 was visualized using a monoclonal antibody that 
specifically detects Rac1-GTP and a FITC-conjugated secondary antibody. Scale bar = 10 
microns.  B. Cells were fixed and their nuclei stained with DAPI. The microtubule 
network was visualized using a monoclonal antibody for β-tubulin conjugated with Cy3 
Alexa Fluor 555 and a mouse monoclonal MAP2 antibody followed by a FITC-
conjugated secondary antibody. While the microtubule network remains largely intact, 
CGNs display condensed or fragmented nuclei characteristic of apoptosis following 
treatment with NSC23766.  Bottom panels: black and white images of DAPI-stained 
nuclei. Scale bar = 10 microns. C.Quantification of CGN apoptosis. Hoechst-stained 
CGNs displaying condensed and/or fragmented nuclei were scored as apoptotic. Data 
represent the mean ± SEM of four independent experiments. **Significantly different 
from control (p< 0.01). I acknowledge Anandi Ramaswami for assistance with 
generating data for this figure.  
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3.4.2 CGN death induced by NSC23766 is largely caspase-ind pendent 
To determine whether NSC23766-mediated CGN death occurs via a mechanism 
that is dependent upon activation of caspases, we examined activation of caspase-3 as its 
proteolytic cleavage signifies commitment to apoptotic cell death (Porter and Jänicke, 
1999). In agreement with this mechanism of cell death, CGNs treated with NSC23766 
displayed increased immunoreactivity for active (cleaved) caspase-3 (Fig. 3.3A). To 
definitively establish the involvement of caspase-3 activation in NSC23766-mediated 
CGN death, we next examined the potential protectiv effects of caspase inhibitors. CGN 
viability assessed by an MTT assay was notably reduc  in NSC23766-treated cells 
compared to untreated controls; however, inclusion of either BOC or QVD, pan-caspase 
inhibitors, had no apparent protective effects against this Rac inhibitor (Fig. 3.3B). In 
marked contrast, BOC and LEHD, a pan-caspase and caspase-9-selective inhibitor, 
respectively, significantly protected CGNs treated with the global Rho GTPase inhibitor 
ToxB (Fig. 3.3C). These data suggest that CGN death induced by targeted inhibition of 
Rac GTPase occurs via a mechanism that involves a dispensable activation of caspase-3. 
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Figure 3.3 CGN death induced by NSC23766 is largely caspase-independent, unlike 
Toxin B-induced apoptosis. A. Cells were incubated for 48 h in either control medium 
alone (Con) or containing NSC23766 (200 µM; NSC). Cells were then fixed and their 
nuclei stained with DAPI. Active caspase-3 was visualized using a polyclonal antibody 
and a Cy3-conjugated secondary.  NSC23766 treatment causes increased activation of 
caspase-3 in CGNs (See arrows) Scale bar = 10 microns. B. Cells were incubated for 48 h 
in either Con medium or medium containing NSC23766 (200 µM; NSC) ± either BOC 
(50 µM) or QVD (20 µM). Percentage cell viability was measured by the reduction of 
MTT. The Con was set as the standard at 100% cell viability. Data represent the mean ± 
SEM of five independently performed experiments. *Significantly different from control 
(p< 0.05); NS = No significant difference between NSC and NSC co-treated with caspase 
inhibitors (BOC or QVD). C. Cells were incubated for 24 h in either Con medium or 
medium containing ToxB (60 ng/mL) ± BOC (50 µM) or LEHD (100 µM; a caspase-9 
inhibitor). Data represent the mean ± SEM of four independently performed experiments. 
*Significantly different from control (p< 0.05); †† Significantly different from ToxB (p< 




3.4.3 NSC23766 reduces the phosphorylation of PAK, but does not suppress the 
downstream MEK1/2 and ERK1/2 signaling cascade in CGNs 
We have previously reported that broad Rho GTPase inhibition with ToxB 
deactivates a pro-survival MAP kinase signaling cascade involving PAK1/2/3, MEK1/2, 
and ERK1/2. Thus, we examined if this signaling cascade was similarly suppressed in 
NSC23766-treated CGNs. While decreased levels of pPAK1/2/3 were detected in CGNs 
incubated with NSC23766 for 48 h, specific Rac inhibition did not result in decreased 
phosphorylation of MEK1/2 or ERK1/2 (Fig. 3.4). These data suggest that targeted 
inhibition of a select pool of Rac activated by Tiam1 and Trio in CGNs induces cell death 





Figure 3.4 NSC23766 reduces the phosphorylation of PAK, but does not suppress 
the downstream MEK1/2 and ERK1/2 signaling cascade in CGNs. CGNs were 
incubated for 48 h in either control medium alone (Con) or containing NSC23766 (200 
µM; NSC). Cells were then lysed, proteins were resolved using SDS-PAGE, and PVDF 
membranes were immunoblotted with antibodies to pPAK1/2, total PAK1/2/3, pMEK1/2, 
pERK1/2, and Actin. The blots shown are representative of three independent 




3.4.4 NSC23766, but not ToxB, decreases MEK5/ERK5 phosphorylati n in CGNs 
The above results suggested the possibility that the more targeted Rac inhibitor 
may work through suppressing MEK5 and ERK5, components of an alternative MAP 
kinase signaling cascade, to repress pro-survival sgnaling downstream of Rac and PAK. 
Indeed, immunoblot analysis indicated that NSC23766 treatment caused decreased 
phosphorylation of both MEK5 and ERK5 in CGNs.  Conversely, ToxB treatment had 
little to no effect on either pMEK5 or pERK5 expression in CGNs (Fig. 3.5). These data 
indicate that the targeted inhibition of Rac GTPase may elicit cell death via deactivation 
of an alternative pro-survival MAP kinase pathway downstream of PAK, MEK5/ERK5, 




Figure 3.5 NSC23766, but not ToxB, decreases MEK5/ERK5 phosphorylation in 
CGNs. CGNs were incubated in either control medium alone (Con), medium containing 
NSC23766 (200 µM; NSC) for 48 h, or medium containing ToxB (60 ng/mL) for 24 h. 
Cells were then lysed, proteins were resolved using SDS-PAGE, and PVDF membranes 
were immunoblotted with antibodies to pMEK5, pERK5, and total ERK5. The blots 
shown are representative of three independent experiments. I acknowledge Anandi 
Ramaswami for assistance with generating data for this figure. 
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3.4.5 NSC23766 treatment in CGNs induces dephosphorylation of p90Rsk and Akt, 
leading to the upregulation and mitochondrial localiz tion of the pro-apoptotic BH3-only 
protein Bad 
A recent study demonstrated that neuronal cell death induced by deletion of 
ERK5 is correlated with a marked decrease in phosphrylation of p90Rsk and Akt 
(Finegan et al., 2009). To determine if the loss of ERK5 phosphorylation induced by 
selective inhibition of Rac has a similar effect inCGNs, we examined the 
phosphorylation of p90Rsk and Akt in NSC23766-treated CGNs. Consistent with this 
previous study, we report distinct decreases in phos rylated p90Rsk and Akt in 
NSC23766-treated CGNs when compared to controls (Fig. 3.6A and 3.6B).  One of the 
shared pro-survival functions of p90Rsk and Akt is to uppress the expression of Bad via 
repression of Bad transcription by the cAMP response element-binding protein (CREB) 
(Bonni et al., 2009; Finegan et al., 2009).  Bad is a member of the Bcl-2 family of 
proteins that promotes apoptosis through its ability to heterodimerize with, and thus 
inhibit, pro-survival members of this family, such as Bcl-xL (Kelekar et al., 1997; Kitada 
et al., 1998). We report that treatment with the targeted Rac inhibitor, NSC23766, 
resulted in upregulation of pro-apoptotic Bad, an effect that was not observed with ToxB 
(Fig. 3.6C). Interestingly, both of the inhibitors also triggered the cleavage of Bad (Fig. 
3.6C), producing a 15kDa truncated form of the protein which is reportedly a more potent 
inducer of apoptosis (Condorelli et al., 2001). 
We next examined Bad phosphorylation as it has been demonstrated that the 
addition of a phosphate group at either Ser112 or Ser136 inactivates the pro-apoptotic 
function of Bad by sequestering the protein away from the mitochondria to 14-3-3 
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scaffolding proteins in the cytosol (Zha et al., 1996).  While we did not detect a change in 
pBad (Ser112; data not shown), expression of pBad (Ser136) was markedly reduced in 
NSC23766-treated, but not ToxB-treated, CGNs (Fig. 3.6D). Prior reports have 
characterized a critical pro-survival function for Akt–dependent phosphorylation of Bad 
at Ser136 (Datta et al., 1997; del Peso et al., 1997).  In agreement with these studies, 
NSC23766-treated CGNs also displayed a marked reduction in pAkt (Ser473; Fig. 3.6B). 
In contrast, we have previously reported that ToxB treatment does not alter the 
phosphorylation of Akt in CGNs (Linseman et al., 2001). Because the Akt-mediated 
phosphorylation of Bad targets it to 14-3-3 scaffolding proteins in the cytosol, we next 
analyzed if the dephosphorylation of Bad induced by inhibition of Rac was associated 
with translocation of this BH3-only protein to mitochondria. Immunofluorescent staining 
for Bad in control CGNs revealed a diffuse localization in the cytosol of the cell bodies 
with little detectable staining in cell processes (Fig. 3.6E, left panels).  In ToxB-treated 
CGNs, a similar distribution of Bad was observed in cells not actively undergoing 
apoptosis, while clearly apoptotic cells displayed undetectable levels of Bad expression 
(Fig. 3.6E, right panels). In marked contrast to these results, CGNs incubated with the 
selective Rac inhibitor, NSC23766, showed a striking redistribution of Bad to neuronal 
processes and an overall punctuate distribution of the protein (Fig. 3.6E, middle panels). 
To establish if the punctuate appearance of Bad induce  by the inhibition of Rac was due 
to its translocation to mitochondria, CGNs were subfractionated into mitochondrial and 
cytosolic fractions which were then immunoblotted for Bad.  In control CGNs Bad was 
exclusively localized to the cytosolic fraction, while in NSC2376-treated CGNs Bad was 
exclusively found in the mitochondrial fraction (Fig. 3.6F).  Collectively, these data 
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indicate that targeted inhibition of Rac with NSC23766 induces CGN apoptosis by 
turning off p90Rsk and Akt, likely downstream of MEK5/ERK5, leading to enhanced 
expression, dephosphorylation, and mitochondrial localization of pro-apoptotic Bad. In 
contrast, neither Bad desphosphorylation nor Bad trnslocation to mitochondria appears 




Figure 3.6 NSC23766 treatment in CGNs deactivates p90Rsk and Akt leading to 
increased expression, dephosphorylation, and mitochondrial localization of the pro-
apoptotic BH3-only protein Bad. A. CGNs were incubated in either control medium 
alone (Con) or medium containing NSC23766 (200 µM; NSC) for 48 h. Cells were then 
lysed, proteins were resolved using SDS-PAGE, and PVDF membranes were 
immunoblotted with antibodies to phospho-p90Rsk and subsequently stripped and 
reprobed for β-tubulin as a loading control. B. CGNs were incubated in either control 
medium alone (Con) or medium containing NSC23766 (200 µM; NSC) for various 
periods up to 48 h. Cell lysates were prepared for immunoblotting as described in (A) and 
PVDF membranes were blotted for pAkt (Ser473). Subsequently, membranes were 
stripped and reprobed for Actin as loading control.  C. CGNs were treated and prepared 
for immunoblotting as described in (A) with the addition of a ToxB-treated condition for 
24 h. Cell were lysed and PVDF membranes were blotted for total Bad and subsequently 
stripped and reprobed for Actin as a loading control. D. CGNs were incubated as 
described in (C). Cell lysates were prepared and PVDF membranes were blotted for pBad 
(Ser136) and subsequently stripped and reprobed for Actin as a loading control. E. CGNs 
were incubated as described in (C). Cells were thenfixed and their nuclei stained with 
DAPI. Bad was visualized using a polyclonal antibody and a Cy3-conjugated secondary. 
Images are representative of three independent experiments. Scale bar = 10 microns. F. 
CGNs were incubated as described in (C) and cells were subfractionated into 
mitochondrial and cytosolic fractions. Subcellular fractions were immunoblotted for Bad 




3.4.6 Unlike ToxB, NSC23766 treatment does not activate a pro-apoptotic JNK/c-
Jun/Bim pathway in CGNs 
We have previously shown that ToxB-mediated repression of MEK1/2/ERK1/2 
signaling induces intrinsic apoptosis of CGNs via decreased phosphorylation, and thus 
diminished degradation, of the pro-apoptotic BH3-only protein Bim (Loucks et al., 2006).  
In addition, we revealed that ToxB-treated CGNs displayed increased activation of a 
JNK/c-Jun signaling cascade that led to enhanced transc iption of Bim (Le et al., 2005). 
Therefore, we next examined whether targeted inhibition of Rac in CGNs had a similar 
effect on c-Jun and/or Bim.  NSC23766-treated CGNs did not display increased c-Jun 
expression at any time point up to 48 h.  As expected, ToxB treatment elevated c-Jun 
expression in CGNs within 8 h of treatment (Fig. 3.7A)   To investigate the potential 
involvement of JNK activation in promoting CGN death downstream of Rac inhibition, 
we examined the neuroprotective effects of the JNK inhibitor SP600125 (JNK Inh).  
While inclusion of the JNK Inh did not significantly protect CGNs from selective Rac 
inhibition with NSC23766, the inhibitor significantly mitigated CGN apoptosis in 
response to ToxB treatment (Fig. 3.7B, and 3.7C). Consistent with activation of a pro-
death JNK/c-Jun signaling pathway acting upstream of the BH3-only protein Bim, the 
expression of Bimshort was elevated in ToxB-treated CGNs. In contrast, we did not detect 
an increase in Bim expression in NSC23766-treated CGNs at any time point up to 48 h 
(Fig. 3.7D). These results indicate that broad inhibition of Rho GTPases with ToxB 
elicits CGN apoptosis primarily through the upregulation of Bim in a JNK/c-Jun-
dependent manner, while neither JNK/c-Jun signaling nor Bim appear to play a 




Figure 3.7 Unlike ToxB, NSC23766 treatment does not activate a pro-apoptotic 
JNK/c-Jun/Bim pathway in CGNs. A. CGNs were incubated in either control medium 
alone (Con), medium containing ToxB (60 ng/mL), or medium containing NSC23766 
(200 µM; NSC) for various periods up to 8 h and 48 h, respectively. Cells were then 
lysed, proteins were resolved using SDS-PAGE, and PVDF membranes were 
immunoblotted with an antibody against c-Jun and subsequently stripped and reprobed 
for Actin as a loading control. B. CGNs were incubated in either control medium alone 
(Con), medium containing ToxB (40ng/mL) for 24 h, or medium containing NSC23766 
(200 µM; NSC) for 48 h. In addition, some cells were xposed to NSC or ToxB in the 
presence of the JNK inhibitor (JNK inhibitor; 20 µM). Cells were then fixed and their 
nuclei stained with Hoescht dye. C. Quantification f CGN apoptosis from three 
independent experiments conducted as described in (B). *** Significantly different from 
Con (p<0.001); ††† Significantly different from ToxB (p<0.001); NS = no significant 
difference from NSC. D. CGNs were incubated in either control medium alone (Con), 
medium containing ToxB (60 ng/mL) for 8 h, or medium containing NSC23766 (200 
µM; NSC) for various periods up to 48 h. Cells were th n lysed, proteins were resolved 
using SDS-PAGE, and PVDF membranes were immunoblotted with an antibody against 
Bim and subsequently stripped and reprobed for β-tubulin as a loading control. Blots 
shown are representative of three independent experiments. 
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3.4.7 Adenoviral infection with constitutively active MEK5 protects CGNs from 
NSC23766 treatment, but not ToxB. 
To definitively establish the precise MAP kinase signaling pathway that is 
deactivated in CGNs exposed to NSC23766-targeted Rac inhibition versus ToxB-
mediated global Rho GTPase inhibition, we examined the protective effects of an 
adenoviral constitutively active mutant of MEK5 (Ad-CA MEK5), in which the dual 
phosphorylation site S311/S315 has been changed to D311/D315.  Infection with Ad-CA 
MEK5, but not Ad-GFP, increased the expression of MEK5 in CGNs (Fig. 3.8A). It is 
important to note that neither adenoviral construct in reased the basal level of apoptosis 
on their own (data not shown). As we have previously shown, global inhibition of Rho 
GTPases with ToxB resulted in significant CGN apoptosis (Fig. 3.8B).  Consistent with 
ToxB inducing death through a mechanism independent of MEK5/ERK5 signaling, pre-
incubation of CGNs with either Ad-GFP or Ad-CA MEK5 did not confer significant 
protection against ToxB treatment (Fig. 3.8B and 3.8C)  Conversely, while CGNs 
exposed to selective inactivation of Rac GTPase with NSC23766 showed condensed and 
fragmented nuclei indicative of apoptotic cell death, CGNs pre-incubated with Ad-CA 
MEK5, but not Ad-GFP, displayed nuclear morphology strikingly more similar to 
controls (Fig. 3.8D). Quantification of these result  demonstrated that adenoviral 
infection with Ad-CA MEK5 significantly protected CGNs from NSC23766 treatment 
(Fig. 3.8E). It is worth noting that the protection conferred in CGNs pre-incubated with 
Ad-CA MEK5 and subsequently treated with NSC23766 was not complete, presumably 
because the infection efficiency was approximately 40-50% as estimated by the 
percentage of CGNs expressing Ad-GFP. Nonetheless, the e results further corroborate 
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that selective inactivation of Rac GTPase versus global inhibition of Rho GTPases 





Figure 3.8 Adenoviral infection with constitutively active MEK5 protects CGNs 
from NSC23766 treatment, but not ToxB.  A. CGNs were incubated in control medium 
(Con) or infected for 48 h with an adenovirus carrying GFP (Ad-GFP) or constitutively 
active MEK5 (Ad-CA MEK5). Cell lysates were separated by SDS-PAGE, transferred to 
PVDF membranes, and immunoblotted for MEK5 expression. Blots were subsequently 
stripped and reprobed for actin expression. B. CGNs were infected for 48 h with either 
Ad-GFP or Ad-CA MEK5. After the 48 h incubation period, CGNs were treated with 
ToxB (40ng/mL) for an additional 24 h as indicated. At the end of the incubation, cells 
were fixed and nuclei were stained with DAPI. Scale bar = 10 microns. C. Quantification 
of apoptosis from cells treated as described in (B) D. CGNs were infected for 48 h with 
either Ad-GFP or Ad-CA MEK5. After the 48 h incubation period, CGNs were treated 
with NSC23766 (NSC; 175 µm) for an additional 48 h as indicated. At the end of the 
incubation, cells were fixed and nuclei were stained with DAPI. Scale bar = 10 microns. 
E. Quantification of apoptosis from cells treated as described in (D). Data represent the 
mean ± S.E. of three independently performed experiments. *Significantly different from 
control (p< 0.05); *** Significantly different from control (p< 0.001); † Significantly 





While a number of studies have highlighted a critical pro-survival role for Rho 
family GTPases in various neuronal cell types (Linseman et al., 2001; Kobayashi et al., 
2004; Kanekura et al., 2005; Le et al., 2005; Loucks et al., 2006; Stankiewicz et al., 
2012), the mechanisms by which these G-proteins induce their neuroprotective effects 
remain largely unknown.  In previous studies, we have utilized Clostrium difficile ToxB 
as a selective inhibitor of Rac, Rho, and Cdc42 to reveal that PAK/MEK/ERK and 
JNK/c-Jun signaling cascades, components of the Rac-activated MAP kinase pathway, 
critically regulate CGN survival (Le et al., 2005; Loucks et al., 2006). To advance our 
understanding of Rho family GTPases in neuronal survival, we compared the effects of 
ToxB to NSC23766, an inhibitor which specifically prevents Rac activation by the GEFs 
Tiam1 and Trio (Gao et al., 2004). Initial results confirmed that NSC23766 promotes 
CGN death through the loss of GTP-bound (active) Rac. However, while both ToxB and 
NSC23766 induce CGN death in the presence of serum and depolarizing potassium, our 
current study indicates that CGNs succumb to cell death via unique signaling pathways in 
response to specific Rac inhibition versus global Rho GTPase inhibition.  
 Similar to ToxB, NSC23766 induces activation of casp se-3 in CGNs; however, 
while ToxB-induced CGN death was sensitive to caspase inhibitors, the effects of 
NSC23766 on neuronal death were not mitigated to a significant degree by co-incubation 
with pan-caspase inhibitors. This is a key point of divergence between the effects of 
ToxB and NSC23766 on neuronal survival and indicates that NSC23766 is capable of 
promoting CGN death through a caspase-independent pathway.  Given the antagonistic 
relationship between Rac and Rho signaling, it is po sible that specific inhibition of only 
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Rac via NSC23766 unmasks a Rho-dependent pathway that does not rely on caspase 
activation for the execution of CGN death. Indeed, Rac directly suppresses Rho activity 
through binding and activating the Rho GAP, p190RhoGAP, in HeLa cells (Wildenberg 
et al., 2006).  Moreover, the downstream effector of Rac, PAK, has been shown to 
regulate the activation of Rho through GEFs in a variety of cell types (Hakoshima et al., 
2003). Consistent with this idea, Rho has been demonstrated to sensitize 
corticohippocampal neurons to cell death (Barberan et al., 2011), and inhibition of the 
Rho effector, ROCK, exerts a neuroprotective effect in various in vitro and in vivo 
models of neuronal cell death such as, cerebral ischemia and excitotoxicity (Rikitake et 
al., 2005; Jeon et al., 2013). In addition to ROCK, Rho GTPase has many other 
downstream effectors that could contribute to neuronal death via a mechanism that is 
independent of caspase activation.  
The second contrast between the activities of ToxB and NSC23766 was apparent 
in their divergent effects upon MAP kinase signaling. While ToxB suppressed 
MEK1/2/ERK1/2 signaling, the selective Rac inhibitor had no effect of this MAP kinase 
pathway and instead suppressed a unique MEK5/ERK5 cascade.  Indeed, adenoviral 
expression of constitutively active MEK5 was only sufficient to mitigate the toxic effects 
of the selective Rac inhibitor, NSC23766, in CGNs and displayed no protective effect 
against global Rho GTPase inhibition with ToxB. It is possible that this stark contrast 
may be attributed to differential regulation of PAK. Upstream of the MEK/ERK signaling 
cascades, both Rho family GTPase inhibitors reduced th  phosphorylation of PAK in 
CGNs. However, one limitation of these findings is that although we have utilized an 
antibody that detects phosphorylation of PAK1/2/3, there are six known isoforms of 
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PAK. Thus, regulation of unique MAP kinase pathways in response to Rac inhibition 
may be a result of differential inactivation of specific PAK isoforms.  Furthermore, an 
additional member of the Rho GTPase family that is inhibited by ToxB, Cdc42, also 
regulates PAK activity in a manner similar to Rac (Kreis et al., 2007).  Inactivation of 
distinct PAK isoforms in response to targeted inhibition of Rac versus global inhibition 
of Rho GTPases may represent a key point at which te signaling cascades regulated by 
these inhibitors deviate.  
Although deactivation of specific PAK isoforms is a potential point at which the 
signaling cascades regulated by distinct Rho family GTPases may diverge, this could also 
be accomplished downstream of PAK signaling through mitogen-activated protein kinase 
kinase kinases (MEKKs). MEKKs are upstream regulators f MAP kinase pathways, 
such as MEK/ERK, c-Jun NH2-terminal kinases (JNK), and p38 (Fanger et al., 1997; Sun 
et al., 2001). As the most well studied MAP kinase signaling pathway, MEK1/2 
activation has largely been attributed to MEKKs that belong to the Raf family of proteins 
(i.e., A-Raf, Raf-1, B-Raf).  This may be a critical point of divergence in MEK/ERK 
signaling as recent studies have demonstrated that MEKK2 and MEKK3 specifically 
activate the downstream effector MEK5 via heterodimer zation of a PB1 domain that is 
specific to MEKK2, MEKK3, and MEK5 (Sun et al., 2001; Nakamura and Johnson, 
2003). Furthermore, while both MEKK2 and MEKK3 bind to MEK5 and activate the 
MEK5/ERK5 pathway, it was shown that MEKK2 binds MEK5 with higher affinity, 
stimulating ERK5 activity to a greater extent (Sun et al., 2001).  Collectively, these 
previous studies suggest that the distinct MAP kinase pathways which are deactivated by 
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either ToxB or NSC23766 in CGNs may diverge downstream of PAK at the level of 
specific MEKK activation.  
Overall, these data suggest that CGN death triggered by the targeted inhibition of 
a select pool of Rac activated by the GEFs Tiam1 and Trio, involves the suppression of a 
MEK5/ERK5 signaling cascade to induce apoptosis. This is in agreement with previous 
studies highlighting a critical pro-survival function for ERK5 in dopaminergic neurons, 
as well as, sympathetic neurons (Cavanaugh et al., 2006; Finegan et al., 2009). Moreover, 
past studies have indicated that ERK5 is activated by MEK5 but not by MEK1 or MEK2, 
speaking to the highly specific nature of the MEK5/ERK5 interaction (English et al., 
1995; Zhou et al., 1995).  Finally, others have demonstrated that Rac1 can signal to 
MEK5/ERK5 (Cheng et al., 2012). This Rac effect presumably occurs through PAK-
mediated activation of MEKK2/3 and their subsequent activation of MEK5 (Porter et al., 
1999; Nakamura and Johnson, 2003).  Thus, selective inhibition of Rac is capable of 
suppressing a putative PAK/MEKK2/3/MEK5/ERK5 pro-survival pathway. 
Previous experimentation has shown that ERK5 is capable of triggering a 
phosphorylation cascade that results in the phosphorylation of the MAPK-activated 
kinase, p90Rsk, and the subsequent activation of the transcription factor cAMP response 
element binding protein (CREB), which regulates transcription of pro-survival and pro-
apoptotic genes in neurons, including repression of the pro-apoptotic Bad gene (Watson 
et al., 2001; Park and Cho, 2006; Ranganathan et al., 2006; Ha and Redmond, 2008). 
Accordingly, recent findings in neurons indicate that, in the absence of ERK5, 
phosphorylation of p90Rsk is impaired and cell death is elicited in a Bad-dependent 
manner (Finegan et al., 2009). Consistent with the observed reduction in phosphorylated 
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p90Rsk in response to NSC23766, we report that NSC23766 treatment also elicited 
upregulation of Bad in CGNs.  Given that ToxB did not enhance Bad expression, it 
appears that deactivation of p90Rsk is unique to NSC23766-treated CGNs. Interestingly, 
both NSC23766 and ToxB induced the cleavage of Bad,generating elevated levels of a 
15kDa cleavage product. This is consistent with a previous report which revealed that 
caspase cleavage of Bad at its N-terminus produces a 15 kDa truncated form of Bad that 
is a more effective inducer of apoptosis than the full length protein (Condorelli et al., 
2001). However, given that pan-caspase inhibitors do not protect NSC23766-treated 
CGNs to a significant extent, our data suggest that caspase cleavage of Bad is not the 
prominent mechanism of death in CGNs exposed to NSC23766.  Together, these data 
suggest an important role for the MEK5/ERK5 pathway in neuronal survival. 
Specifically, targeted inhibition of a discrete pool f Rac activated by Tiam1 and Trio 
appears to trigger CGN death through repression of a novel pro-survival pathway 
involving PAK, possibly MEKK2/3, and the MEK5/ERK5 signaling cascade including 
its downstream targets, p90Rsk and Bad (Fig. 3.9).   
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Figure 3.9 Conclusion: comparing CGN death induced by NSC23766 and ToxB. The 
concluding schematic illustrates the Rac-dependent sig aling cascades examined in this 
study. A. Pathway regulated by the Rho GTPases Rac,ho  and Cdc42. B. Pathway 
regulated by the specific pool of Rac activated by the GEFs Tiam1 and Trio. Dashed lines 
represent hypothesized effects. Our findings suggest that targeted inhibition of the 
specific pool of Rac activated by the GEFs, Tiam1 and Trio, promotes CGN death 
through an alternative pathway to that employed by the broad-spectrum Rho family 
inhibitor, ToxB. These pathways diverge downstream of PAK, with NSC23766 
repressing the MEK5/ERK5 signaling cascade while ToxB inhibits MEK1/2 and 
ERK1/2. ToxB also induces the activation of JNK/c-Jun, a pathway that is not activated 
by NSC23766. ToxB ultimately results in decreased degradation and enhanced 
transcription of Bim while NSC23766 promotes the dephosphorylation, mitochondrial 




In addition to regulation of Bad at the transcriptional level via CREB, p90Rsk 
also catalyzes the phosphorylation of Bad at serine 112, suppressing Bad-mediated 
apoptosis in neurons (Bonni et al., 1999, Bertolott et al., 2000). However, we did not 
detect any decrease in the phosphorylation of Bad at Ser112 (data not shown).  Instead, 
we observed that NSC23766-treated CGNs exhibited a marked reduction in levels of 
pBad (Ser136).  Interestingly, several studies have highlighted that phosphorylation of 
Bad at Ser136 may be the more critical 14-3-3 binding site which enhances the 
association of Bad with cytosolic 14-3-3 scaffolding proteins, effectively sequestering 
Bad away from mitochondria (Zha et al., 1996, Masters et al., 2001). Several reports have 
indicated that phosphorylation of Bad at this particular site is largely attributed to Akt 
activation (Datta et al., 1997; del Peso et al., 1997). This is consistent with our data 
demonstrating reduced phosphorylation (activation) f Akt (Ser473) in NSC23766-
treated CGNs.  As we have previously reported that ToxB does not regulate Akt signaling 
in CGNs (Linseman et al., 2001), the finding that NSC23766-treated CGNs display a 
marked reduction in activated Akt highlights an additional signaling pathway that is 
differentially regulated in response to specific Rac inhibition versus global Rho GTPase 
inhibition. However, the particular mechanism by which Akt is deactivated in 
NSC23766-treated CGNs is currently unknown. For insta ce, although it is well 
documented that Akt can be phosphorylated and activated by Rac through phosphatidyl-
inositol-3 kinase (del Peso et al., 1997; Kanekura et al., 2005), ERK5 has also been 
shown to modestly activate Akt to promote survival of non-neuronal cells (Lennartsson et 
al., 2010).  Thus, the precise mechanism by which Akt is dephosphorylated following 
Rac inhibition warrants further investigation. Despite these considerations, our data 
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indicate that inhibition of a specific pool of Rac tivated by the GEFs Tiam1 and Trio 
induces apoptosis through a mechanism consistent with Akt deactivation and subsequent 
dephosphoylation and translocation of Bad to the mitochondria.  
Finally, in addition to the distinct differences in MEK/ERK, p90Rsk, and Akt 
signaling, ToxB and NSC23766 also appear to dissimilarly regulate JNK/c-Jun signaling 
in CGNs. While we previously reported that ToxB induced mitochondrial-dependent 
CGN apoptosis through a mechanism consistent with JNK/c-Jun-dependent 
transcriptional upregulation of the BH3-only protein Bim (Le et al., 2005), we currently 
report that c-Jun was not induced in CGNs exposed to the specific Rac inhibitor 
NSC23766.  Moreover, inclusion of the JNK inhibitor, SP600125, did not exert a 
protective effect in NSC23766-treated CGNs.  Furthermore, although we report an 
increase in expression of the pro-apoptotic protein Bim in response to ToxB in CGNs, 
Bim was not elevated above control levels in NSC23766-treated CGNs. Thus, while 
ToxB appears to induce CGN death through a mechanism dependent upon JNK/c-Jun-
mediated induction of Bim, Bim does not appear to execute cell death in CGNs exposed 
to the specific Rac inhibitor NSC23766. Many studies have indicated that Rac and Cdc42 
can regulate JNK activation; thus this distinction n signaling may be due to the intrinsic 
differences between inactivation of specifically Rac versus global inhibition of Rho 
GTPases.  
In conclusion, the specificity with which NSC23766 suppresses Rac activity 
allowed us to further investigate signaling pathways regulated by this Rho family GTPase 
which are involved in neuronal survival. We have revealed that CGNs exposed to ToxB 
or NSC23766 succumb to neuronal death through inactivation of distinct MAP kinase 
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signaling pathways. Comparison of the mechanisms behind specific Rac inhibition with 
those associated with broader Rho family GTPase inhibition has been central to 
elucidating the signaling pathways that regulate survival in CGNs.  It is interesting to 
note that inhibition of the select pool of Rac activa ed by Tiam1 and Trio is sufficient to 
induce dysregulation of multiple signaling pathways including MEK5/ERK5, p90Rsk, 
and Akt.  Furthermore, the critical function of Rac in maintaining neuronal survival is 
highlighted by the fact that targeted inhibition of Rac is sufficient to induce CGN death in 
the presence of both serum and depolarizing potassium. Accordingly, this study serves to 
advance our understanding of the key pro-survival roles of Rho family GTPases in 
neurons. These findings may ultimately contribute to the discovery of novel signaling 
molecules which could be targeted therapeutically for debilitating neurodegenerative 
diseases, such as amyotrophic lateral sclerosis, for which loss of Rac function is thought 
to play a significant role in neuronal cell death. 
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CHAPTER FOUR: C-TERMINAL BINDING PROTEINS ARE ESSENTIAL 
PRO-SURVIVAL FACTORS THAT UNDERGO CASPASE-DEPENDENT 




 C-terminal binding proteins (CtBPs) are transcriptional co-repressors that are 
subject to proteasome-dependent downregulation during apoptosis. Alternative 
mechanisms that regulate CtBP expression are currently u der investigation and the role 
of CtBPs in neuronal survival is largely unexplored. Here, we show that CtBPs are 
downregulated in cerebellar granule neurons (CGNs) induced to undergo apoptosis by a 
variety of stressors. Moreover, antisense-mediated downregulation of CtBP1 is sufficient 
to cause CGN apoptosis. Similarly, the CtBP inhibitor, 4-methylthio-2-oxobutyric acid, 
induces expression of the CtBP target Noxa and causes actinomycin-sensitive CGN 
apoptosis. Unexpectedly, we found that the mechanism of CtBP downregulation in CGNs 
undergoing apoptosis varies in a stimulus-specific manner involving either the 
proteasome or caspases. In the case of CGNs deprived of depolarizing potassium (5K 
apoptotic condition), caspases appear to play a dominant role in CtBP downregulation. 
However, incubation in 5K does not enhance the kinetics of CtBP1 degradation and 
recombinant CtBP1 is not cleaved in vitro by caspase-3. In addition, 5K has no 
significant effect on CtBP transcript expression. Finally, mouse embryonic stem cells 
display caspase-dependent downregulation of CtBP1 following exposure to 
staurosporine, an effect that is not observed in DGCR8 knockout cells which are deficient 
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in miRNA processing. These data identify caspase-dependent downregulation of CtBPs 
as an alternative mechanism to the proteasome for regulation of these transcriptional co-
repressors in neurons undergoing apoptosis. Moreove, caspases appear to regulate CtBP 
expression indirectly, at a post-transcriptional leve , and via a mechanism that is 
dependent upon miRNA processing. We conclude that CtBPs are essential pro-survival 
proteins in neurons and their downregulation contribu es significantly to neuronal 
apoptosis via the de-repression of pro-apoptotic genes. 
4.2 Introduction 
 C-terminal binding proteins (CtBPs) were originally identified as binding partners 
for the adenovirus E1A transforming proteins (Schaeper et al., 1995). CtBP1 and CtBP2 
are highly homologous transcriptional co-repressors that function as partners for 
repressor proteins like ZEB and basic krüppel-like factor (BKLF) (Postigo and Dean, 
1999 and Turner and Crossley, 1998). CtBPs recruit a number of key chromatin 
modifying enzymes (e.g., histone deacetylases) to gene promoters primarily via PXDLS-
dependent interactions with the CtBP hydrophobic cleft (Kuppuswamy et al., 
2008 and Quinlan et al., 2006). In a similar manner, CtBPs repress p300-dependent 
transcriptional activation by directly binding to a PXDLS motif in the bromodomain of 
this co-activator (Kim et al., 2005). CtBPs are directed to the nuclear compartment either 
via a nuclear localization signal (which is unique to CtBP2) or by binding to PXDLS 
motif-containing partners like BKLF (Verger et al., 2006). CtBPs are functional 
dehydrogenases which bind to NADH with greater than 100-fold higher affinity than 
NAD + (Fjeld et al., 2003, Kumar et al., 2002 and Zhang et al., 2002). Binding of 
NAD(H) appears to stabilize the protein and promotes dimerization of CtBPs which is 
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required for transcriptional repression (Fjeld et al., 2003, Kuppuswamy et al., 
2008 and Mani-Telang et al., 2007). Thus, CtBPs act as redox-sensitive transcriptional 
co-repressors of a specific subset of target genes. 
 CtBPs are key transcriptional co-repressors of epith lial and pro-apoptotic gene 
expression programs (Bergman and Blaydes, 2006 and Grooteclaes et al., 2003). By 
repressing epithelial cell adhesion (via repression of E-cadherin) and concomitantly 
suppressing apoptosis and anoikis, CtBPs promote cancer cell migration, invasion, and 
survival (Grooteclaes and Frisch, 2000 and Straza et al., 2010). In the context of 
apoptosis, CtBPs act as co-repressors at several pro- poptotic Bcl-2 family member gene 
promoters, such as Bax and the Bcl-2 homology-3 domain (BH3)-only proteins, Noxa, 
Bik, Bim, and Bmf (Bergman and Blaydes, 2006, Grooteclaes et al., 2003 and Kovi et al., 
2010). Murine embryonic fibroblasts (MEFs) isolated and immortalized from 
Ctbp1/Ctbp2 double knockout embryos show constitutive upregulation of Bax and Noxa, 
and demonstrate enhanced sensitivity to diverse apoptotic stimuli (Grooteclaes et al., 
2003). Both the increased expression of Bax and Noxa, as well as the enhanced 
susceptibility to apoptosis, were reversed by Ctbp1 or Ctbp2 rescue expression. 
 To date, relatively few studies have examined the rol s of CtBPs in CNS 
development or neuronal survival. Based largely on the results of genetic deletion 
experiments, it appears that C bp1 and Ctbp2 display both duplicative and independent 
roles in mouse development including maturation of the CNS (Hildebrand and Soriano, 
2002). Ctbp2 homozygous null mice display delayed development of the forebrain and 
midbrain, and typically die by E10.5. In contrast, C bp1 homozygous null mice are viable 
and fertile. In a genetic interaction experiment, icreasing the dosage of Ctbp1 decreased 
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the severity of the Ctbp2 null phenotype. For instance, Ctbp1+/- Ctbp2-/- embryos did not 
complete neural tube closure and arrested at the turning stage while Ctbp1+/+  Ctbp2-/- 
embryos completed both processes. In the context of cell survival, CtBPs are targeted for 
proteasomal degradation in response to pro-apoptotic stimuli that induce p53-independent 
apoptosis in non-neuronal cells (Paliwal et al., 2006, Wang et al., 2006, Zhang et al., 
2003 and Zhang et al., 2005). In contrast, the role of CtBPs in neuronal apoptosis has not 
previously been explored. Here, we identify a novel caspase-dependent pathway for CtBP 
downregulation during neuronal apoptosis and further s ow that loss of CtBP function is 
sufficient to induce neuronal cell death. 
4.3 Materials and Methods 
4.3.1 Reagents 
 
 Clostridium difficile Toxin B (ToxB) and Clostridium sordellii lethal toxin 
(LTox) were kindly provided by Dr. Klaus Aktories (Albert-Ludwigs-Universität 
Freiburg, Germany). The high-throughput immunoblotting screen was performed by BD 
Pharmingen (Palo Alto, CA, USA) and monoclonal antibodies used for subsequent 
western blotting of CtBP1 and CtBP2 were obtained from BD Biosciences (San Diego, 
CA, USA). Polyclonal antibody against actin was obtained from Cell Signaling 
(Berverly, MA, USA). The polyclonal antibody used to detect Noxa was from Abcam 
(Cambridge, MA, USA). Horseradish peroxidase-linked secondary antibodies and 
reagents for enhanced chemiluminescence detection were from Amersham Biosciences 
(Piscataway, NJ, USA). The polyclonal antibody used to detect active caspase-3 was 
from Promega (Madison, WI, USA). 4,6-Diamidino-2-phenylindole (DAPI), Hoescht dye 
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33258, monoclonal antibody against β- ubulin, 1-methyl-4-phenylpyridinium (MPP +), 6-
hydroxydopamine (6-OHDA), 4-methylthio-2-oxobutyric (MTOB), staurosporine, 
actinomycin D, and recombinant PARP were from Sigma (St. Louis, MO, USA). Cy3- 
and FITC-conjugated secondary antibodies for immunofl orescence were from Jackson 
Immunoresearch Laboratories (West Grove, PA, USA). H 14-1 and BOC were obtained 
from Alexis (San Diego, CA, USA). MG-132, sodium nitroprusside (SNP), and 
recombinant caspase-3 were from Calbiochem (Darmstadt, Germany). The polyclonal 
antibody to PARP was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Morpholino-antisense oligonucleotides and the EndoPorter delivery reagent were 
obtained from Gene Tools (Philomath, PA, USA). Wild type and DGCR8 knockout 
mouse embryonic stem cells, as well as, recombinant CtBP1 were obtained from Novus 
Biologicals (Littleton, CO, USA). 
4.3.2 Cerebellar granule neuron (CGN) culture 
 Rat CGNs were isolated from 7-day-old Sprague-Dawley rat pups of both sexes 
(15–19 g) as previously described (Linseman et al., 2001). CGNs were plated on 35-mm 
diameter plastic dishes coated with poly-L-lysine at a density of 2.0 × 106 cells/ml in 
basal modified Eagle's medium containing 10% fetal bovine serum, 25 mM KCl, 2 mM 
L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (Life Techonologies, 
Grand Island, NY, USA). Cytosine arabinoside (10 µM) was added to the culture medium 
24 h after plating to limit the growth of non-neuronal cells. With use of this protocol, the 
cultures were approximately 95% pure for granule neurons. In general, experiments were 
performed after 6–7 days in culture. 
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4.3.3 BD Pharmingen PowerBlot™ analysis 
 CGNs were incubated in either control medium or medium containing 40 ng/ml 
Clostridium difficile Toxin B (ToxB) for 24 h and subsequently lysed according to the 
manufacturer's protocol. Lysates from three independent experiments were pooled and 
subjected to high-throughput immunoblotting against a panel of 1009 purified 
monoclonal antibodies (BD PowerBlot™). Raw data wasobtained from the manufacturer 
in the form of image files of the actual blots and densitometric measurements of the 
immunoreactive proteins. The blots shown for CtBP1, CtBP2, and G protein-coupled 
receptor kinase-interacting protein-z-short are representative of 2 × 2 comparisons of 
duplicate control and ToxB lysates. 
4.3.4 Cell lysis and immunoblotting 
 Following treatment, whole cell lysates of CGNs were prepared essentially as 
previously described (Loucks et al., 2006). Briefly, protein concentrations were 
determined by a commercially available protein assay kit (BCA; Thermo Fisher 
Scientific, Waltham, MA, USA), and SDS-polyacrylamide gel electrophoresis was 
performed using equal amounts of protein followed by transfer to polyvinylidene 
difluoride membranes. Nonspecific binding sites were blocked in PBS-T (1X phosphate-
buffered saline (PBS, pH 7.4) containing 0.1% Tween 20) containing 1% BSA and 
0.01% sodium azide for 1 h at room temperature (22 °C). Membranes were incubated for 
1 h in primary antibody diluted in blocking solution. Membranes were subsequently 
washed 5 times over 30 min in PBS-T to remove excess primary antibody. Membranes 
were then incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies 
diluted in PBS-T. Following secondary incubation, membranes were washed 5 times over 
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30 min in PBS-T to remove excess secondary antibody. Immunoreactive proteins were 
detected by enhanced chemiluminescence. Blots shown are representative of a minimum 
of three independent experiments. 
4.3.5 Immunofluorescence microscopy 
 CGNs were plated at a density of 4.5 × 105 cells per ml on glass coverslips coated 
with polyethylene-imine. After treatment, cells were fixed in 4% paraformaldehyde, 
washed once in PBS, and permeabilized and blocked in 0.2% Triton X-100 and 5% BSA 
in PBS (pH 7.4). Cells were incubated for 16 h at 4 °C in primary antibodies diluted in 
2% BSA and 0.2% Triton X-100 in PBS. They were subsequently washed 5 times in PBS 
over 30 min and then incubated for 1 h at room temperature with Cy3- or FITC-
conjugated secondary antibodies and DAPI diluted in 2% BSA and 0.2% Triton X-100 in 
PBS. The cells were washed five additional times over 30 min with PBS before mounting 
coverslips onto slides with anti-quench composed of 0.1% p-phenylenediamine in 75% 
glycerol in PBS. Fluorescent images were captured using a 63x oil immersion objective 
on a Zeiss Axioplan 2 epifluorescence microscope that was equipped with a Cooke 
Sensicam deep-cooled charge-coupled device (CCD) camera and a Slidebook software 
analysis program for digital deconvolution (Intelligent Imaging Innovations Inc., Denver, 
CO, USA). 
4.3.6 Morpholino-antisense oligonucleotide treatment 
 CGNs were plated at a density of 4.5 × 105 cells per ml on glass coverslips coated 
with polyethylenimine. On day 6 in vitro, cells were treated with EndoPorter reagent 
(6 µM) alone or in combination with morpholino-antisens or inverse oligonucleotides 
(3 µM final concentration). After 72 h of treatment, cells were fixed with 4% 
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paraformaldehyde and nuclei were stained with Hoechst dye. CGNs containing 
condensed and/or fragmented nuclei were scored as apoptotic. 
4.3.7 N27 dopaminergic cell culture 
 N27 cells were maintained in culture in RPMI medium containing 10% fetal 
bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. 
4.3.8 6-Hydroxydopamine treatment 
 For treatment with 6-OHDA, the compound was diluted in a vehicle solution 
consisting of ddH2O containing 0.15% ascorbic acid and 10 mM DETAPAC. This 
solution was purged with nitrogen gas for 30 min while on ice. After removal of oxygen, 
6-OHDA was added to the solution and used to treat N27 cells at a concentration of 
25 µM or 50 µM for 24 h. 
4.3.9 Pulse-chase assay 
 CGNs were incubated for 4 h in cysteine-methionine-fre  medium containing 35S-
methionine. Following this labeling “pulse”, cells were washed and medium was replaced 
with control (25K) or apoptotic (5K) medium for the “chase” period. At the times 
indicated, cells were lysed, CtBP1 was immunoprecipitated, and immune complexes 
were resolved by SDS-PAGE followed by transfer to plyvinylidine difluoride 
membranes. Membranes were exposed directly to film and bands representing 35S-CtBP1 
were quantified by densitometry. 
4.3.10 In vitro caspase-3 cleavage assay 
 In separate microcentrifuge tubes, 5 µg of recombinant PARP or 1.5 µg of 
recombinant CtBP1 were incubated alone or in combinatio  with 100 units of 
recombinant caspase-3. All samples were queued to 100 µl with caspase buffer (100 mM 
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NaCl, 5 mM DTT, 50 mM EDTA, 20 mM PIPES, 1% Chaps, and 10% sucrose in 
ddH20). Samples were incubated for 4 h at 37 °C in a thermomixer. Following 
incubation, proteins were resolved by SDS-PAGE, proteins transferred onto membranes, 
and immunoblotted as previously described. 
4.3.11 RT-PCR  
 CGNs were incubated in control (25K) or apoptotic (5K) medium for 24 h. RNA 
was isolated using a miRCURY RNA isolation kit purchased from Exiqon (Woburn, MA, 
USA). cDNA was synthesized from the isolated RNA samples using an Omniscript 
reverse transcriptase kit that was purchased from Qiagen (Valencia, CA, USA). DNA 
was analyzed by polymerase chain reaction (PCR) using an Accuprime Pfx Supermix kit 
from Life Technologies (Grand Island, NY, USA). Primers were purchased from 
Integrative DNA Technologies (Coralville, IA, USA) corresponding to CtBP1, CtBP2, 
and beta-actin. The forward primer to CtBP1 was 5′-TTGGGCAT 
CATTGGACTAGGTCGT-3′ and the reverse primer was 5′-TCAGGTGGTCCTTGTT 
GACACAGT-3′. The forward primer to CtBP2 was 5′-
TGTGATGCACAGTCCACTCAG GAA-3′ and the reverse primer was 5′-
CCATTGAACACGGCATTGTCACCA-3′. The forward primer to beta-actin was 5′-
CCATTG AACACGGCATTGTCACCA-3′ and the reverse primer was 5′-
ACTCCTGCTTGCTGA TCCACATCT-3′. PCR was performed using the following 
conditions: 95 °C for 5 min followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and 
68 °C for 1 min. 
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4.3.12 Mouse embryonic stem cell culture 
 Wild type and DGCR8 knockout mouse embryonic stem c lls were purchase from 
Novus Biologicals (Littleton, CO, USA). Cell culture plates were coated with a solution 
containing 1% gelatin that was purchased from Millipore (Billerica, MA, USA). Cells 
were maintained in basal modified Eagle's medium containing 10% fetal bovine serum, 
1X non essential amino acids, 1% beta-mercaptoethanol, d 1000 units/ml leukemia 
inhibitory factor (Millipore). In general, the cultre medium of both wild type and 
DGCR8 knockout cells was replaced daily. 
4.3.13 Data analysis 
 Results represent the mean ± S.E. for the number (n) of independent experiments 
performed. Statistical differences between the means of unpaired sets of data were 
evaluated by one-way analysis of variance with a post hoc Tukey's test. A p value 
of < 0.05 was considered statistically significant. Images and immunoblots shown are 
representative of at least three independent experiments. 
4.4 Results 
4.4.1 CtBP1 and CtBP2 are downregulated in CGNs exposed to Clostridium difficile 
Toxin B, an inhibitor of Rho family GTPases 
 In our initial studies using a high throughput immunoblotting screen (BD 
PowerBlot™), we identified CtBP1 and CtBP2 as two pr teins that were significantly 
downregulated in CGNs following a 24 h incubation with the Rho family GTPase 
inhibitor, Clostridium difficile toxin B (Fig. 4.1A). Toxin B is a monoglucosyltransferase 
that directly glucosylates and inhibits the small GTPases Rho, Rac, and Cdc42 (Just et al., 
1995). We have previously shown that toxin B induces intrinsic apoptosis in CGNs that is 
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largely dependent on its capacity to inhibit pro-survival signaling by Rac GTPase (Le et 
al., 2005, Linseman et al., 2001, Loucks et al., 2006 and Stankiewicz et al., 2012). CtBP1 
appeared on polyacrylamide gels as a single band of approximately 48 kDa and CtBP2 
appeared as a doublet of approximately 48/50 kDa. In the initial PowerBlot™ analysis, 
the expression of each of these proteins was significa tly decreased by at least two-fold 
in CGNs incubated for 24 h with toxin B (Fig. 4.1B). In a separate experiment using a 
distinct preparation of primary CGN cultures, the toxin B-induced decrease in CtBP1 and 






Figure 4.1 CtBP1 and CtBP2 are downregulated in CGNs exposed to Clostridium 
difficile Toxin B, an inhibitor of Rho family GTPases. A. CGNs were incubated for 
24 h in control medium containing 25 mM KCl and 10% FBS (Con) in the absence or 
presence of Toxin B (Tox B; 40 ng/ml). Cells were th n lysed and protein extracts were 
subjected to PowerBlot™ analysis. Incubation with Tox B resulted in the downregulation 
of both CtBP1 (indicated by the black arrows) and CtBP2 (a doublet indicated by the 
asterisks). G protein-coupled receptor kinase-interacting protein-z-short (GITz-short; 
white arrows) is shown to demonstrate equal protein loading of the PowerBlot™ gels. B. 
Densitometric quantification of CtBP1 and CtBP2 protein expression in Con and Tox B-
treated CGNs. Results shown are the mean ± range from duplicate PowerBlot™ gels and 
are expressed as the fold change in CtBP expression between Tox B-treated cells and 
Con. C. To confirm the results of the Powerblot™, CGNs obtained from a different 
primary culture than those utilized in the PowerBlot™ analysis were incubated for 24 h 
in either Con medium or medium containing Tox B. After incubation, CtBP1 and CtBP2 
expression was analyzed by western blotting. Blots were then stripped and re-probed for 
actin as a loading control. I acknowledge Emily Schroeder for assistance with generating 




4.4.2 Multiple pro-death stimuli induce downregulation of CtBPs in CGNs 
 
 Next, we examined the effects of a number of diverse pro-death stimuli on the 
expression of CtBPs in CGNs. Primary CGN cultures rquire serum-derived growth 
factors and depolarizing extracellular potassium for their survival. Removal of 
depolarizing potassium (i.e., 5K conditions) induces apoptosis of CGNs through an 
intrinsic pathway (D'Mello et al., 1993 and Linseman et al., 2002). Upon removal of 
serum and depolarizing potassium (5K conditions), the expression of both CtBP1 and 
CtBP2 was significantly decreased (Fig. 4.2A). Similar reductions in CtBP expression 
were observed when CGNs were incubated with the BH3mimetic, HA14-1, the nitric 
oxide donor, sodium nitroprusside (SNP), or the complex I inhibitor, 1-methyl-4-
phenylpyridinium (MPP +) (Fig. 4.2B). The expression f CtBP1 was also analyzed by 
immunofluorescent staining under control, 5K, and MPP + treatment conditions. In 
control CGNs, CtBP1 was localized almost exclusively to the nucleus (Fig. 4.2C, upper 
panels). However, whether CGNs were exposed to either 5K or MPP +, two completely 
distinct stressors, CtBP1 immunoreactivity essentially disappeared in cells that 
demonstrated condensed and/or fragmented chromatin indicative of apoptotic 
morphology (Fig. 4.2C, middle and lower panels). These results demonstrate the 
downregulation of CtBP1 and CtBP2 in neurons undergoing apoptosis and further show 
that CtBPs are downregulated in response to a number of mechanistically distinct pro-





Figure 4.2 Multiple pro-death stimuli induce downregulation of CtBPs in CGNs. A. 
CGNs were incubated for 24 h in either control medium containing 25 mM KCl and 10% 
FBS (Con) or apoptotic medium containing only 5 mM KCl and lacking FBS (5K). Cells 
were then lysed, proteins resolved by SDS-PAGE, and immunoblotted for CtBP1 and 
CtBP2. Blots were subsequently stripped and re-probed for actin to show equal loading. 
B. CGNs were incubated for 24 h in either Con medium alone or containing the Bcl-2 
inhibitor HA14-1 (HA14; 15 µM), the nitric oxide donor sodium nitroprusside (SNP; 
100 µM), or the complex I inhibitor 1-methyl-4-phenylpyridinium (MPP +; 150 µM). 
After incubation, protein extracts were western blotted for CtBP1 and CtBP2. Blots were 
also stripped and re-probed for actin as a loading control. C. CGNs were incubated for 
24 h in either Con medium, 5K medium, or medium containing MPP +, as described 
above in (A) and (B). Following incubation, cells were fixed with 4% paraformaldehyde 
and their nuclei stained with DAPI. The microtubule n twork was stained with a 
polyclonal antibody to β-tubulin and a Cy3-conjugated secondary antibody. CtBP1 was 
detected using a monoclonal antibody to CtBP1 and a secondary antibody conjugated to 
FITC. White arrows indicate cells with condensed an/or fragmented nuclei indicative of 
apoptotic cell death. Note that regardless of the simulus, CGNs with apoptotic nuclear 
morphology displayed essentially no detectable CtBP1. Scale bar = 10 microns. I 
acknowledge Emily Schroeder for assistance with generating data for this figure. 
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4.4.3 Antisense oligonucleotides to CtBP1 induce CGN apoptosis 
 To determine if forced downregulation of CtBP1 is sufficient to trigger CGN 
apoptosis, we transfected cells with morpholino-antise se oligonucleotides to rat CtBP1 
using an EndoPorter delivery reagent. As negative controls, CGNs were transfected with 
inverse morpholino oligonucleotides or were exposed to the EndoPorter reagent alone. 
Transfections and subsequent 24 h incubations were p formed in control medium 
containing 25 mM KCl and 10% FBS. CGNs transfected with morpholino-antisense 
oligonucleotides to rat CtBP1 underwent significant poptosis characterized by nuclear 
condensation and fragmentation (Fig. 4.3A and 4.3B). In contrast, CGNs exposed to the 
EndoPorter reagent alone or transfected with inverse morpholino oligonucleotides 
displayed a similar level of apoptosis to untreated control CGNs. Although the 
morpholino-antisense oligonucleotides were fluorescently labeled with fluorescein, we 
were unable to accurately assess the extent of CtBP1 downregulation within the 
transfected cell population using immunofluorescent staining for CtBP1. This was 
primarily because the cells that fluoresced positive for the morpholino-antisense 
oligonucleotides were most often apoptotic and their nuclei were essentially devoid of 
CtBP1 immunoreactivity. However, given that CtBP1 nuclear staining disappears in 
apoptotic cells (see Fig. 4.2C), we cannot discern whether the CtBP1 staining is lost due 
to the antisense treatment or due to the fact that the cell is undergoing apoptosis. Given 
this limitation, our data suggest that antisense-mediat d down-regulation of CtBP1 is 




Figure 4.3 Morpholino-antisense oligonucleotides to CtBP1 induce CGN apoptosis. 
A. CGNs were incubated for 24 h in Con medium alone r containing the vehicle 
Endoporter (EP; 6 µl/ml), EP plus morpholino-antisense oligonucleotides to CtBP1 (Anti; 
10 µM), or EP plus inverse control morpholino-oligonucleotides (Inv; 10 µM). Apoptosis 
was quantified from 3 separate experiments each performed in triplicate. Antisense 
treatment induced significant CGN apoptosis (*p < 0.05) when compared to Inv, EP, or 
Con treatments. B. Representative images of CGNs following incubation with 
morpholino-antisense oligonucleotides or appropriate controls, as described in (A). Cells 
were fixed and nuclei stained with Hoechst. CGNs containing nuclei that were visibly 
condensed and/or fragmented were scored as apoptotic. I acknowledge Emily Schroeder 




4.4.4 The CtBP inhibitor, 4-methylthio-2-oxobutyric a id (MTOB), induces actinomycin 
D-sensitive apoptosis of CGNs 
 As an alternative means of knocking out CtBP functio  in CGNs, we next 
incubated cells with the putative CtBP inhibitor, MTOB. This compound is a CtBP 
dehydrogenase substrate which acts as a CtBP inhibitor and is toxic to cancer cells at 
high (1–10 mM) concentrations (Straza et al., 2010). In agreement with this previous 
study, incubation of CGNs with MTOB for 24 h reveald that significant apoptosis was 
induced at a concentration of 5 mM (Fig. 4.4A). More ver, the CGN apoptosis induced 
by this concentration of MTOB was delayed and required 24 h of incubation (Fig. 4.4B). 
In accordance with MTOB inducing apoptosis of CGNs, its toxic effects were completely 
suppressed by blocking the transcription of new genes with actinomycin D (Fig. 4.4C and 
D). Moreover, consistent with MTOB inhibiting the co-repressor function of CtBP, 
incubation with this compound induced a late induction of the CtBP target, the BH3-only 
protein Noxa, at 24 h post-treatment (Fig. 4.4E). Collectively, these results demonstrate 
that inhibition of CtBP co-repressor function is capable of inducing actinomycin D-






Figure 4.4 The CtBP inhibitor, MTOB, induces CGN apoptosis. A. MTOB dose 
response: CGNs were incubated for 24 h in Con medium containing increasing 
concentrations of MTOB. Apoptosis was quantified as the percentage of cells with 
condensed and/or fragmented nuclei. B. MTOB time course: CGNs were incubated for 
increasing durations with 5 mM MTOB and apoptosis was quantified. C. Representative 
fluorescence images of CGNs incubated for 24 h in Co  medium alone or containing 
5 mM MTOB ± actinomycin D (AD). D. Quantification of CGN apoptosis for the 
experiment described in (C). E. CGNs were incubated for increasing durations with 
5 mM MTOB. Cell lysates were prepared and western blotted for Noxa and actin. For 
(A), (B), and (D); **p < 0.01 compared to Con, ††p < 0.01 compared to MTOB. The 
results shown represent the means ± SEM of three ind pendent experiments each 
performed in duplicate. 
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4.4.5 In addition to the recognized proteasome degradation pathway, CtBPs are also 
downregulated through a novel caspase-dependent mechanism in CGNs 
Several previous reports have demonstrated that CtBPs are downregulated via 
proteasomal degradation during p53-independent apoptosis in non-neuronal cells (Paliwal 
et al., 2006, Wang et al., 2006, Zhang et al., 2003 and Zhang et al., 2005). However, the 
mechanism by which CtBPs are downregulated in neurons undergoing apoptosis has not 
previously been explored. To address this question, we analyzed the effects of inhibitors 
of the proteasome or caspases on the downregulation of CtBPs induced by various pro-
death stimuli in CGNs. Downregulation of CtBP1 and CtBP2 induced under 5K apoptotic 
conditions in CGNs was completely prevented by the pan-caspase inhibitor, BOC, but 
was only partially attenuated by the proteasome inhib tor MG132 (Fig. 4.5A). In response 
to apoptosis induced by toxin B or the related Clostridium sordellii lethal toxin which 
also inhibits Rac GTPase (Just et al., 1996), the observed downregulation of CtBP1 and 
CtBP2 was significantly blocked by caspase inhibition with BOC or zVAD but was 
unaffected by proteasome inhibition with MG132 (Fig. 4.5B and 4.5C). In contrast to 5K 
and the Clostridial toxins which are each known to activate caspases in CGNs, we have 
previously shown that CGN death induced by MPP + occurs through a caspase-
independent mechanism (Harbison et al., 2011). In agreement with this, the 
downregulation of CtBP1 and CtBP2 induced by MPP + in CGNs was unaltered by BOC 
but was significantly inhibited by MG132 (Fig. 4.5D). These data indicate that distinct 
pro-death stimuli act through a proteasome-dependent pathway and/or an alternative 
caspase-dependent pathway to downregulate CtBPs in neurons. To our knowledge, this is 
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Figure 4.5 Caspases and the proteasome contribute to CtBP downregulation in a 
stimulus-specific manner and CtBPs are downregulated in an exclusively 
proteasome-dependent manner following exposure to the complex I inhibitor 
MPP +. A. CGNs were incubated for 24 h in Con medium or 5K medium ± the pan-
caspase inhibitor BOC (50 µM) or the proteasome inhibitor MG132 (10 µM). B. CGNs 
were incubated for 24 h in Con medium alone or containing ToxB (40 ng/ml) ± either 
BOC or MG132. C. CGNs were incubated for 24 h in Con medium alone or containing 
Clostridium sordellii lethal toxin (400 µg/ml) ± the pan-caspase inhibitor zVAD (50 µM) 
or MG132. Following incubation, cells were lysed, proteins resolved by SDS-PAGE and 
transferred onto PVDF membranes. Blots were probed for CtBP1 and CtBP2 followed by 
stripping and re-probing for actin to indicate equal lo ding. D. CGNs were incubated for 
24 h in Con medium alone or containing MPP + (150 µM) ± BOC or MG132. Following 
incubation, cells were lysed, proteins resolved by SDS-PAGE, and immunoblotted using 
CtBP1 and CtBP2 antibodies. Blots were stripped and re-probed for actin to show equal 





4.4.6 6-hydroxydopamine (6-OHDA) induces caspase-dep ndent downregulation of 
CtBPs in the dopaminergic N27 cell line 
 In order to establish that the novel caspase-dependent mechanism of CtBP 
downregulation observed in CGNs undergoing apoptosis was not unique to this cell 
system, we next investigated the mode of CtBP downregulation in an in vitro model 
relevant to Parkinson's disease. The N27 cell line is a large T-antigen-immortalized, 
mesencephalon-derived cell line with characteristics of dopaminergic neurons (Zhou et 
al., 2000). Exposure of N27 cells to the neurotoxin, 6-OHDA, induces caspase-dependent 
apoptosis (Latchoumycandane et al., 2011). Incubation of N27 cells with 6-OHDA 
resulted in the downregulation of CtBP1 and CtBP2 in a dose-dependent manner 
(Fig. 4.6A). In addition, the downregulation of CtBPs induced by 6-OHDA was largely 
prevented by the pan-caspase inhibitor, BOC, but was actually accentuated by the 
proteasome inhibitor MG132 (Fig. 4.6B). Thus, caspase-dependent downregulation of 






Figure 4.6 Incubation of N27 dopaminergic cells with 6-OHDA induces 
downregulation of CtBP1 and CtBP2 through a caspase-dependent mechanism. A. 
N27 cells were incubated for 24 h in Con medium alone r containing either 25 µM or 
50 µM concentrations of 6-OHDA. Because of cell detachment induced by 6-OHDA, 
medium containing floating cells was obtained in a microcentrifuge tube and pelleted. 
The supernatant was then discarded and cells remaining i  the 6-well dish were lysed, 
scraped, and added to the previously pelleted cells which had detached. Combined 
contents in the microcentrifuge tube were then lysed, and proteins were resolved by SDS-
PAGE. Once transferred onto PVDF membranes, samples were immunoblotted with 
antibodies to CtBP1 and CtBP2. Membranes were stripped and re-probed for actin to 
show equal loading. B. N27 cells were incubated for 24 h in Con medium alone or 
containing 6-OHDA (25 µM) ± BOC (50 µM) or MG132 (10 µM). Cells lysates were 
immunoblotted as described in (A). I acknowledge Emily Schroeder for assistance with 




4.4.7 CtBP downregulation induced by 5K apoptotic conditions in CGNs does not occur 
through an enhanced rate of protein degradation 
 The downregulation of CtBP1 observed under 5K apoptotic conditions occurred 
in a relatively protracted manner over the course of many hours (Fig. 4.7A). One 
principal mechanism by which proteins are downregulated is by an enhanced rate of 
degradation. Given that the downregulation of CtBPs under 5K apoptotic conditions was 
sensitive to caspase inhibition, we utilized pulse-chase methodology to determine if 
CtBPs were being actively degraded during CGN apoptosis. Quantification of a discrete 
pool of 35S-labeled CtBP1 (pulse) following incubation in eith r 25K or 5K serum-free 
medium (chase) resulted in nearly identical t1/2 values for CtBP1 of approximately 10 h 
(Fig. 4.7B and 4.7C). These data suggest that CtBP1 does not undergo an enhanced rate 
of degradation during 5K-induced apoptosis in CGNs. In tead, the downregulation of 




Figure 4.7 Pulse-chase analysis of the kinetics of CtBP1 downregulation in CGNs 
incubated in apoptotic (5K) medium. A. CGNs were incubated in 5K medium for 
various times over the course of 56 h. CtBP1 protein l vels were assessed by western 
blotting and membranes were stripped and re-probed for actin to show equal loading. B. 
CGNs were initially incubated for 4 h in cysteine-mthionine-free medium containing 
35S-methionine. Following this “pulse” incubation, cells were washed and medium was 
replaced with serum-free Con medium or 5K medium. At various time points during this 
“chase” incubation, cells were lysed and CtBP1 was immunoprecipated using a 
monoclonal antibody. Immunoprecipitated samples were resolved on a 10% 
polyacrylamide gel, transferred onto a PVDF membrane, d exposed directly to film. C. 
Quantification of 35S-CtBP1 densitometry from (B) was graphed to compare the kinetics 
of loss of CtBP1 during the 24 h “chase” incubation period. Values are plotted as a 
percentage of the time 0 band density. CtBP1 displayed a half-life of approximately 10 h 
in CGNs incubated in either Con or 5K medium. I acknowledge Emily Schroeder for 




4.4.8 CtBP1 is not directly cleaved by caspase-3 in vitro 
 Upon examination of the CtBP1 amino acid sequence, a consensus DXXD 
caspase-3 cleavage motif was noted in human CtBP1 at residues 103DNID106. This 
consensus caspase-3 cleavage site is highly conserved and is present in CtBP1 and CtBP2 
proteins of human, mouse, and rat species (Fig. 4.8A). An identical DNID motif present 
in the adenomatous polyposis coli protein was previously shown to be directly cleaved by 
caspase-3 (Webb et al., 1999). To determine if this 103DNID106 site serves as a viable 
caspase-3 cleavage site in CtBP1 we performed an in vitro proteolysis experiment with 
recombinant caspase-3 and recombinant CtBP1. As a positive control for caspase-3 
activity, we utilized poly(ADP-ribose) polymerase (PARP) which is cleaved by caspase-3 
to generate an 85 kDa fragment (Tewari et al., 1995). As expected, recombinant caspase-
3 cleaved PARP to produce the 85 kDa fragment but it failed to cleave CtBP1 to any 
appreciable extent (Fig. 4.8B). Thus, despite the pr sence of a consensus caspase-3 
cleavage motif, CtBP1 is not a direct substrate of caspase-3. This result is in agreement 
with the above data and further suggests that the downregulation of CtBPs observed in 





Figure 4.8 Despite the presence of a highly conserved, consensus caspase-3 cleavage 
site, CtBP1 is not directly cleaved by recombinant caspase-3 in vitro. A. CtBP1 and 
CtBP2 sequences across numerous species indicate a highly conserved caspase-3 
cleavage site (DXXD; shaded residues). B. Recombinant CtBP1 (1.5 µg) or recombinant 
PARP (5 µg) were incubated in the absence or presence of recombinant caspase-3 
(rCasp3; 100 U) for 4 h at 37 °C. Recombinant proteins were then run on 7.5% 
polyacrylamide gels and western blotted with monoclona  antibodies to CtBP1 and 
PARP. The full length CtBP1 and PARP proteins are indicated by “fl”. The expected 
85 kDa PARP cleavage fragment produced by caspase-3-dependent proteolysis is 





4.4.9 CtBP transcript levels are not significantly decreased during 5K-induced apoptosis 
in CGNs 
 If the downregulation of CtBPs under 5K apoptotic conditions is due to decreased 
synthesis of new protein, then one possible point of regulation is at the level of CtBP 
gene transcription. To determine if CtBP1 and CtBP2 mRNA levels are reduced when 
CGNs are incubated in 5K apoptotic medium, we performed RT-PCR analysis. 
Surprisingly, even after 24 h incubation in 5K medium, no significant decrease in either 
CtBP1 or CtBP2 transcript expression was observed (Fig. 4.9A and 4.9B). Similar results 
were also obtained using quantitative real-time PCR analysis (data not shown). These 
results indicate that the downregulation of CtBPs ob erved during CGN apoptosis is not 





Figure 4.9 Incubation of CGNs in apoptotic (5K) medium has no significant effect 
on CtBP1 or CtBP2 transcript expression. A. CGNs were incubated in either Con or 
5K medium for 24 h. Total RNA was isolated and subjected to RT-PCR using primers 
specific for CtBP1, CtBP2, and actin mRNA transcripts. Representative bands are shown. 
B. Quantification of three independent experiments performed in duplicate as described 
in (A). CtBP1 and CtBP2 transcript expression levels were divided by the corresponding 
actin signals for normalization. 
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4.4.10 CtBP1 undergoes caspase-dependent downregulation in staurosporine-treated, 
wild type (WT) mouse embryonic stem cells (mESCs) but not DGCR8 knockout (KO) 
mESCs 
 The above findings indicate that CtBP function is es ential for CGN survival and 
furthermore, during CGN apoptosis CtBPs undergo an indirect, caspase-dependent 
downregulation that occurs via a post-transcriptional mechanism. Micro RNAs 
(miRNAs) are small noncoding RNAs that act as negative post-transcriptional regulators 
by binding to the 3′ UTRs of target mRNAs (Lai, 2002). Mature miRNAs are produced 
by a series of tightly regulated processing events. First, the primary miRNA transcript 
(pri-miRNA) is cleaved by the Microprocessor, a protein complex consisting of the 
ribonuclease Drosha and its essential cofactor, DiGeorge Critical Region 8 (DGCR8) 
(Gregory and Schiekhattar, 2005). Microprocessor cleavage of pri-miRNAs generates 
intermediate precursor miRNAs (pre-miRNAs) which are in turn, processed by Dicer to 
produce the mature miRNAs (Triboulet and Gregory, 2010). As a first step to determine 
if the caspase inhibitor-sensitive downregulation of CtBPs induced during apoptosis 
might be mediated via a miRNA-dependent pathway, we compared the expression of 
CtBP1 in WT mESCs to DGCR8 KO mESCs which are deficient in miRNA biogenesis 
(Wang et al., 2007). Incubation of WT mESCs with the classical apoptosis inducer, 
staurosporine, caused a marked downregulation of CtBP1 that was prevented by the pan-
caspase inhibitor QVD (Fig. 4.10A, left blot). In contrast, incubation of DGCR8 KO 
mESCs with staurosporine failed to have any significant effect on the expression of 
CtBP1 (Fig. 4.10A, right blot). It is important to note that staurosporine treatment caused 
significant cell death in both cell lines that was partially blunted by co-treatment with 
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QVD (Fig. 4.10B). These data indicate that the caspase-dependent downregulation of 






Figure 4.10 DGCR8 knockout mouse embryonic stem cells (mESCs) do not display 
caspase-dependent downregulation of CtBP1 in response to staurosporine 
treatment. A. Wild-type (WT) and DGCR8 knockout (KO) mESCs were incubated for 
24 h in Con medium alone or containing staurosporine (STS; 100 nM) ± the pan-caspase 
inhibitor QVD (20 µM). Following incubation, cell lysates were resolved by SDS-PAGE 
and western blotted for CtBP1. Membranes were subsequently stripped and reprobed for 
actin as a loading control. B. WT or KO mESCs were treated as described in (A). 
Representative bright field images are shown following a 24 h treatment period. Scale 




 CtBPs act as transcriptional co-repressors of a number of pro-apoptotic genes 
including the Bcl-2 family members Bax, Noxa, Bik, Bim, and Bmf (Bergman and 
Blaydes, 2006, Grooteclaes et al., 2003 and Kovi et al., 2010). Therefore, it is not 
surprising that CtBPs might be downregulated in cells undergoing apoptosis. However, to 
our knowledge the present study is the first to document this effect during neuronal 
apoptosis. Previous studies of CtBP function in the nervous system have been mostly 
limited to the role of these proteins in development. For instance, the Drosophila CtBP 
(dCtBP) significantly impacts development of the fly peripheral nervous system by 
negatively regulating formation of mechanosensory bristles, perhaps by influencing extra 
sensory organ precursor cell fate (Biryukova and Heitzler, 2008 and Stern et al., 2009). 
CtBPs are expressed throughout the developing avian CNS, often in overlapping regions 
but sometimes in unique localizations such as CtBP1 expression in dorsal root ganglia 
and CtBP2 expression in emigrating neural crest cells (Van Hateren et al., 2006). The 
functional significance of CtBP expression in the developing chick CNS is demonstrated 
by the key role that these proteins play in regulating he transition of neural precursor 
cells in the ventricular zone of the dorsal spinal cord from a proliferative to a 
differentiated state (Xie et al., 2011). In a similar manner, CtBP1 and CtBP2 display both 
duplicative and independent roles in mouse CNS development including maturation of 
the forebrain and midbrain (Hildebrand and Soriano, 2002). Additional studies have 
demonstrated interactions of CtBPs with a number of neuronal proteins including 
neuronal nitric oxide synthase, actin-related protein alpha, and calsenilin, although the 
physiological significance of these interactions is not well defined (Oma et al., 2003, 
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Riefler and Firestein, 2001 and Zaidi et al., 2006). Finally, CtBPs have been loosely 
associated with some types of CNS injury. For example, CtBP expression has been 
shown to decline rapidly following spinal cord injury in the mouse (Cai et al., 2012). In 
another study, the glycolytic inhibitor, 2-deoxy-D-glucose, suppressed seizure activity in 
a rat kindling model of temporal lobe epilepsy via an NRSF/CtBP-dependent repression 
of the BDNF gene promoter (Garriga-Canut et al., 2006). These studies demonstrate that 
CtBPs are key factors in CNS and peripheral nervous system development; however, the 
role of CtBPs in determining neuronal survival and death has not been explicitly 
investigated. 
 In the present study, we have identified CtBPs as essential pro-survival proteins in 
CGNs. The expression of CtBP1 and CtBP2 was significantly downregulated in CGNs 
exposed to a number of pro-apoptotic stressors. Moreover, forced downregulation of 
CtBP1 using morpholino-antisense oligonucleotides was sufficient to induce CGN 
apoptosis. In a similar manner, incubation of CGNs with the CtBP inhibitor, MTOB, 
induced the upregulation of pro-apoptotic Noxa and triggered actinomycin D-sensitive 
CGN apoptosis. These results are consistent with CtBPs functioning in CGNs as pro-
survival factors which are subject to downregulation during neuronal apoptosis. One may 
consider the downregulation of CtBPs as a major factor in determining whether neurons 
succumb to apoptosis since loss of CtBP function ultimately leads to the de-repression of 
pro-apoptotic genes. 
 In non-neuronal cells, CtBPs have previously been shown to be targeted for 
proteasomal degradation in response to pro-apoptotic stimuli that induce p53-independent 
apoptosis (Paliwal et al., 2006, Wang et al., 2006, Zhang et al., 2003 and Zhang et al., 
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2005). In contrast, CGNs exposed to Rac GTPase-inhibitory Clostridial toxins displayed 
downregulation of CtBP1 and CtBP2 that was insensitive to proteasome inhibition but 
sensitive to caspase inhibition. This novel caspase-dependent downregulation of CtBPs 
also predominated under 5K apoptotic conditions in CGNs and in N27 dopaminergic 
cells exposed to 6-OHDA. In contrast, the downregulation of CtBPs induced in CGNs by 
the complex I inhibitor, MPP +, was completely inseitive to caspase inhibition but was 
significantly attenuated by proteasome inhibition. These results demonstrate that the 
downregulation of CtBPs during neuronal apoptosis occurs via a stimulus-specific 
mechanism with both proteasome-dependent and caspase-dependent modes of 
downregulation. 
 Previous studies on the regulation of CtBP expression have focused largely on the 
proteasome-dependent degradation of these transcriptional co-repressors. During p53-
independent apoptosis of non-neuronal cells, CtBPs are phosphorylated on Ser422 or Ser 
428 (CtBP1 or CtBP2, respectively) by either homeodomain interacting protein kinase-2 
or c-Jun NH2-terminal kinase, targeting these proteins for subsequent ubiquitinylation 
and proteasomal degradation (Wang et al., 2006, Zhang et al., 2003 and Zhang et al., 
2005). Under some conditions, targeting of CtBP to the proteasome may require 
interaction with additional proteins such as the tumor suppressor ARF (Paliwal et al., 
2006). Recently, additional pathways have been suggested to regulate CtBP expression 
via the proteasome. For instance, Akt1 has recently been shown to cooperate with the 
SUMO E3 ligase Pc2 to induce phosphorylation and ubiquitinylation of CtBP resulting in 
its enhanced degradation (Merrill et al., 2010). Another pathway for CtBP degradation 
involves its interaction with the X-linked inhibitor of apoptosis protein which directly 
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ubiquitinylates CtBP and targets it for proteasomal degradation (Lee et al., 2012). On the 
other hand, B-cell lymphoma-3 (Bcl-3) is a proto-onc gene that has recently been shown 
to interact with and stabilize CtBP by preventing its ubiquitinylation and subsequent 
proteasomal degradation (Choi et al., 2010). Interes ingly, CtBP1 protein levels were 
downregulated in HEK293T cells incubated with the apoptosis inducer etoposide, but this 
effect was prevented by overexpression of Bcl-3. Thus, proteasome-dependent 
degradation appears to be a dominant pathway for turnover of CtBPs in non-neuronal 
cells undergoing apoptosis. 
 In marked contrast to these previous studies, we hav  identified a novel caspase-
dependent pathway for CtBP downregulation in neurons u dergoing apoptosis. Despite 
the presence of a conserved caspase-3 consensus cleavage site in the CtBP1 and CtBP2 
proteins, CtBPs do not appear to be direct caspase-3 substrates in vitro. Although it 
cannot be ruled out that other caspase family members may directly cleave CtBPs in 
neurons undergoing apoptosis, the rate of degradation of CtBP1 in CGNs is not 
significantly altered in 5K (apoptotic) medium suggesting that the downregulation of 
CtBPs observed under these conditions is not due to enhanced proteolysis. Intriguingly, 
CtBP1 and CtBP2 mRNA transcripts are not significantly decreased in CGNs subjected 
to 5K apoptotic conditions indicating that the downregulation of CtBPs likely occurs via 
a post-transcriptional mechanism. Consistent with this idea, the caspase-dependent 
downregulation of CtBP1 observed in mESCs exposed to staurosporine does not occur in 
DGCR8 KO cells that are deficient in miRNA biogenesis. Collectively, these data 
suggest that the caspase-dependent downregulation of CtBPs observed in neurons 
undergoing apoptosis may occur via a miRNA-dependent mechanism. 
143 
 
 Several recent studies add support to the hypothesis that CtBPs are subject to 
significant post-transcriptional regulation by miRNAs. For instance, the expression of 
miR-137 was found to inversely correlate with CtBP1 expression in melanoma cell lines. 
Moreover, miR-137 suppressed CtBP1 3′ UTR luciferase-reporter activity and 
overexpression of miR-137 decreased CtBP1 levels and c used a corresponding increase 
in expression of the CtBP1 target Bax (Deng et al., 2011). Interestingly, the miR-137 
gene is found on chromosome 1p22 which is a known susceptibility region for melanoma 
and furthermore, miR-137 was found to be under expressed in a subset of patient-derived 
melanomas (Bemis et al., 2008, Chan et al., 2011 and Walker et al., 2004). In a similar 
manner, the miR-141-200c cluster was recently shown t  downregulate the expression of 
CtBP2 and its transcriptional repressor partner, ZEB, in PANC-1 human pancreatic 
carcinoma cells (Sass et al., 2011). ZEB is a key inducer of the epithelial-to-
mesenchymal transition which is thought to promote malignant tumor progression, 
particularly in pancreatic, colorectal, and breast cancer (Burk et al., 2008). These studies 
indicate that specific miRNAs may act as tumor suppressors in part by targeting CtBPs 
for translational repression. It is noteworthy that miR-137 has recently been shown to act 
as a key regulator of embryonic neural stem cell fate (Sun et al., 2011). However, 
whether miR-137 regulates CtBP expression in the CNS is presently unknown. In the 
future, it will be important to determine if downregulation of CtBPs is associated with 
particular neurodegenerative diseases, particularly those for which caspases are 
implicated in the underlying pathogenesis. 
 Finally, elucidating the mechanism by which caspases indirectly influence CtBP 
expression during neuronal apoptosis will require additional study. One possibility is that 
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caspases degrade a protein that under healthy conditions acts as a suppressor of specific 
miRNAs. Once this suppressor is degraded, miRNAs are induced and target CtBPs for 
translational repression. This in turn, leads to the de-repression of a subset of CtBP target 
pro-apoptotic genes that contribute to the execution of neuronal apoptosis. The existence 
of “RNA silencing suppressor” (RSS) proteins is evidenced by the HIV-1 Tat and Rex 
proteins which suppress specific siRNAs or miRNAs by competing for their binding with 
Dicer or other proteins of the RNA-induced silencing complex (Houzet and Jeang, 
2011 and Rawlings et al., 2011). Thus, it is reasonble to hypothesize that neurons may 
possess intrinsic RSS proteins that are degraded by caspases during neuronal apoptosis. 
Identification of these putative neuronal RSS proteins may be necessary to resolve the 




CHAPTER FIVE: DYSREGULATION OF RHO OR RAC ELICITS DEATH OF 
MOTOR NEURONS AND ACTIVATION OF THESE GTPASES IS ALTERED IN 
G93A MUTANT SOD1 MICE  
5.1 Abstract 
 
 Numerous studies have demonstrated a critical function for Rho GTPase family 
members (i.e., Rac, Rho, Cdc42) in neuronal survival. Although a pro-survival function 
for Rac has been reported in several neuronal cell types, the antagonistic relationship 
between Rac and Rho/ROCK signaling in neuronal survival remains poorly understood. 
In the current study, we examined the effects of Rac GTPase inhibition on motor 
neuronal survival. We demonstrate that treatment with NSC23766, a selective inhibitor of 
the Rac-specific GEFs, Tiam1 and Trio, induces death of embryonic stem cell (ESC)-
derived motor neurons which is characterized by caspase-3 activation, dephosphorylation 
of ERK5 and Akt, and nuclear translocation of the BH3-only protein Bad. We also 
examined the effects of a constitutive activator of Rho, CN03, on motor neuronal survival 
in vitro. In a manner similar to selective inhibition of Rac GTPase, treatment of ESC-
derived motor neurons with CN03 results in a marked loss of neurites and significant cell 
death.  Furthermore, inclusion of either ROCK inhibitor, Fasudil or Y-27632, 
significantly protects ESC-derived motor neurons against constitutive activation of Rho. 
These data suggest that the balance between Rac and Rho signaling is critical for motor 
neuron survival. Moreover, in the G93A mutant Cu,Zn-superoxide dismutase (SOD1) 
mouse model of amyotrophic lateral sclerosis (ALS), active Rac1-GTP immunoreactivity 
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is markedly decreased in choline acetyltransferase (ChAT)-positive motor neurons of the 
lumbar spinal cord when compared to age-matched wil type (WT) littermates. In 
addition, although total RhoB localizes principally to nuclei of ChAT-positive motor 
neurons from WT mice, RhoB appears to redistribute to motor neuronal processes in end-
stage mice harboring the G93A SOD1 mutation. Collectiv ly, our data demonstrate that 
Rac and Rho are critical regulators of neuronal survival and as a result, disruptions in the 
balance of their activities may contribute to the etiology of motor neurodegenerative 
diseases such as ALS. 
5.2 Introduction 
 ALS is a devastating and progressive neurodegenerativ  disease characterized by 
severe muscle weakness and atrophy due to loss of motor neurons in the spinal cord, 
brain stem, and motor cortex. Following diagnosis, ALS patients typically survive 2-5 
years and succumb to death due to respiratory failure. Approximately 90% of ALS cases 
are classified as sporadic while the remaining 10% appear to be caused by a genetic 
component. In particular, mutations in SOD1 account for approximately 20% of all 
familial cases of ALS. Currently, mice harboring G93A mutant SOD1 (mSOD1) are the 
most extensively described rodent model of the disease (Pandya et al., 2013). Although 
the mechanism of motor neuron loss underlying the eiology of ALS is presently unclear, 
recent findings suggest that dysregulated Rho family GTPase activity may be a 
contributing factor. 
 Rho family GTPases are monomeric G-proteins that belong to the Ras 
superfamily of GTPases. Within the Rho GTPase family, RhoA, Rac1, and Cdc42 are the 
best described members. Numerous studies in neurons have demonstrated that Rho 
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GTPases are critical regulators of growth cone dynamics, dendritic spine morphogenesis, 
and neuronal survival (Linseman and Loucks, 2008). Specifically, Rac GTPase elicits 
neurite outgrowth and neuronal survival while Rho GTPase provokes neurite retraction 
and neuronal apoptosis (Luo, 2000). Many studies suggest that this intricate balance 
between Rho family GTPase activities is important for maintaining neuronal survival. For 
example, we have previously shown in primary cerebellar granule neurons (CGNs) that 
inhibition of Rac utilizing large Clostridial cytotxins or overexpression of a dominant 
negative Rac1 mutant induces mitochondrial-dependent apoptosis (Linseman et al., 2001; 
Le et al., 2005; Loucks et al., 2006; Stankiewicz et al., 2012).  Conversely, RhoA GTPase 
activation in CGNs elicits apoptosis following glutamate-induced excitotoxity (Semenova 
et al., 2007).  These studies underscore the importance of maintaining tight regulation of 
Rho family GTPase activity in order to promote neuronal survival.   
 More recent data have demonstrated that a disrupted balance between Rho family 
GTPases, particularly diminished Rac activity and/or enhanced Rho activity, may 
contribute to the pathogenesis of neurodegenerative d s ases such as ALS. Indeed, 
dominant negative Rac expression alone is sufficient to induce death of cultured motor 
neurons (Jacquier et al., 2006). Moreover, expression of G93A mSOD1 induces redox-
sensitive apoptosis of SH-SY5Y neuroblastoma cells that is dependent on inactivation of 
Rac GTPase (Pesaresi et al., 2011). In addition to mutations in SOD1, the involvement of 
Rac GTPase in maintaining motor neuron survival is underscored by the fact that loss-of-
function mutations in a Rac guanine nucleotide exchange factor (GEF), alsin (ALS2), are 
causative in juvenile-onset ALS (Yang et al., 2001; Yamanaka et al., 2003; Hadano et al., 
2007).  Although alsin functions as a GEF for both Rac and Rab5 (Topp et al., 2004), 
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overexpression of constitutively active Rac, but not Rab5, attenuates the cellular 
apoptosis and reduced axonal growth observed following siRNA knockdown of alsin in 
primary motor neurons (Jacquier et al., 2006). Furthermore, alsin has been specifically 
demonstrated to antagonize mutant SOD1-induced NSC34 motor neuronal death via 
activation of a Rac-dependent pro-survival signaling cascade (Kanekura et al., 2005).  
Finally, a recent study identified that ARHGEF16, an upstream regulator of Rac GTPase 
(Blanke and Jäckle, 2008), is hyper-methylated and downregulated in patients with 
sporadic ALS (Figueroa-Romero et al., 2012). Collectiv ly, these findings indicate that a 
loss of Rac GTPase activity may be a common factor underlying the death of motor 
neurons in both familial and sporadic forms of ALS.   
 In accordance with previous studies demonstrating a pro-apoptotic function for 
Rho GTPase in neurons, expression of the Rho GTPase effector Rho kinase (ROCK) is 
elevated 221% in the spinal cord of G93A mSOD1 mice wh n compared to WT mice, 
suggesting a potential increase due to enhanced Rho GTPase activity (Hu et al., 2003). 
These data indicate that in a manner similar to loss of Rac GTPase activity, gain of Rho 
GTPase/ROCK signaling may contribute to the selectiv  motor neuron death underlying 
the etiology of ALS.  This hypothesis is consistent wi h prior studies demonstrating 
aberrant activation of the Rho/ROCK pathway in other animal models of 
neurodegenerative disease (Mueller et al., 2005; Rikitake et al., 2005; Satoh et al., 2007; 
Zhang et al., 2010; Rodriguez-Perez et al., 2013). Nonetheless, detailed studies 
examining the activation status of Rac and Rho GTPases during ALS disease progression 
have not previously been investigated.    
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 In the present study, we aimed to determine the eff cts of altered Rho family 
GTPase activity on motor neuron survival in vitro and whether dysregulated activation of 
Rho family GTPases may contribute to ALS disease progression in vivo in the G93A 
mSOD1 mouse. We report that targeted inhibition of Rac GTPase via NSC23766 
treatment or constitutive activation of Rho via CN03 treatment induced neurite retraction 
and apoptosis of ESC-derived motor neurons in vitro. Moreover, in vivo, active Rac1-
GTP is significantly decreased in motor neurons from pre-symptomatic and end-stage 
G93A mSOD1 mice when compared to age-matched WT mice. Finally, we demonstrate 
that WT motor neurons express total RhoB in a diffuse distribution throughout the 
nucleus and soma while motor neurons of end-stage G93A mSOD1 mice demonstrate a 
significant redistribution of RhoB immunoreactivity to their axonal processes. 
Collectively, these findings demonstrate that Rac and Rho are critical mediators of motor 
neuronal survival. Consequently, diminished Rac GTPase activity or elevated Rho 
GTPase activity may contribute to the selective motor neuron degeneration observed in 
ALS. 
5.3 Materials and Methods 
5.3.1 Reagents  
 NSC23766, Fasudil, and the antibody used to detect ChAT were from EMD 
Millipore (Billerica, MA). Alexafluor 647 used to detect ChAT staining was from Life 
Technologies (Carlsbad, CA). CN03 and Y-27632 were purchased from Cytoskeleton 
(Littleton, CO). The polyclonal antibody used to detect active caspase-3 by 
immunocytochemistry was from Promega (Madison, WI). The polyclonal antibodies used 
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for immunostaining phosphorylated Akt (pAkt; S473), phosphorylated ERK5 (pERK5; 
T218/Y220), and Bad were from Cell Signaling Technology (Beverly, MA). The 
monoclonal antibodies used to detect active Rac1-GTP and active RhoA-GTP were 
purchased from NewEast Biosciences (King of Prussia, PA). The polyclonal antibodies 
used to detect total RhoB and the vesicular acetylcholine transporter (VAChT) were 
purchased from Santa Cruz Biotechnology (Dallas, Tx). 4,6-Diamidino-2-phenylindole 
(DAPI) and retinoic acid were purchased from Sigma (St. Louis, MO). The antibody 
utilized to detect CD11b was purchased from Abcam (Cambridge, MA). Anti-mouse 
Cy3- or anti-rat FITC-conjugated secondary antibodies utilized for immunofluorescence 
were from Jackson ImmunoResearch Laboratories (West Grove, PA). Sonic hedgehog 
(SHH), recombinant human brain-derived neurotrophic factor (BDNF), recombinant rat 
ciliary neurotrophic factor (CNTF), recombinant ratglial cell line-derived neurotrophic 
factor (GDNF), and recombinant human neurotrophic-3 (NT3) were all purchased from 
R&D Systems (Minneapolis, MN).  
5.3.2 Hb9::GFP embryonic stem cell (ESC) culture 
 The Hb9 mouse embryonic stem cell (ESC) line was derived from a transgenic 
mouse line expressing green fluorescent protein (Hb9::GFP) cDNA under the motor 
neuron-specific Hb9 promoter and was kindly provided by Wichterle and colleagues. 
Hb9::GFP ESCs were maintained in an undifferentiated s ate in culture and propagated as 
previously described (Wichterle et al., 2002). Briefly, Hb9::GFP ESCs were grown on a 
monolayer of mouse embryonic fibroblasts in ESC-grade DMEM medium containing 
4500 mg/L glucose and 2250 mg/L Na-bicarbonate supplemented with 15% hyclone fetal 
bovine serum (FBS), 2 mM L-glutamine, 1x Penicillin/Streptomycin, 1x non-essential 
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amino acids, 1x nucleosides, 0.1 mM 2-mercaptoethanol, and 1000 U/mL leukemia 
inhibitory factor (EMD Millipore).  
5.3.3 Hb9::GFP ESC differentiation 
 ESC-derived motor neurons were differentiated as previously described 
(Wichterle et al., 2002). Briefly, ESC cell colonies were partially dissociated and grown 
in aggregate culture in ADFNK medium [DMEM/F12 differentiation medium containing 
4500 mg/L glucose and supplemented 2 mM L-glutamine, 1x Penicillin/Streptomycin, 
0.1 mM 2-mercaptoethanol, 1x Insulin-Transferrin-Selenium supplement (Life 
Technologies), and 10% Knockout Serum Replacement (Life Technologies)] to promote 
the formation of embryoid bodies. After 2 days in culture, ADFNK medium was replaced 
and supplemented with retinoic acid (2µM; Sigma) to induce the formation of neuronal 
precursor cells. After 24 h, recombinant SHH and GDNF were added for an additional 4 
days to promote the differentiation of neural precusor cells into spinal motor neurons. 
Embryoid bodies were dissociated with papain (Worthington Bio, Lakewood, NJ) into 
single cell suspensions and plated onto dishes coated wi h matrigel (BD Biosciences, San 
Jose, CA). Differentiated ESC-derived motor neurons were cultured in DMEM/F12 
medium containing 4500 mg/L glucose and 2250 mg/L Na-bicarbonate supplemented 
with 5% horse serum, 1x Insulin-Transferrin-Selenium Supplement, 1x B27 Supplement, 
and neurotrophic factors (BDNF, CNTF, GDNF, NT3; each at 10 ng/mL). Consistent 
with the previously established protocol, typically 30% of the cells were EGFP-
expressing motor neurons that could be maintained i culture for at least 7 days for 




5.3.4 Immunofluorescence microscopy 
 For green fluorescent images, live fluorescent images were captured using a 20× 
air objective on an Olympus IX71 microscope with a Di gnostics Insight Spot 2 charge-
coupled device (CCD) camera and a Diagnostics capture software analysis program for 
digital deconvolution (Spot Imaging Solutions, Sterling Heights, MI).  
 For triple fluorescent images, motor neurons cultures were fixed in 4% 
paraformaldehyde, washed once in PBS, and then permeabilized and blocked in PBS 
containing 0.2% Triton X-100 and 5% BSA. Cell were incubated for 1 h in primary 
antibodies diluted in 2% BSA and 0.2% Triton X-100 in PBS and subsequently washed 
five times in PBS. Next, cells were incubated with DAPI and a Cy3-conjugated 
secondary antibody diluted in 2% BSA and 0.2% Triton X-100. The cells were washed 
five additional times with PBS before the addition of an antiquench solution composed of 
0.1% p-phenylenediamine in 75% glycerol in PBS. Fluorescent images were captured 
using a 63× water immersion objective on a Zeiss Axioplan 2 microscope with a Cooke 
Sensicam deep cooled CCD camera and a Slidebook software analysis program for 
digital deconvolution (Intelligent Imaging Innovations Inc., Denver, CO). 
5.3.5 Quantification of cell death and neurite integrity 
 As NSC23766- and CN03-induced cell death resulted in etachment of EGFP+ 
ESC-derived motor neurons from the culture dish, as an indicator of cell death and 
neurite integrity, the number of EGFP+ cells in tenra domly selected 20× fields was 
counted as was the number of motor neurons with neurites greater than three times the 
length of their soma. Typically, ~100-200 cells were quantified from each 22.73mm well. 
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Final counts represent the data obtained from at least three independent experiments 
performed in duplicate.  
5.3.6 Animals 
 Wild type FVB (WT) and mice expressing G93A mutant human SOD1 (mSOD1) 
on an FVB background were obtained from Jackson Laboratories (Bar Harbor, ME). 
When two observers independently noted for two consecutive days that a mouse 
displayed either hind limb trembling or failure to extend either hind limb fully when held 
by its tail, the mouse was considered to display signs of disease onset (~90 days). Mice 
unable to right themselves within 15 seconds after b ing placed on their side were 
considered end-stage (~120 days).  Male and female ic corresponding to pre-onset 
(~60 days), onset (~90 days), and end-stage (~120 days) were sacrificed in an isofluorane 
chamber followed by decapitation.  Lumbar spinal cord sections were identified by 
vertebrae, isolated, and immediately preserved in OCT for immunohistochemical 
analysis.  
5.3.7 Immunohistochemistry 
 For immunohistochemical studies, 18 µM lumbar spinal cord tissue sections 
obtained from paired animal sets (each G93A mSOD1 mouse and its WT littermate) were 
fixed in 4% paraformaldehyde. Next, the sections were blocked in PBS containing 5% 
BSA and 0.2% Triton X-100. Primary antibodies were diluted in PBS containing 2% 
BSA and 0.2% Triton X-100 and sections were incubated in primary antibody overnight 
at 4°C. Next, sections were washed five times in PBS. Sections were then incubated with 
Hoescht dye and Alexafluor 647-, Cy3-, or FITC-conjugated secondary antibody diluted 
in PBS containing 2% BSA and 0.2% Triton X-100. Sections were washed five 
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additional times with PBS before the addition of an antiquench solution composed of 
0.1% p-phenylenediamine in 75% glycerol in PBS. Fluorescent images were captured 
using a 40× air objective on a Zeiss Axioplan 2 micros ope with a Cooke Sensicam deep 
cooled CCD camera and a Slidebook software analysis program for digital deconvolution 
(Intelligent Imaging Innovations Inc., Denver, CO). 
5.3.8 Immunohistochemical Quantification 
 For paired sets of animals (each G93A mSOD1 mouse and its WT littermate), 
identical exposure times were used to capture fluorescent fields containing a total of 
approximately 100 ChAT-positive motor neurons per mouse. The DAPI and ChAT 
signals were transposed onto a corresponding bright field image of the same field. To 
select a specific motor neuron for quantitative analysis, only cells with large nuclei and 
significant ChAT immunofluorescence were chosen. The bright field image was then 
used to free hand draw an outline of the cell. The outline was then transposed onto the 
triple fluorescent image. The Rac1-GTP or RhoA-GTP fluorescent signal (red) was then 
measured within the outlined cell in relative units of average fluorescence intensity per 
pixel using Adobe Photoshop CS. An average background red fluorescence signal was 
also calculated for each individual field imaged by measuring the average fluorescence 
intensity per pixel in regions of the field which were completely devoid of cell nuclei. 
This background value was then subtracted from eachof t e individual cell fluorescence 
values obtained from that specific field. Using this method, the Rac1-GTP and RhoA-
GTP fluorescence was quantified from approximately 100 ChAT-positive motor neurons 




5.3.9 Data Analysis 
 Results represent the mean ± S.E.M. for the number (n) of independent 
experiments performed. Statistical differences betwe n the means of unpaired sets of data 
were evaluated by one-way analysis of variance with a post hoc Tukey's test or a 
student’s t test. A p value of <0.05 was considered statistically significant. Images are 
representative of at least three independent experiments.  
5.4 Results 
5.4.1 Generation and differentiation of ESC-derived motor neurons 
 To examine the involvement of Rho GTPases in regulating the survival of motor 
neurons, we utilized the HBG3 mouse ESC cell line developed by Wichterle and Peljto 
(Wichterle et al., 2002; Wichterle and Peljto, 2008). This ESC line was derived from a 
transgenic mouse line expressing enhanced green fluorescent protein (EGFP) cDNA 
under control of the mouse Hb9 promoter. The homeobox gene, Hb9, is expressed 
selectively by postmitotic motor neurons and is a cl ssical marker of mature motor 
neuron identity (Arber et al., 1999). ESC colonies were partially dissociated and grown in 
aggregate culture in differentiation medium to promote formation of embryoid bodies. 
After 2 days in aggregate culture, retinoic acid was added to promote differentiation into 
neural precursor cells (Fig. 5.1A; left panel). Following a 24 h exposure to retinoic acid, 
recombinant sonic hedge hog (SHH) and glial cell line-derived neurotrophic factor 
(GDNF) were added for an additional 4 days to promote differentiation and survival of 
spinal motor neurons (Fig. 5.1A; right panel). Embryoid bodies containing differentiated 
EGFP+ ESC-derived motor neurons (Fig. 5.1B; top image) were dissociated into single 
cell suspensions (Fig. 5.1B; middle image) and plated onto dishes coated with matrigel 
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(Fig. 5.1B; lower image and 5.1C). Following this protocol, approximately 30% of cells 
terminally differentiated into EGFP expressing motor neurons (Fig. 5.1B; lower panel 
and 5.1C). These EGFP+ motor neurons stain positively for Hb9, choline 




Figure 5.1 Generation and differentiation of ESC-derived motor neurons. A. HBG3 
mouse ESCs harboring an EGFP transgene driven by the motor neuron-specific Hb9 
promoter (Hb9::EGFP) were initially cultured on a monolayer of mouse embryonic 
fibroblasts in medium containing serum and leukemia inhibitory factor to suppress 
differentiation. After detachment with trypsin, ESCs were cultured in suspension with 
differentiation medium containing retinoic acid to induce development of motor neuron 
progenitors (left image). After 24 h of exposure to retinoic acid, sonic hedgehog (SHH) 
and glial cell line-derived neurotrophic factor (GDNF) were added to further promote the 
differentiation of neuronal precursor cells into spinal motor neurons (right image). After 
48 h incubation with SHH, embryoid bodies typically were larger and contained more 
EGFP+ motor neurons than those maintained in medium containing only retinoic acid 
(compare right panels to left panels). Scale bar = 100 micron. B. Following the 48 h 
incubation period with SHH and GDNF (top panel), embryoid bodies (EBs) were 
collected and gently digested with papain to produce a single cell suspension (middle 
panel). These cells were then plated onto matrigel-coated culture dishes (bottom panel). 
After 24 h on matrigel, EGFP+ motor neurons appear healthy and extend long processes 
as well as multiple shorter neurites (lower panel). Scale bar = 20 micron. C. 2x 
magnification of bottom, right image from 1B. Scale bar = 20 micron.  
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5.4.2 A selective inhibitor of the Rac-specific GEFs, Tiam1 and Trio (NSC23766; Rac 
Inh), causes a marked loss of neurites and death of ESC-derived motor neurons 
 To establish the involvement of Rac-GTPase in maintaining survival of ESC-
derived motor neurons, motor neuronal cultures were treated with the Rac inhibitor 
NSC23766.  This compound selectively and reversibly hinders GDP/GTP exchange 
carried out by the Rac-specific GEFs, Tiam1 and Trio, which are significant regulators of 
Rac in the central nervous system (Schmidt and Hall, 2002; Gao et al., 2004).  In a 
manner consistent with previous observations in CGNs (Chapter 3 of this thesis), ESC-
derived motor neuron cultures succumbed to cell death following exposure to targeted 
Rac GTPase inhibition. Incubation with the Rac inhibitor for only 6 h caused significant 
shrinkage of motor neuron soma and fragmentation of euronal processes (Fig. 5.2A). 
Following 24 h of Rac inhibition, these effects were even more pronounced with more 
than 50% of the motor neurons detached from the culture dish and essentially none of the 
remaining motor neurons exhibited significant neuronal processes (Fig. 5.2B).  
Consistent with a critical pro-survival function for Rac GTPase, we also observed 
activation of the death executioner caspase-3 in approximately 30% of the EGFP+ motor 
neurons that remained attached to the culture dish after a 24 h exposure to the Rac 
inhibitor (Fig. 5.4A). These results indicate that NSC23766-mediated inhibition of Rac 
GTPase in ESC-derived motor neurons elicits cell death via a mechanism consistent with 
both apoptosis and anoikis, a form of programmed cell d ath characterized by the 





Figure 5.2 A selective inhibitor of the Rac-specific GEFs, Tiam1 and Trio 
(NSC23766; Rac Inh), causes a marked loss of neurites and death of ESC-derived 
motor neurons. A. ESC-derived motor neuron cultures were left untreated (Control) or 
incubated with the Rac Inh (200 µM) for 6 h. Note that incubation with the Rac Inh 
caused the motor neuron cell bodies to round up and induced marked fragmentation of 
neuronal processes. Scale bar = 20 micron. B. ESC-derived motor neuron cultures were 
left untreated (Con) or incubated with the Rac Inh (200 µM) for 24 h. After 24 h, the total 
number of EGFP+ motor neurons was quantified as was the number of motor neurons 
with neurites greater than three times the length of their soma. Results shown are the 
mean ± SEM of 3 independent experiments performed on duplicate wells. *p<0.05, 




5.4.3 Inhibition of Rho Kinase (ROCK) only modestly protects ESC-derived motor 
neurons subjected to selective Rac-GTPase inhibition 
 Recent evidence demonstrates that phenylalanine treatment of cortical neurons 
results in a reduction of Rac expression and an induction of mitochondrial-dependent 
apoptotic cell death in a RhoA/ROCK-dependent mechanism (Zhang et al., 2007; Zhang 
et al., 2010). Therefore, we next examined whether inhibition of Rac GTPase induces 
neurite retraction and subsequent cell death through unopposed Rho/ROCK signaling. In 
ESC-derived motor neuron cultures treated with NSC23766, inclusion of either ROCK 
inhibitor, Fasudil or Y-27632, showed a very modest attenuation of cell loss and neurite 
fragmentation/retraction (Fig. 5.3A). However, quantification revealed that neither 
ROCK inhibitor displayed a statistically significant protective effect against selective Rac 
inhibition (Fig. 5.3B and 5.3C). These data suggest tha  the principal mechanism by 
which ESC-derived motor neurons subjected to Rac inhibition undergo apoptosis is not 




Figure 5.3 Inhibition of ROCK only modestly protects ESC-derived motor neurons 
subjected to selective Rac-GTPase inhibition. A. ESC-derived motor neuron cultures 
were incubated in either control medium (Con), Con medium + Rac Inh (200 µM), Rac 
Inh + Fasudil (10µM), or Rac Inh + Y-27632 (10µM) for 24 h. Images of EGFP+ cells 
were captured at 24 h. Scale bar = 20 micron. B. ESC-derived motor neuron cultures 
were treated as described in (A). After a 24 h incubation, the total number of EGFP+ 
motor neurons was quantified. C.  ESC-derived motor neuron cultures were treated as 
described in (A). After a 24 h incubation, the number of EGFP+ cells containing neurites 
at least 3x the length of the soma was quantified. Results shown are the mean ± SEM of 3 
independent experiments performed on duplicate wells. Values are expressed as a 




5.4.4 Selective inhibition of Rac GTPase in ESC-derived motor neurons induces 
dephosphorylation of ERK5 and Akt and nuclear translocation of the BH3-only protein 
Bad 
 The modest protection afforded by ROCK inhibitors indicates that other pathways 
known to regulate cellular survival downstream of Rac GTPase may be altered in 
NSC23766-treated ESC-derived motor neurons. In previous studies carried out in 
primary CGNs, we have demonstrated that NSC23766-mediated Rac inhibition 
deactivates a pro-survival signaling cascade involving MEK5/ERK5 and Akt, ultimately 
leading to an induction, dephosphorylation, and mitochondrial localization of the pro-
apoptotic BH3-only protein Bad (Chapter 3 of this thesis).  As anticipated based on these 
prior results, incubation with NSC23766 similarly induced dephosphorylation 
(inactivation) of the pro-survival proteins ERK5 (T218/Y220) and Akt (S473) in ESC-
derived motor neurons (Fig. 5.4B and 5.4C). Remarkably, NSC23766 treatment evoked a 
marked redistribution of the BH3-only protein Bad from a diffuse cytosolic pattern to an 
exclusively nuclear localization (Fig. 5.4D). These findings indicate that inhibition of Rac 
induces motor neuron death via a mechanism that involves inactivation of critical pro-
survival ERK5- and Akt-dependent signaling pathways, in addition to a redistribution of 




Figure 5.4 Selective inhibition of Rac GTPase in ESC-derived motor neurons 
induces activation of caspase-3, dephosphorylation of ERK5 and Akt, and nuclear 
translocation of the BH3-only protein Bad.  ESC-derived motor neuron cultures were 
left untreated (Control) or incubated with the Rac Inh (200µM) for 24 h. Cells were fixed 
and signaling proteins were visualized with a Cy3-conjugated secondary antibody as 
indicated (shown in red). Nuclei were stained with DAPI (shown in blue). Arrows 
indicate EGFP+ motor neurons. A. Active (cleaved) form of caspase-3. B. pERK5 
(T218/Y220). C. pAkt (S473). D. BH3-only protein Bad. Scale bar = 20 micron.  
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5.4.5 Constitutive activation of Rho via CN03 treatment induces a marked loss of neurites 
and death of ESC-derived motor neurons 
 In a manner similar to loss of active Rac GTPase, pr vious studies have 
demonstrated that activation of Rho GTPase is sufficient to provoke apoptosis in several 
neuronal models (Bertrand et al., 2007; Semenova et l., 2007; Sanno et al., 2010; 
Barberan et al., 2011). Thus, we examined whether a specific activator of Rho GTPase, 
CN03, is toxic to ESC-derived motor neurons.  CN03 is a fusion protein made up of the 
catalytic domain of a bacterial cytotoxic necrotizing factor and a proprietary cell 
penetration moiety. CN03 potently and selectively activ tes Rho GTPase by deamidating 
glutamine 63 within the switch 2 region of the protein, thus locking it in an active 
conformation (Flatau et al., 1997; Schmidt et al., 1997). Following a 24 h incubation 
period with CN03, ESC-derived motor neuron cultures displayed an approximately 35% 
reduction in EGFP+ motor neurons and a nearly 50% decrease in the number of EGFP+ 
motor neurons with neurites at least three times th length of their soma (Fig. 5.5A).  
Quantification revealed that constitutive activation f Rho GTPase induces significant 
cell death and neurite retraction (Fig. 5.5B). As anticipated, these data highlight that in a 
manner similar to inhibition of Rac function, constitutive activation of Rho triggers motor 





Figure 5.5 Constitutive activation of Rho via CN03 treatment induces a marked loss 
of neurites and death of ESC-derived motor neurons. A. ESC-derived motor neuron 
cultures were left untreated (Control) or incubated with the CN03 (1µg/mL) for 24 h. 
Scale bar = 20 micron. B. ESC-derived motor neuron cultures were left untreated (Con) 
or incubated with CN03 (1 µg/mL) for 24 h After 24 h, the total number of EGFP+ motor 
neurons was quantified as was the number of motor neu o s with neurites greater than 
three times the length of their soma. Results shown are the mean ± SEM of 3 independent 




5.4.6 Inhibition of ROCK significantly protects ESC-derived motor neurons subjected to 
constitutive Rho GTPase activation 
 Recent evidence suggests a necessary role for ROCK in apoptosis induced by Rho 
activation (Godin and Ferguson, 2010; Zhang et al., 2010). To definitively establish 
whether downstream activation of ROCK is required to induce cell death in ESC-derived 
motor neurons subjected to Rho activation, we evaluated whether co-incubation with 
either ROCK inhibitor, Fasudil or Y-27632, exerted a protective effect against CN03 
treatment.  In ESC-derived motor neurons treated with CN03, co-incubation with either 
Fasudil or Y-27632 protected against membrane blebbing and neurite retraction (Fig. 
5.6A). Quantification of cell loss and neurite fragmentation/retraction in ESC-derived 
motor neurons co-incubated with CN03 and Fasudil or Y-27632 revealed that inhibition 
of ROCK conferred significant neuroprotection against Rho activation (Fig. 5.6B and 
5.6C). These data support a model in which activation of Rho induces motor neurite 
retraction, fragmentation, and cell loss that is dependent on activity of the downstream 





Figure 5.6 Inhibition of ROCK significantly protects ESC-derived motor neurons 
subjected to constitutive Rho GTPase activation. A. ESC-derived motor neuron 
cultures were incubated in either control medium (Con), Con medium + CN03 (1µg/mL), 
CN03 + Fasudil (10µM), or CN03 + Y-27632 (10µM) for 24 h. At 24 h, images of 
EGFP+ cells were captured. Scale bar = 20 micron. B. ESC-derived motor neuron 
cultures were treated as described in (A). After th 24 h incubation, the total number of 
EGFP+ motor neurons was quantified. C.  ESC-derived motor neuron cultures were 
treated as described in (A). After the 24 h incubation, the number of EGFP+ cells 
containing neurites at least 3x the length of the soma was quantified. Results shown are 
the mean ± SEM of 3 independent experiments performed on duplicate wells. Values are 
expressed as a percentage of the Con condition. ***p<0.001 vs. Control, #p<0.05, 




5.4.7 Rac1-GTP immunoreactivity is decreased in ChAT-labeled motor neurons from 
G93A mSOD1 mice 
 Our data in ESC-derived motor neurons suggest that Rac GTPase activity is 
essential to maintain motor neuronal survival. To begin to unravel the complex role of 
Rac GTPase in ALS disease progression, lumbar spinal cord sections from end-stage 
G93A mSOD1 mice (G93A) and their age-matched wild type (WT) littermates were 
stained for DAPI, active Rac1-GTP, and ChAT. Quantification of Rac1-GTP intensity 
revealed that there is markedly reduced Rac1-GTP immunoreactivity in ChAT-positive 
motor neurons in the spinal cord of end-stage G93A mSOD1 mice when compared to WT 
mice (Fig. 5.7A and 5.7B). Furthermore, a similar reduction in Rac1-GTP 
immunoreactivity was observed at 90 days (disease onset) but not 60 days (pre-
symptomatic; Fig 5.7B). To our knowledge, these findings are novel in that they are the 
first to identify a substantial and progressive loss of active Rac1-GTP specifically in 




Figure 5.7 Rac1-GTP immunoreactivity is decreased in ChAT-labeled motor 
neurons from G93A mSOD1 mice. A. Spinal cords from end-stage (~120 days) mice 
harboring the G93A SOD1 mutation (G93A) or wild type (WT) littermates were 
cryosectioned into 18µM sections. Sections were stained for DAPI, active Rac1-GTP 
(red), and choline acetyltransferase (ChAT; to label motor neurons; green). Note that 
Rac1-GTP immunoreactivity is consistently high in WT motor neurons but is 
substantially decreased in ChAT-positive cells from G93A mutant mice. Arrows indicate 
prominent ChAT-positive motor neurons. Scale bar = 10 micron. B. Lumbar spinal cord 
tissue was stained as described in (A) and quantified for paired animal sets (each pair 
consisting of an end-stage G93A mSOD1 mouse and its age-matched WT littermate) at 
end-stage (~120 days), disease onset (~90 days), and pre-symptomatic (~60 days). The 
graph shown represents the average fluorescence intens ty (per pixel) per ChAT-positive 
cell and is presented as the mean ± SEM for 4 paired sets of mice at each disease stage. 
Values are expressed as a percentage of WT. *p<0.05 compared to WT by a paired t-test. 
NS denotes not significant. 
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5.4.8 Rac1-GTP immunoreactivity is enhanced in CD11b-positive microglia of end-stage 
G93A mSOD1 mice when compared to WT littermates 
 Collectively, our data in mouse ESC-derived motor neurons indicate an essential 
pro-survival function for Rac GTPase. Yet, previous studies have also shown that Rac1 
activation within microglia can activate NADPH oxidase to enhance the production of 
reactive oxygen species (ROS) and significantly contribute to the death of neighboring 
neurons (Harraz et al., 2008). To determine whether increased activation of Rac1 in 
microglia may contribute to the progression of disease in the G93A mSOD1 mouse 
model of ALS, lumbar spinal cord sections were stained for DAPI, Rac1-GTP, and 
CD11b. In agreement with aberrant Rac1 GTPase activity contributing to ALS disease 
progression, we observed increased Rac1-GTP immunoreactivity in CD11b-labeled 
microglia in the spinal cord of end-stage G93A mSOD1 mice (G93A) when compared to 
WT mice (Fig. 5.8). Collectively, our data support a model in which aberrant Rac1 
activity may contribute to ALS disease progression n a cell type-specific manner; 
through loss of its pro-survival function in motor neurons and enhancement of its ROS-




Figure 5.8 Rac1-GTP immunoreactivity is enhanced in CD11b-positive microglia of 
end-stage G93A mSOD1 mice when compared to WT littermates. Spinal cords from 
end-stage (~120 days) mice harboring the G93A SOD1 mutation (G93A) or wild type 
(WT) littermates were cryosectioned into 18µM sections. Sections were stained for 
DAPI, active Rac1-GTP (red), and CD11b (to label microglia; green). Scale bar = 10 
micron. Right image: 2.5X magnification of demarcated boxes from the upper image. 
Note that Rac1-GTP immunoreactivity is essentially bsent in WT microglia but is very 
high in CD11b-positive cells from G93A mutant mice. Arrow indicates CD11b-labeled 




5.4.9 RhoA-GTP immunoreactivity is not altered in ChAT-labeled motor neurons from 
G93A mSOD1 mice 
 Given the antagonistic relationship between Rac GTPase and Rho GTPase 
signaling in neurons, we predicted that diminished expression of active Rac1-GTP in 
ChAT-positive motor neurons in the G93A mSOD1 mouse would correlate with 
increased expression of active Rho GTPase. Although three isoforms of Rho GTPase 
(RhoA, RhoB, and RhoC) have been identified, RhoA activity has been widely 
demonstrated to provoke apoptosis in a variety of neuronal models (Dubreuil et al., 2006; 
Semenova et al., 2007; Sanno et al., 2010).  Thus, we stained lumbar spinal cord sections 
from end-stage G93A mSOD1 mice (G93A) and their age-matched WT littermates for 
DAPI, active RhoA-GTP, and ChAT. To our surprise, quantification of RhoA-GTP 
staining revealed that there was no statistical difference between RhoA-GTP expression 
in ChAT-positive motors neurons of end-stage G93A mSOD1 mice when compared to 
WT mice (Fig. 5.9A).  These results indicate that increased activation of RhoA GTPase 
does not contribute to the motor neuronal cell death observed in the G93A mSOD1 
mouse model of ALS. 
5.4.10 RhoB immunoreactivity is enhanced in motor neuron axons of G93A mSOD1 mice 
 In addition to RhoA, enhanced RhoB activation has been demonstrated to be an 
early marker of neuronal death in a murine stroke model (Trapp et al., 2001), and 
cultured corticohippocampal neurons isolated from RhoB knockout mice are significantly 
less sensitive than WT neurons to apoptosis induced by staurosporine (Barberan et al., 
2011). Therefore, we next stained lumbar spinal cord sections from end-stage G93A 
mSOD1 mice (G93A) and their age-matched wild type litt rmates for DAPI, RhoB, and 
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ChAT. Although the overall expression of RhoB did not appear to be enhanced in motor 
neurons from end-stage ALS mice, the localization of RhoB was drastically altered. In 
WT mice, ChAT-positive motor neurons expressed RhoB in a diffuse distribution 
throughout the nucleus and soma; however, essentially no immunoreactivity was 
observed in neuronal processes. In marked contrast, motor neurons of end-stage G93A 
mSOD1 mice demonstrated significant RhoB immunoreactivity within their processes 
(Fig. 5.9B and 5.9D).  To definitively establish the axonal expression of RhoB in motor 
neurons, spinal cord sections from end-stage G93A mSOD1 mice and WT mice were 
stained for DAPI, RhoB and the vesicular acetylcholine transporter (VAChT). Our data 
demonstrate that RhoB expression partially co-localizes with the VAChT in motor 
neuron axons of end-stage G93A mSOD1, but not WT, mice (Fig. 5.9C). Interestingly, 
RhoB redistribution appears to occur at a relatively late stage during disease progression 
as RhoB was consistently localized to the nuclei and soma of both WT and G93A 





Figure 5.9 RhoB immunoreactivity is enhanced in motor neuron axons of G93A 
mSOD1 mice A. Spinal cords from end-stage mice (~120 days) harboring the G93A 
SOD1 mutation (G93A) or wild type (WT) littermates were cryosectioned into 18µM 
sections. Sections were stained for DAPI, active RhoA-GTP (red), and choline 
acetyltransferase (ChAT; to label motor neurons). The graph shown represents the 
average fluorescence intensity (per pixel) per ChAT-positive cell and is presented as the 
mean ± SEM for 3 paired sets of mice (each pair consisti g of an end-stage G93A 
mSOD1 mouse and its age matched WT littermate). Values are expressed as a percentage 
of WT. NS denotes not significant compared by a paired t-test. B. Spinal cords were 
processed and cryosectioned as described in (A). Sections were stained for DAPI, RhoB 
(red), and choline acetyltransferase (ChAT; to label motor neurons; green). Note that 
RhoB immunoreactivity is not observed in neuronal processes of WT motor neurons but 
brightly labels processes of ChAT-positive cells from G93A mutant mice. Scale bar = 5 
micron. C. Spinal cords were cryosectioned as described in (A). Sections were stained for 
DAPI, RhoB (red), and vesicular acetylcholine transporter (VAChT; to label motor 
neuron axons; green). Note that RhoB immunoreactivity is not observed in neuronal 
processes of WT motor neurons but brightly labels processes of VAChT-positive motor 
neuron axons from G93A mSOD1 mice. Scale bar = 10 micron. D. Lumbar spinal cord 
tissue was stained as described in (A) for 3 paired sets of end-stage mice (~120 days) 
mice. Note that in each animal set RhoB immunoreactivity is not observed in neuronal 
processes of WT motor neurons but brightly labels processes of ChAT-positive cells from 
G93A mSOD1 mice. Arrows indicate RhoB expression in motor neuron processes. Scale 
bar = 10 micron. E. Lumbar spinal cord tissue was st ined as described in (A) for 3 
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paired sets of disease onset mice (~90 days) mice. Note that in each 90 day animal set 
RhoB expression principally localizes to the soma in both WT and G93A ChAT-positive 
motor neurons. Scale bar = 10 micron. 
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5.4.11 Proposed model depicting the mechanisms by which dysregulated Rho family 
GTPase activity may contribute to selective motor neuron degeneration in the G93A 
mSOD1 mouse model of ALS 
 We propose in healthy spinal cords (Fig. 5.10A), microglia retain Rac1 in an 
inactive GDP-bound state while motor neurons promote pro-survival signaling by 
maintaining Rac1 in an active GTP-bound state. Furthermore, we propose that RhoB 
localizes principally to the soma of healthy motor neurons. Conversely, in the diseased 
spinal cords of G93A mSOD1 mice (Fig. 5.10B), we hypothesize that enhanced 
activation of Rac1-GTP in microglia contributes to the activation of NADPH oxidase and 
the release of toxic ROS from microglia. Furthermore, loss of Rac1-GTP pro-survival 
signaling in G93A mSOD1 motor neurons leads to neurit  retraction and motor neuron 
death through deactivation of critical Rac1-dependent pro-survival signaling cascades. 
Finally, we hypothesize that RhoB redistribution to axons of motor neurons leads to 







Figure 5.10 Proposed model depicting the mechanism by which dysregulated Rho 
family GTPase activity may contribute to selective motor neuron degeneration in 
the G93A mSOD1 mouse model of ALS.  A. In wild type spinal cords, active Rac1 
(GTP-bound) transmits pro-survival signals in motor neurons. RhoB is localized to the 
cytosol of motor neurons. In healthy microglia, Rac1 exists primarily in an inactive 
(GDP-bound) state.  B. In G93A mSOD1 spinal cords, decreased Rac1-GTP in motor 
neurons promotes death via diminished pro-survival signals. The localization of RhoB 
from the cytosol to motor neuron processes also promotes axonal retraction and motor 
neuron death.  Increased microglia in the spinal cord is indicative of microgliosis. Within 
reactive microglia, increased Rac1-GTP leads to enhanced activation of NADPH oxidase 
and the release of toxic reactive oxygen species (ROS). Red indicates increased 
activation. Blue indicates decreased activation. Green indicates altered localization. I 






It is well documented that the antagonistic relationship between Rac GTPase and 
Rho GTPase is a determinant of neuronal survival. Therefore, it is perhaps not surprising 
that inhibition of Rac GTPase or constitutive activa ion of Rho GTPase induces cell death 
and neurite fragmentation/retraction of ESC-derived motor neurons. Indeed, inhibition of 
Rac GTPase in embryonic rat spinal motor neurons is sufficient to cause suppression of 
axon outgrowth and induce cell death (Jacquier et al., 2006). Moreover, in NSC34 motor 
neuron-like cells, constitutively active Rac protects these cells from the toxic expression 
of ALS-causing SOD1 mutants (Kanekura et al., 2005). Although the involvement of 
Rho GTPase in regulating motor neuron survival is not as well established, RhoA is 
activated in vulnerable brain regions following eith r traumatic brain injury or epileptic 
insult (Dubreuil et al., 2006), and RhoB null cortical neurons are significantly less 
sensitive to apoptotic stimuli than wild type neurons (Barberan et al., 2011). Thus, Rac 
GTPase and Rho GTPase play key roles in a regulating neuronal survival. 
Our data indicate that inhibition of Rac GTPase induces neurite fragmentation and 
motor neuronal cell death through activation of thedeath executioner of apoptosis, 
caspase-3, and via deactivation of essential pro-survival kinases, including ERK5 and 
Akt. These results were anticipated based on our prior findings in primary CGNs 
demonstrating that selective Rac inhibition with an inhibitor of Tiam1 and Trio induces 
apoptosis through diminished pro-survival MEK5/ERK5 and Akt signaling (Chapter 3 of 
this thesis). These findings are consistent with those of Kanekura et al. (2005) who 
showed that a Rac/PI3K/Akt-dependent pro-survival signaling cascade attenuated mutant 
SOD1-induced toxicity in the NSC34 motor neuron cell line. Furthermore, our findings in 
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ESC-derived motor neurons substantiate the critical mportance of Rac GTPase in 
transmitting key pro-survival signaling cascades in terminally differentiated motor 
neurons.  
A critical pro-survival function of active pAkt (S473) is to phosphorylate the pro-
apoptotic BH3-only protein Bad to sequester it to 14-3-3 cytosolic scaffolding proteins, 
effectively diminishing its ability to induce apoptsis at the mitochondria (Zha et al., 
1996). Indeed, we have previously shown in NSC23766-treated CGNs that diminished 
pAkt (S473) induces mitochondrial localization of Bad (Chapter 3 of this thesis). 
Surprisingly, in the present study, we report that NSC23766 treatment evokes a marked 
redistribution of the BH3-only protein Bad from a diffuse cytosolic pattern to an 
exclusively nuclear localization in ESC-derived motor neurons. This result differs from 
the mitochondrial translocation of Bad observed in CGNs exposed to the Rac inhibitor; 
however, it is an intriguing finding since nuclear localization of Bad has been suggested 
to stimulate entry of cells into the cell cycle (Chattopadhyay et al., 2001; Al-Bazz et al., 
2009), which is a known trigger of apoptosis in post-mitotic neurons (Folch et al., 2012).  
Although our data indicate that inhibition of Rac GTPase induces neurite 
fragmentation and motor neuronal death, it was surprising to reveal that inclusion of two 
distinct ROCK inhibitors (i.e. Fasudil, Y-27632) did not significantly protect motor 
neurons from loss of Rac GTPase activity.  Supporting crosstalk between Rac and 
Rho/ROCK signaling, Rac GTPase has been shown to repress Rho/ROCK signaling in 
HeLa cells through binding and activating the Rho GAP, p190RhoGAP (Wildenberg et 
al., 2006). Furthermore, it has been previously demonstrated that Rho/ROCK signaling 
can antagonize transmission of pro-survival Rac-dependent signaling pathways.  In 
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particular, activation of Rho/ROCK enhances the phos lipid phosphatase activity of 
PTEN which when coexpressed with RhoA, results in asynergistic reduction in active 
Akt in human embryonic kidney cells (Li et al., 2005). Nonetheless, given that our data 
do not support significant involvement of ROCK in mediating death of Rac-inhibited 
ESC-derived motor neurons, it is possible that unopposed Rho GTPase activation may 
induce neurite retraction and subsequent apoptosis hrough an alternative downstream 
effector.  Indeed, Semenova et al. (2007) previously demonstrated that ROCK activity 
was dispensable in CGNs undergoing Rho-dependent glutamate excitotoxicity as 
inclusion of Y-27632 did not attenuate nuclear fragmentation. Thus, our data do not 
exclude the possibility that inhibition of Rac GTPase leads to unopposed pro-apoptotic 
Rho GTPase signaling that occurs independent of ROCK activation in motor neurons.  
Interestingly, although ROCK inhibitors were not protective against selective 
inhibition of Rac GTPase in ESC-derived motor neurons, both Fasudil and Y-27632 
protected against neurite loss and apoptosis elicited via constitutive activation of Rho 
GTPase with CN03. These data highlight that activation of Rho GTPase may induce cell 
death through downstream activation of a ROCK/PTEN pathway as PTEN indirectly 
terminates Akt activation to induce neuronal death (Wu et al., 2012; Lai et al., 2014). 
Furthermore, a recent report demonstrated that inhibition of ROCK utilizing a metabolite 
of Fasudil, hydroxyfasudil, reduced G93A mSOD1-induced neurotoxicity in NSC34 
motor neuronal-like cells in a manner that was dependent on reducing elevated PTEN 
levels and restoring diminished levels of active Akt. Moreover, inhibition of Akt 
abolished the neuroprotective effects afforded by hydroxyfasudil in G93A mSOD1-
transfected NSC34 cells (Takata et al., 2013). Collectively, these data predict that 
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enhanced activation of Rho/ROCK signaling induces slective motor neuronal death 
through activation of PTEN and subsequent deactivation of the pro-survival protein Akt. 
To further investigate whether dysregulated Rho family GTPase activity 
contributes to the etiology of ALS, we examined theexpression of active Rac1 GTPase 
and RhoA GTPase in the spinal cord of G93A mSOD1 mice. We report that active Rac1-
GTP immunoreactivity is significantly decreased in ChAT-positive motor neurons of 
G93A mSOD1 mice when compared to age-matched littermates. Significant deficits in 
active Rac1-GTP were observed in motor neurons of G93A mSOD1 mice at 120 days 
(end-stage) and 90 days (onset), but not at 60 days (pre-symptomatic). This is consistent 
with our findings demonstrating an essential role for Rac GTPase in maintaining ESC-
derived motor neuron survival and is further supported by studies reporting that 
expression of Rac1 can antagonize cell death caused by mSOD1 expression in a variety 
of neuronal models, including primary motor neurons (Kanekura et al., 2005; Jacquier et 
al., 2006; Pesaresi et al., 2011). A potential mechanism by which G93A mSOD1 may 
inactivate Rac1 GTPase in diseased motor neurons involves the growth factor adaptor 
protein p66Shc. Upon oxidative stress, p66Shc is phos orylated and translocates to the 
mitochondria where it acts as an oxidoreductase to generate ROS (Giorgio et al., 2005; 
Gertz and Steegborn, 2010). While G93A mSOD1 expression in SH-SY5Y cells induces 
cell death consistent with decreased Rac1 GTPase activity, expression of an inactive 
mutant of p66Shc abrogates this effect. The ability of p66Shc to regulate Rac1 activity 
occurs via a redox-sensitive mechanism as treatment of SH-SY5Y cells with H2O2 led to 
a proportionate decrease in Rac1 GTPase activity tha  was attenuated by expression of an 
inactive p66Shc mutant (Pesaresi et al., 2011). While t e precise mechanism by which 
183 
 
active Rac1-GTP is downregulated in spinal motor neurons of G93A mSOD1 mice 
remains to be determined, these findings highlight loss of Rac1 activity as a significant 
factor in the selective motor neuron death observed in ALS.  
Given the antagonistic relationship exerted between Rac GTPase and Rho GTPase 
in conjunction with extensive evidence specifically implicating RhoA in neuronal 
apoptosis, we predicted that decreased active Rac1-GTP immunoreactivity would 
correlate with enhanced active RhoA-GTP expression in ChAT-positive motor neurons. 
We were surprised to find that there was no significant difference between RhoA-GTP 
expression in G93A mSOD1 and WT motor neurons. Instead, we found a marked 
redistribution of total RhoB expression. While RhoB exclusively localizes to the soma in 
WT motor neurons, RhoB significantly redistributed to neurites of spinal motor neurons 
in end-stage, but not disease onset, ALS mice. This is an important finding given 
substantial evidence demonstrating that RhoB can induce neurite retraction and 
subsequent neuronal apoptosis (Trapp et al., 2001; Conrad et al., 2005; Barberan et al., 
2011). Indeed, in ALS mouse models, analysis of neurom scular junctions reveals axonal 
retraction and denervation prior to loss of alpha motor neuron cell bodies in the lumbar 
spinal cord and associated development of clinical symptoms (Frey et al., 2000; Fischer 
et al., 2004). However, collectively, our data suggest that loss of active Rac1-GTP may 
underlie neurite retraction and motor neuron death in early disease stages (disease onset), 
while RhoB redistribution may contribute to neurite retraction in later disease stages 
(end-stage).   
Contrary to the loss of active Rac1 GTPase observed in spinal cord motor 
neurons, we show increased Rac1-GTP staining in CD11b-positive microglia of end-
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stage G93A mSOD1 mice when compared to WT littermates.  In agreement with these 
findings, a previous report demonstrated that Rac1-GTP is actually upregulated in total 
spinal cord lysates isolated from G93A mSOD1 mice (Harraz et al., 2008), lending to the 
hypothesis that Rac1 activation plays a cell type-scific role in the progression of ALS.  
Indeed, although selective motor neuron degeneration is a hallmark of ALS, several 
reports indicate that death does not occur strictly via a cell-autonomous mechanism 
(Ilieva et al., 2009). Importantly, in addition to its role in neuronal development and 
survival, Rac1 is required to activate both Nox1 and Nox2, catalytic subunits of NADPH 
oxidase, and activation of this complex may contribute to the death of neighboring motor 
neurons through the generation of toxic superoxide (O2
-) molecules (Wu et al., 2006; Raz 
et al., 2010). Nox1, Nox2, and NADPH oxidase activity are upregulated in spinal cord 
microglia from genetic mouse models of ALS and ALS patients (Wu et al., 2006). 
Moreover, previous studies have demonstrated that either genetic deletion or chemical 
inhibition of Nox1 or Nox2 can slow disease progression and improve survival in familial 
ALS mice (Wu et al., 2006; Harraz et al., 2008). Further substantiating a role for 
enhanced activation of Rac1 GTPase in microglia as  causative factor underlying the 
progression of ALS, Harraz et al. (2008) demonstrated that mSOD1 stimulates Rac1-
dependent activation of NADPH oxidase in glial cells expressing ALS-causing forms of 
mutant SOD1. Collectively, these studies indicate that aberrant Rac1 GTPase activation 
in microglia may enhance NADPH oxidase activation and the release of toxic ROS to 
elicit motor neuron death in this particular mouse model of ALS.  
In addition to activation of NADPH oxidase, expression of G93A mSOD1 in 
microglia leads to the Rac1-dependent secretion of pr -apoptotic TNFα and subsequent 
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cell death of neighboring motor neurons in co-culture experiments (Li et al., 2011). 
Intriguingly, a recent report by Tönges et al. (2014) demonstrated that inhibition of 
ROCK via oral administration of Fasudil is protective against motor neuron loss in the 
G93A mSOD1 mouse and this occurs at least partially via reduced secretion of TNFα 
from microglia. Overall, these data support the notion that balanced signaling between 
Rac and Rho/ROCK is ultimately disrupted in the spinal cord of G93A mSOD1 mice.  
One potential mechanism by which G93A mSOD1 may activ te Rac1 GTPase in 
microglia is through the P2X7 receptor (Apolloni et al., 2013), which is responsible for 
the release of pro-inflammatory factors from microglia, such as TNFα (Skaper et al., 
2010). Although the precise mechanism by which activ tion of Rac1 in microglia 
enhances disease progression in the G93A mSOD1 mouse model of ALS requires further 
investigation; collectively, these data suggest that Rac1 may contribute to 
neurodegenerative disease in multiple cell type-specific ways; through loss of its pro-
survival function in motor neurons and enhancement of its ROS-generating function in 
glial cells.  
Takata et al. (2013) recently administered Fasudil to G93A mSOD1 mice to 
elucidate the involvement of ROCK activation on theintegrity and viability of motor 
neurons. Indeed, administration of Fasudil reduced motor neuronal loss, slowed disease 
progression, and extended lifespan of G93A mSOD1 mice. Furthermore, this study 
confirmed that ROCK inhibition attenuated elevated PTEN activation while restoring 
diminished Akt activation that is typically observed in this particular familial mouse 
model of ALS. It is interesting to note that in each study examining ROCK inhibition in 
vivo, Fasudil was administered at a relatively early stage in disease progression (Takata et 
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al., 2013; Tönges et al. 2014). In conjunction with our data implicating RhoB 
redistribution to neuronal processes in end-stage mice as a potential causative factor 
underlying disease progression, these data suggest that ROCK inhibition may prove to be 
an effective treatment even after disease onset. However, it is important to note that the 
antibody we utilized detected total RhoB expression as an antibody to active RhoB-GTP 
is not yet commercially available. Nonetheless, given this limitation, our data aid in 
clarifying the temporal and cell type-specific role that aberrant Rac1 GTPase and/or 
RhoB GTPase activity may contribute to the underlying pathology in the G93A mSOD1 
mouse model of ALS.   
 In summary, we show that selective inactivation of Rac GTPase or constitutive 
activation of Rho GTPase is sufficient to evoke neurite retraction and subsequent cell 
death of ESC-derived motor neurons. Further confirming the pro-survival role of Rac 
GTPase in motor neurons, we report that Rac1-GTP is significantly reduced in ChAT-
positive spinal cord motor neurons of G93A mSOD1 mice, when compared to age-
matched WT littermates, at disease onset through end-stage. However, our data indicate 
that the involvement of dysregulated Rac1 GTPase in contributing to the pathology of 
ALS is much more complex as Rac1-GTP is upregulated in microglia from end-stage 
mice harboring the G93A SOD1 mutation. Finally, we highlight that although RhoB 
localizes principally to the soma of ChAT-positive motor neurons from WT mice, RhoB 
redistributes to neuronal processes, including motor neuron axons, in end-stage mice 
harboring the G93A SOD1 mutation. To our knowledge, th se data are novel in that they 
are the first to reveal the temporal and cell type-s cific dysregulation of Rho family 
GTPases in a familial mouse model of ALS.   
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CHAPTER SIX: DISCUSSION 
 Accumulating evidence suggests an important and conserved role for Rho family 
GTPases in mediating neuronal survival and death. Pivotal studies have demonstrated 
that while Rac GTPase stimulates neurite outgrowth and neuronal survival, Rho GTPase 
typically provokes neurite retraction and neuronal apoptosis. Nonetheless, the precise 
pro-survival and pro-apoptotic signaling pathways mediated by Rho family GTPases in 
neurons remains incompletely understood. We have previously shown that the Rho 
family GTPase inhibitor ToxB induces CGN apoptosis primarily through deactivation of 
Rac1 GTPase (Linseman et al., 2001; Le et al., 2005; Loucks et al., 2006). Thus, a 
principal focus of this thesis was to examine the pr cise signaling pathways that are 
regulated by Rac1 GTPase in primary CGNs. Furthermore, given recent evidence 
suggesting that dysregulation of Rho GTPases may underlie the pathology of motor 
neurodegenerative diseases such as ALS, an additional f cus of this thesis was to 
examine the effects of dysregulation of Rac GTPase or Rho GTPase in terminally 
differentiated ESC-derived motor neurons and in an in vivo familial mouse model of 
ALS.  
6.1 Summary of Major Findings 
 We have previously shown that ToxB, a broad spectrum inhibitor of Rho, Rac, 
and Cdc42, induces apoptosis of primary CGNs predominantly through deactivation of 
Rac1 GTPase (Linseman et al., 2001; Le et al., 2005; Loucks et al., 2006). Indeed, in 
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healthy CGNs, Rac GTPase promotes neuronal survival through activation of a pro-
survival MEK1/2/ERK1/2 signaling cascade, acting downstream of PAK, that functions 
to repress  JNK/c-Jun activation of the BH3-only protein Bim, as well as, a pro-apoptotic 
JAK/STAT signaling cascade (Linseman et al., 2001; Le et al., 2005; Loucks et al., 
2006). The aim of Chapter 2 of this thesis was to examine which particular member of 
the STAT family induced CGN apoptosis downstream of Rac GTPase inhibition. In 
CGNs treated with ToxB, STAT5 was upregulated, hyper-phosphorylated, and 
translocated to nuclei to suppress transcription of the pro-survival protein Bcl-xL. These 
data helped clarify a critical pro-apoptotic pathway that is activated in primary CGNs in 
response to Rac GTPase inhibition.  
 Given that ToxB inhibits Rho, Rac, and Cdc42, the aim of Chapter 3 was to 
examine the effects of a more targeted inhibitor of Rac GTPase in CGNs. NSC23766 is 
an inhibitor of the Rac-specific GEFs, Tiam1 and Trio, and treatment with this compound 
elicited apoptosis of CGNs via a mechanism that wasdistinct from ToxB. While ToxB 
suppressed a pro-survival MEK1/2/ERK1/2 signaling cascade that led to reduced 
degradation of the BH3-only protein Bim, the selective Rac inhibitor instead suppressed a 
distinct pro-survival MEK5/ERK5 pathway that led to increased expression and 
mitochondrial localization of the BH3-only protein Bad. These data demonstrate that 
global inhibition of Rho GTPases versus selective inactivation of Rac GTPase induces 
apoptosis through suppression of unique MAP kinase signaling pathways, which regulate 
distinct pro-apoptotic members of the BH3-only subfamily of Bcl-2 family proteins.  
 An intriguing finding revealed in Chapter 4 of this thesis was that treatment of 
CGNs with LTox or ToxB, which have overlapping specificity for inhibiting Rac 
189 
 
GTPase, induced apoptosis concomitant with reduced expression of the transcriptional 
corepressors, CtBPs. Thus, Chapter 4 of this thesis aimed to clarify the involvement of 
CtBP downregulation in neuronal apoptosis. In CGNs undergoing apoptosis, CtBPs 
appear to be regulated post-transcriptionally and in a mechanism dependent on both 
caspase activation and intact miRNA biogenesis machinery. Furthermore, MTOB-
induced inhibition of CtBPs induced apoptosis that w s consistent with upregulation of 
the CtBP target and BH3-only protein, Noxa. Although the exact mechanism by which 
Rho GTPases regulate CtBP expression warrants further investigation, these data 
demonstrate that CtBPs are essential pro-survival factors in CGNs.  
 Chapter 5 of this thesis aimed to extend our findings elucidating the involvement 
of Rho GTPases in regulating CGN survival into an in vitro motor neuron model more 
relevant to the etiology of ALS. Supporting an antagonistic relationship between Rac 
GTPase and Rho GTPase, we report that inhibition of Rac GTPase or constitutive 
activation of Rho GTPase was sufficient to induce apoptosis of ESC-derived motor 
neurons.  Similar to our findings in CGNs, selective inhibition of Rac GTPase via 
NSC23766 evoked apoptosis through suppression of pr-survival kinase pathways 
involving ERK5 and Akt, as well as, nuclear translocation of the BH3-only protein Bad. 
Furthermore, we report that Rac1-GTP is diminished in motor neurons and enhanced in 
microglia in the spinal cords of mice harboring the G93A mSOD1 mutation, when 
compared to age-matched WT littermates. Interestingly, we also demonstrated a marked 
redistribution of RhoB from the cell soma of WT motor neurons to neuronal processes of 
motor neurons in mice carrying the G93A SOD1 mutation. These data are the first to 
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identify the cell type–specific and temporal dysregulation of Rho family GTPases in a 
mouse model of familial ALS.  
6.2 Elucidating the relationship between Rho GTPases and CtBPs  
 The downregulation of CtBP1 and CtBP2 in CGNs exposed to the small GTPase 
inhibitors ToxB and LTox is a novel finding that warr nts future investigation. As ToxB 
(an inhibitor of Rac, Rho, and Cdc42) and LTox (an inhibitor of Rac, Ras, and Rap) have 
overlapping specificity for inhibiting Rac GTPase, these findings suggests that Rac 
GTPase may function upstream of CtBPs to regulate their expression and consequently, 
the transcriptional repression of BH3-only pro-apoptotic proteins, such as Noxa. While 
the precise mechanism by which CtBPs are downregulated in neurons exposed to small 
GTPase inhibitors requires further investigation, recent studies have suggested a positive 
correlation between the expression of CtBPs and the activity of Rho family GTPases in 
non-neuronal cells. For example, overexpression of CtBP2 enhances Rac-dependent 
migration of human non-small cell lung carcinoma cells consistent with both PTEN 
inactivation and Akt activation (Paliwal et al., 2007).   
 Intriguingly, the CtBP-dependent activation of Rac requires the Rac-specific 
GEF, Tiam1. Initial studies demonstrated that Tiam1 appears to be regulated by the CtBP 
binding partner E1A. For instance, E1A expression led to the upregulation of Tiam1 and 
the formation of Rac-dependent cadherin-based adhesions in mesenchymal V12Ras-
transformed Madin-Darby canine kidney II cells (Malliri et al., 2004). More recently, it 
has been shown that CtBP2 occupies the Tiam1 promoter and enhances its transcription 
in a Basic Kruppel-like factor (BKLF8)-dependent manner in HCT116 human colon 
carcinoma cells (Paliwal et al., 2012). Indeed, although the recruitment of CtBPs to 
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DNA-binding repressors (e.g. E1A, BKLF8) typically results in transcriptional 
repression, more recent studies have demonstrated that CtBP may also activate 
transcription in a gene-dependent manner. For instance, Drosophila CtBP activates 
transcription of Wnt target genes following Wnt stimulation, while repressing other Wnt 
target genes in the absence of Wnt (Fang et al., 2006).  Thus, CtBP may enhance 
transcription of some genes (i.e. Tiam) while repressing others (i.e. PTEN, Noxa).  
  In conjunction with our own findings, these data suggest that CtBP1/CtBP2 and 
Rac GTPase may function in a positive feedback loop to regulate the expression and 
activities of one another (Fig. 6.1).  Nonetheless, it is important to consider that our 
studies demonstrating that CtBPs are regulated downstream of Rac GTPase were 
conducted in primary neurons, while the CtBP2-dependent upregulation of Tiam1 and 
subsequent activation of Rac GTPase was shown in H1299 cell lung and HCT116 colon 
carcinoma cells. Thus, whether or not Rac GTPase lies upstream or downstream of 
CtBP1 and CtBP2 may simply depend on the cell type. In future studies, it will be 
important to determine whether CtBP2 similarly triggers Tiam1-dependent activation of 
Rac GTPase in neurons. Indeed, the link between CtBPs and Rho family GTPases is only 
recently being elucidated and future studies will be necessary to decipher the precise 




Figure 6.1 Proposed positive feedback loop between CtBPs and Rho GTPases. 
Through a presently unknown mechanism, Rac GTPase enhances the expression of 
CtBPs. CtBPs bind to DNA binding proteins (e.g. BKLF8) and occupy the promoter 
region of the Rac-specific GEF Tiam1 to stimulate transcription. Increased levels of 




 6.3 Inhibition of Rac1 GTPase as a novel in vivo model to study the pathology 
of ALS 
Collectively, the in vitro experiments presented in this thesis highlight a critical 
function for Rac GTPase in regulating neuronal survival. While Chapter 2 and Chapter 3 
demonstrate a crucial function for Rac GTPase in maintaining the survival of primary 
CGNs; more recently, our work in Chapter 5 has identifi d a critical function for Rac 
GTPase in maintaining the survival of terminally differentiated ESC-derived motor 
neurons.  The importance of Rac GTPase in maintainig motor neuron survival is 
substantiated by the fact that the Rac GEF alsin is mutated in juvenile onset forms of 
ALS (Yang et al., 2001; Hadano et al., 2007). As previously discussed, alsin activates 
Rac to maintain survival of embryonic rat spinal motor neurons (Jacquier et al., 2006) 
and it has also been demonstrated that alsin can ant gonize mSOD1-induced cell death of 
NSC34 motor neuronal-like cells (Kanekura et al., 2005). However, the complexity of 
whether or not Rac GTPase is responsible for motor neuron specific death associated 
with alsin loss-of-function in in vivo rodent models is complicated by the fact that alsin 
loss-of-function models do not fully recapitulate the aspects of the human disease. 
Indeed, although four groups have independently generated different lines of ALS2 
knockout (ALS2-/-) mice, each group found that the loss of alsin does not have a dramatic 
effect on the survival or function of motor neurons i  mice (Cai et al., 2005; Devon et al., 
2006; Hadano et al., 2006; Yamanaka et al., 2006). This could be due to the intrinsic 
differences in organization of the human and mouse motor systems.  In addition, the 
paradox may be explained by compensatory mechanisms due to the fact that gene knock 
out typically occurs prior to embryonic development (Hadano et al., 2006).  Nonetheless, 
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it is interesting to note that a cross between ALS2-/- mice and mice expressing G93A 
mSOD1 did not exacerbate G93A mSOD1-associated disease symptoms such as body 
weight loss and motor dysfunction (Hadano et al., 2010), underscoring the possibility that 
Rac activity is already compromised in transgenic mi e expressing G93A mSOD1.  
Furthermore, while we and others have demonstrated that a loss of Rac GTPase 
activity may contribute to the etiology of disease progression in the G93A mSOD1 
mouse model of familial ALS, one caveat of these studies that must be considered is the 
poor clinical relevance of this particular model to human cases of ALS (reviewed in 
Wilkins et al., 2011). For instance, the only drug currently approved by the FDA for the 
treatment of ALS, the anti-glutamateric compound Riluzole, demonstrates signs of 
preserved motor neuron function and prolongs survival of the G93A mSOD1 mouse by 
approximately two weeks (Gurney et al., 1996; 1998). Nonetheless, Riluzole has only a 
minimal effect in human ALS progression and extends lifespan a mere three months 
(Miller et al., 2007; Brooks, 2009). In addition toRiluzole, a number of compounds 
targeting different facets of ALS disease progression (e.g. the antioxidant Vitamin E, the 
antibiotic Minocycline, etc.) have shown no effect in the clinic after demonstrating 
promising results in the G93A mSOD1 mouse (Wilkins et al., 2011). These data highlight 
the necessity to develop new rodent models to study the pathogenesis of ALS.  
 A prominent field of research worthy of future investigation is the design of new 
in vivo rodent models to study the underlying pathology and progression of ALS. Based 
on the work presented in this thesis in conjunction with human studies demonstrating that 
diminished Rac GTPase activity may be a causative factor in both familial and sporadic 
forms of ALS (Yamanaka et al., 2003; Topp et al., 2004; Kanekura et al., 2005; Jacquier 
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et al., 2006; Harraz et al., 2008; Figuera-Romero et al., 2013), development of a Rac 
GTPase loss-of-function mouse expressing an inducible dominant negative mutant of 
Rac1 under a motor neuron-specific promoter (e.g. ChAT, HB9) may aid in clarifying the 
precise consequence that a of loss of Rac1 GTPase activity in motor neurons contributes 
to motor neuron disease. In a similar manner, generation of a mouse model expressing 
inducible constitutively active Rac1 under a microglia-specific promoter (e.g. CD11b) 
may aid in clarifying the precise involvement that gain of Rac1 GTPase activity in 
microglia contributes to the death of neighboring motor neurons. As it stands, while the 
G93A mSOD1 mouse model of ALS has been helpful in clarifying the molecular 
mechansims that underlie ALS disease progression, the fact that mSOD1 research has not 
led to clinically applicable therapeutic advances indicates the necessity for more 
therapeutically relevant models.  
6.4 Mechanisms and consequences of dysregulated Rho GTPase activity in ALS 
disease progression 
6.4.1 Mechanisms and consequences of dysregulated Rc GTPase activity in ALS disease 
progression 
Supporting a pro-survival function for Rac GTPase, veral studies have 
substantiated an essential role for Rac GTPase in maintaining survival of various 
different neuronal types, including motor neurons. These data lend to the hypothesis that 
a loss of Rac GTPase function may underlie the selective motor neuronal death 
associated with neurodegenerative disorders such as ALS.  Nonetheless, this hypothesis 
has been challenged by recent evidence demonstrating that active Rac1-GTP is actually 
upregulated in total spinal cord homogenates isolated from mice expressing G93A 
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mSOD1 when compared to age-matched littermates (Harraz et al., 2008).  These findings 
are not necessarily mutually exclusive and the datapresented in this thesis aid in bridging 
the gap in current research by demonstrating that Rac1 GTPase activity is diminished in 
motor neurons and enhanced in microglia of mice harboring the G93A SOD1 mutation.  
Given the large increase in microglia coincident with the death of substantial numbers of 
motor neurons in the spinal cord of end-stage ALS mice, our data and those of Harraz et 
al. seem to be compatible. Moreover, within the diseased spinal cord of transgenic mice 
expressing G93A mSOD1, recent research indicates that mutant forms of SOD1 may 
either increase or decrease the activity of Rac1 GTPase in a redox sensitive and cell-type 
specific manner.   
The ability of mutant forms of SOD1 to influence Rac1 GTPase in a redox 
sensitive manner is particularly interesting given the proposed role of oxidative stress in 
the disease progression of ALS.  For example, several distinct mutant forms of SOD1 
form aggregates in the mitochondria of motor neurons and cause a shift in the 
mitochondrial redox state, ultimately resulting in a more oxidized environment (Ferri et 
al., 2006). Consistent with our data demonstrating diminished Rac1-GTP expression in 
motor neurons from G93A mSOD1 mice, a recent study has established the ability of 
G93A mutant SOD1 to induce cell death via decreased expression of active Rac1 GTPase 
in a redox sensitive manner in SH-SY5Y neuroblastoma cells. In this case, the growth 
factor adaptor p66shc, a known regulator of mitochondrial-dependent oxidative balance, 
diminishes the activity of Rac1 GTPase following adenoviral-driven expression of 
mutant, but not wild type, SOD1. Intriguingly, p66Shc-mediated downregulation of Rac1 
GTPase activity in SH-SY5Y cells expressing G93A mSOD1 appears to occur in a 
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redox-sensitive manner as increasing concentrations of H2O2 results in a proportional 
decrease in Rac1 GTPase activity and cell viability that is prevented by expression of an 
inactive p66Shc mutant.  The potential significance of p66shc-induced downregulation of 
Rac1 GTPase activity is underscored by the fact that G93A mSOD1 mice crossed with 
p66Shc-/- mice show improved motor performance, delayed disease onset, and increased 
survival with respect to G93A mSOD1 mice (Pesaresi et al., 2011).  While this previous 
study was pivotal in demonstrating that G93A mSOD1 expression can cause a decrease 
in Rac1 GTPase activity in SH-SY5Y cells, further studies will need to be conducted to 
determine whether decreased expression of Rac1 GTPase occurs in a G93A mSOD1- and 
p66Shc-dependent mechanism in motor neurons in particul r.  
In addition to G93A mSOD1-mediated downregulation of Rac1 GTPase activity 
in motor neurons, it is also possible that Rac1 GTPase activity is decreased during the 
progression of ALS due to alterations in the activity of Rac-specific GEFs. Indeed, as 
previously discussed, loss-of-function mutations in the GEF alsin underlie early-onset 
familial forms of ALS (Yang et al., 2001; Yamakana et al., 2003; Hadano et al., 2007). 
Interestingly, recent evidence also suggests that epigenetic alterations of genes encoding 
GEFs for Rac GTPase may underlie some sporadic forms f ALS. For example, the Rac 
GEF, ARHGEF16, is hypermethylated and downregulated in postmortem sporadic ALS 
spinal cord samples when compared to samples from neurologically normal controls 
(Figueroa-Romero et al., 2012). These data indicate that loss of Rac activation due to 
diminished GEF activity may also underlie motor neuron degeneration in both familial 
and sporadic ALS disease progression.  
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In a manner dissimilar to motor neurons, several studies indicate that mutant 
forms of SOD1 associated with the pathology of ALS have an opposing function in 
microglia, ultimately resulting in enhanced activaton of Rac1 GTPase in a redox-
sensitive manner. For example, Harraz et al. (2008) demonstrated WT SOD1 binds to 
Rac1 and inhibits its intrinsic GTPase activity under reducing conditions, ultimately 
increasing active Rac1 GTPase activity. In the presence of H2O2 (oxidizing conditions), 
the interaction between WT SOD1 and Rac1 GTPase was uncoupled.  Intriguingly, ALS-
causing mutations in SOD1 prevent the enzyme from redox uncoupling, resulting in 
enhanced activation of Rac1 GTPase in microglia cells. Inevitably, aberrant Rac1 
GTPase activity leads to increased activation of Nox2, a catalytic subunit of NADPH 
oxidase, resulting in an overproduction of damaging ROS. Indeed, in agreement with 
Rac1-dependent activation of NADPH oxidase as a contributing factor underlying motor 
neuron degeneration in the G93A mSOD1 mouse, inhibition of or genetic deletion of 
Nox2 improves disease progression and increases survival in this particular mouse model 
of familial ALS (Wu et al., 2006; Marden et al,, 2007; Valdmanis et al., 2008).  
Furthermore, Apolloni et al., (2013) recently identified extracellular ATP as a potential 
mechanism by which Rac1 GTPase activity may be enhanced in microglia of G93A 
mSOD1 mice.  In primary microglia cells isolated from G93A mSOD1 mice, stimulation 
of the P2X7 receptor by its agonist, 2’-3’-O-(benzoyl-benzoyl) ATP enhanced Nox2 
activation and the production of ROS in a Rac1-dependent manner when compared to 
microglia derived from non-transgenic animals. Thus, recent experimental evidence 
suggests that G93A mSOD1 may stimulate Rac1 GTPase activation in a P2X7-dependent 
mechanism to enhance the release of toxic ROS from microglia.    
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6.4.2 Mechanisms and consequences of dysregulated Rho GTPase activity in ALS disease 
progression 
 In contrast to a critical pro-survival role for Rac GTPase, many reports indicate 
that Rho GTPase has an opposing function and leads to the transmission of pro-apoptotic 
signals in neurons, including motor neurons. Although three isoforms of Rho GTPase 
(RhoA, RhoB, and RhoC) have been identified, the involvement of RhoA and RhoB in 
provoking neuronal apoptosis has been best described.  While we predicted that a loss of 
Rac1-GTP would correlate with increased active RhoA-GTP expression, we did not 
detect a significant increase in active RhoA-GTP in motor neurons of G93A mSOD1 
mice.  However, we found a distinct redistribution of total RhoB in end-stage G93A mice 
when compared to age-matched littermates. While RhoB principally localized to the 
soma of WT motor neurons, it drastically redistributed to neuronal processes, including 
motor neuron axons, of end-stage (~120 days), but not disease onset (~90 days), mice. 
This is an important finding considering the involvement of RhoB GTPase in inducing 
both neurite retraction and apoptosis (Conrad et al., 2005). Consistent with these 
functions, we found that constitutive activation of Rho induced both neurite retraction 
and membrane blebbing indicative of apoptosis in ESC-derived motor neurons.  In future 
studies, it will be important to discern whether RhoB redistribution leads to neurite 
retraction and/or motor neuron apoptosis in the G93A mSOD1 mouse. Indeed, several 
studies have highlighted that axonal retraction may occur independent of motor neuron 
apoptosis in the familial mouse models of ALS.  For example, studies indicate that in 
early stages of the disease the nerve terminals and neuromuscular junctions are 
disassembling while cell bodies in the spinal cord a e relatively intact, leading to the 
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notion that a “dying back” phenomenon underlies the pathology of ALS (Frey et al., 
2000; Fischer et al., 2004).  This is somewhat conflicting with our finding that total RhoB 
redistribution to axons occurs in end-stage, but not disease onset, G93A mSOD1 motor 
neurons. Future studies will need to be performed to clarify the involvement of RhoB in 
mediating neurite retraction and motor neuron death in rodent ALS models. 
Alternatively, the loss of Rac1-GTP observed in motor neurons at disease onset may also 
contribute to inhibition of axonal outgrowth in early disease stages of ALS progression.  
Given the antagonistic relationship exerted between Rac GTPase and Rho GTPase, it is 
likely that dysregulated activity of both GTPases contributes to axonal retraction and 
motor neuron death observed during the progression of ALS.   
6.5 Pharmacological targeting of Rho GTPase signaling pathways as a therapeutic 
strategy for the treatment of ALS 
6.5.1 Nox inhibitors to target aberrant Rac GTPase ctivation in microglia during ALS 
disease progression 
 Collectively, the data presented in this thesis along with the work of others, has 
suggested that increased Rac1 GTPase activity in microgl a may contribute to the 
activation of Nox2, the subsequent activation of NADPH oxidase, and generation of toxic 
ROS.  Thus, one potential therapeutic target for the reatment of ALS may be 
pharmacological inhibition of Nox. Indeed, Marden et al. (2007) reported that 
homozygous knockout of Nox1 and Nox2 increased the lifespan of B6SJ G93A mSOD1 
mice by 33 and 97 days, respectively.  In a similar study, it was found that Nox2 deletion 
extended the survival of C57BL/6J G93A mSOD1 mice by 15 days (Wu et al., 2006).  
Pharmacological inhibition of Nox with high dose apocynin in B6SJL G93A mSOD1 
201 
 
mice increased survival 113 days (Harraz et al., 2008). Recent efforts have also examined 
whether diapocynin, the activated metabolite of apocynin, similarly extends survival of 
G93A mSOD1 mice. While diapocynin and apocynin protected primary motor neurons 
from nitric oxide-induced death in vitro, Trumbull et al. (2012) did not observe any 
significant effect of these compounds on survival in B6SJL G93A mSOD1 expressing 
mice. Although both of these studies treated mice harboring the G93A SOD1 mutation on 
the same genetic background, the disparity in these r ports may have occurred because 
Trumbull et al. (2012) began apocynin and diapocynin treatment at 21 days of age, while 
Harraz et al. (2008) began apocynin treatment at 14 days of age.  Nonetheless, in the 
Trumbull et al. (2012) study, mice treated with eith r apocynin or diapocynin did show a 
trend toward increased survival. These conflicting studies underscore the need for 
additional mouse models of ALS that are not related to mutations in SOD1 to futher 
evaluate the potential use of Nox inhibitors as a tre tment option for ALS patients. 
 Apocynin represents an attractive therapeutic compound for the treatment of ALS 
due to its low toxicity and lack of side effects in humans (Van den Worm et al., 2001; 
Stefanska and Pawliczak, 2008). Furthermore, diapocynin is also an attractive therapeutic 
compound as it is predicted to be more permeable to the blood-brain barrier due to its 
greater hydrophobicity.  Indeed, in addition to rodent models of ALS, oral treatment with 
apocynin is safe and effective in the MPTP marmoset model of Parkinson’s disease (PD).  
During disease progression, apocynin relieved PD symptoms and increased the number of 
surviving dopaminergic neurons compared to controls (Philippens et al., 2013). Thus, 
these prior studies highlight the safety of apocynin for the treatment of devastating 
neurodegerative disorders. Apocynin appears to be arelatively safe compound and it is 
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worthy of consideration for future clinical trials in ALS patients. Nonetheless, further 
examination is required to determine the safety of long-term use of Nox inhibitors in 
humans.  
6.5.2 ROCK inhibitors to target aberrant Rho GTPase ctivation in motor neurons 
during ALS disease progression 
 The data presented in this thesis suggest that redistribution of RhoB to neuronal 
processes and potential activation of the downstream ffector ROCK may contribute to 
axonal retraction and motor neuron death in the G93A mSOD1 mouse model of ALS. 
Thus, inhibition of ROCK represents an attractive th rapeutic target for examination in 
preclinical trials using familial mouse models of ALS.  Indeed, we recently conducted 
preliminary experiments to determine whether treatment with the ROCK inhibitor Fasudil 
was protective in the G93A mSOD1 mouse model.  Mice were administered 100 mg/kg 
of Fasudil in their drinking water beginning at 30 days of age. FVB G93A mSOD1 mice 
administered Fasudil showed a delay in disease onset compared to untreated mutant mice 
as measured by hind limb trembling or failure to extend either hind limb fully when held 
by its tail (Fig. 6.3A). In addition, utilizing a paw grip endurance (PaGE) test that 
measures the muscle strength of forelimbs and hindlimbs, G93A mSOD1 mice receiving 
Fasudil treatment showed a delay in the decline in gr p strength when compared to 
untreated G93A mSOD1 mice (Fig. 6.2A).  Fasudil treated mice also displayed a delay in 
weight loss (Fig. 6.2B). Finally, we noted an increas  in survival of G93A mSOD1 mice 
treated with Fasudil when compared to untreated mutant mice (Fig. 6.3B). Although very 
preliminary, these results suggest that inhibition of ROCK may prove to be an effective 
treatment option for ALS patients.   
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Figure 6.2 Administration of the ROCK inhibitor Fasudil delays latency to fall and 
weight loss in the G93A mSOD1 mouse. Beginning at 60 days, mice were administered 
100 mg/kg Fasudil daily in their drinking water. A.PaGE hanging wire test represented 
as mean latency to fall at indicated ages. Note the delay in latency to fall in G93A 
mSOD1 mice when compared to untreated mutant mice (n=2). B. Percent of peak body 
weight at indicated ages. Note that the weight lossobserved in untreated G93A mSOD1 
is abrogated by Fasudil treatment (n=2). I would like to acknowledge Aimee Winter for 






Figure 6.3 Administration of the ROCK inhibitor Fasudil delays onset and extends 
survival in the G93A mSOD1 mouse. Beginning at 60 days, mice were administered 
100 mg/kg Fasudil daily in their drinking water. A.Onset was determined when a mouse 
displayed for two consecutive days either hind limb trembling or failure to extend either 
limb fully when held by its tail (n=2). B. End-stage was determined when mice were 
unable to right themselves within 15 seconds after being placed on their side (n=2). I 
would like to acknowledge Aimee Winter for assistance in generating data for this figure.  
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 Consistent with non-cell autonomous death underlying the etiology of ALS, our 
preliminary data is consistent with two recent reports examining the effect of Fasudil on 
both microgliosis (Tönges et al., 2014) and motor neurons death (Takata et al., 2013) in 
G93A mSOD1 mice on a BJSJL background.  Tönges et al. (2014) demonstrated that 
inhibition of ROCK preserved neuromuscular junctions and extended the survival of 
G93A mSOD1 via a mechanism consistent with reduced microgliosis and decreased 
release of pro-inflammatory cytokines and chemokines such as TNFα and IL-6. When 
examining motor neuron death in G93A mSOD1 mice, Takata et al. (2013) demonstrated 
that administration of Fasudil slowed disease progression and reduced motor neuron loss 
by a mechanism consistent with reduced activation of ROCK and PTEN and restored 
activation of the pro-survival kinase Akt. In future studies, it will be important to discern 
whether the protection afforded by ROCK inhibitors correlates with reduced inhibition of 
Rac1 GTPase in motor neurons of mice harboring mutations in SOD1. In conjunction 
with our own work demonstrating that dysregulation f both Rac GTPase and Rho 
GTPase may contribute to microglial activation and motor neuron death in G93A mutant 
SOD1 mice, these studies serve to highlight that the intricate balance between Rho 
GTPases is a critical determinant of motor neuronal survival and may be disrupted in 
neurodegenerative disease such as ALS.   
 Collectively, these data highlight ROCK as a promising target for the treatment of 
ALS patients. Currently, Fasudil is already in clinical use as a vasodilator agent (Zhao et 
al., 2011) and inhibition of ROCK in patients with cerebral vasospasm does not appear to 
cause any adverse side effects (Shibuya et al., 1992).  Furthermore, Fasudil has not 
shown any severe side effects or changes in blood pressure and heart rate in patients with 
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angina or acute ischemic stroke (Shimokawa, 2002; Shibuya et al., 2005; Vicari et al., 
2005). Nonetheless, it is important to note that ROCKII knockout mice show embryonic 
lethality whereas ROCKI knockout mice experience failure of eyelid closure and closure 
of the ventral wall (Thumkeo et al., 2003; Shimizu et al., 2005), highlighting a critical 
function for both ROCK isoforms in development. In addition, it was reported that 
intracerebroventicular administration of the ROCK inhibitor Y-27632 increased anxiety-
related behavior in mice (Saitoh et al., 2006).  Thus, while inhibition of ROCK offers a 
promising therapeutic target for the treatment of ALS, further examination is required to 
determine the safety of long-term use of nonselectiv  inhibitors of ROCKI and ROCKII 
(such as Fasudil and Y-27632) in humans.  
Alternatively, the development of a safe ROCKII inhibitor may offer a viable 
option for the clinical treatment of ALS.  Although Fasudil targets both ROCKI and 
ROCKII, ROCKII is preferentially expressed in brain a d skeletal muscle tissue while 
ROCKI shows more ubiquitous expression (Nakagawa et l., 1996).  The expression 
pattern of ROCKII is particularly interesting given that current research suggests that 
motor neuron death in ALS appears to be consistent with a “dying back” mechanism in 
which the neuromuscular junction (NMJ) begins to disassemble while the motor neuron 
cell bodies in the spinal cord remain relatively intact (Dadon-Nachum et al., 2011). Given 
that our data demonstrate a marked redistribution of Rh B to neuronal processes of end-
stage G93A mSOD1 mice, aberrant activation of ROCKII downstream of RhoB 
activation in both motor neuron processes and skeletal muscle may underlie the selective 
degeneration of NMJs during the progression of ALS. Indeed, Conti et al. (2014) recently 
demonstrated that ROCKII expression is increased in the skeletal muscle of sporadic 
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ALS patients. Thus, selective inhibition of ROCKII may prove to be a more direct and 
effective target for the treatment of ALS.  
Interestingly, recent data suggest that unopposed Rho/ROCK signaling may be a 
common factor underlying additional neurodegenerative diseases. In fact, inhibition of 
ROCK has been demonstrated to be an effective treatment option in other models of 
neurodegenerative disease, including Parkinson’s diease (Tönges et al., 2012), 
Alzheimer’s Disease (Song et al., 2013), and cerebral ischemia (Gibson et al., 2014). 
Thus, ROCK inhibitors show promise for the treatment of ALS patients as well as those 
diagnosed with other neurodegenerative diseases.  
6.6 Conclusion 
 In conclusion, this thesis has elucidated the involvement of Rho family GTPases 
in regulating neuronal survival. In particular, the work presented here has aided in 
deciphering the precise signaling pathways that are regulated by Rac GTPase in primary 
CGNs. Consistent with prior studies demonstrating a antagonistic relationship between 
Rac GTPase and Rho GTPase, we have also demonstrated th  inhibition of Rac GTPase 
or activation of Rho GTPase induces neurite retraction and death of ESC-derived motor 
neurons. In agreement with a pro-survival function, Rac1 GTPase activation is decreased 
in spinal motor neurons of mice harboring the G93A mSOD1 mutation. Conversely, 
RhoB GTPase appears to redistribute to motor neuronal processes in ALS mice. Thus, 
while the pathology of ALS remains complex and multifaceted, the data presented in this 
thesis highlight the potential involvement of dysregulated Rho GTPases as a causative 
factor underlying the etiology of ALS. These data suggest that targeting Rho GTPase 
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APPENDIX A: ABBREVIATIONS 
 
5K, 5K- apoptotic medium 
6-OHDA, 6-hydroxydopamine 
AD, actinomycin D 
AD, Alzheimer’s disease 
Ad; adenoviral 
Ad-CA, adenoviral constitutively active 
Ad-DN, adenoviral domiant negative 
Ad-GFP, adenoviral green fluorescent protein 
Ad-WT, adenoviral wild type 
ALS, amyotrophic lateral sclerosis 
ALS2, alsin 
Anti, morpholino-antisense oligonucleotides 
APAF-1, apoptotic protease-activating factor-1 
Arp2/3, actin related protein 2/3 
Bcl-2, B-cell lymphoma-2 
Bcl-3, B-cell lymphoma-3 
BDNF, brain-derived neurotrophic factor 
BH3, Bcl-2 homology-3 domain 
BKLF, basic krüppel-like factor 
BKLF8, basic kruppel-like factor 8 
BSA, bovine serum albumin 
CBP, CREB binding protein 
CCD, charge-coupled device 
CD11b, cluster of differentiation 11b 
CDK, cyclin-dependent kinase 
CGN, cerebellar granule neuron 
ChAT, choline acetyltransferase 
ChIP, chromatin immunoprecipitation  
CNTF, ciliary neurotrophic factor  
Con, control 
CREB, cAMP response-element binding protein 
CRIB, Cdc42/Rac-interactive binding  
Ct, cycle threshold 
CtBP, C-terminal binding protein 
CytC, cytochrome C 
Cyto, cytosolic 
DAPI, 4,6-diamidino-2-phenylindole 
dCtBP, drosophila CtBP 
DGCR8, DiGeorge critical region 8 
DH, Dbl homology 
Dia, Diaphanous formin 
DISC, death-inducing signaling complex 
DMEM, Dulbecco’s modified Eagle’s medium 
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DN, dominant negative 
DRG, dorsal root ganglion 
EB, embryoid bodies 
eGFP, enhanced GFP 
EP, endoporter 
ERK, extracellular signal-regulated kinase 
ESC, embryonic stem cell 
FADD, Fas-associated death domain 
FBS, fetal bovine serum 
GAP, GTPase activating protein 
GDI, guanine dissociation inhibitor 
GDNF, glial cell line-derived neurotrophic factor 
GDP, guanine diphosphate 
GEF, guanine nucleotide exchange factor 
GITz-short G protein-coupled receptor kinase-interacting protein-z-short 
GM-CSF, granulocyte-macrophage colony-stimulating factor 
GR, glucocorticoid receptor 
GTP, guanine triphosphate 
HD, Huntington’s disease 
HDAC, histone deactylases  
IB, immunoblot 
Inh Pep, inhibitory peptide 
Inv, inverse 
IP, immunoprecipitate 
JAK, Janus kinase 
JAK3 Inh, JAK3 Inhibitor 
JNK Inh, SP60012 
JNK, c- Jun N-terminal kinase  
JSI, JSI-124 
KO, knockout 
LPA, lysophosphatidic acid  
LTox, lethal toxin 
MAPK, mitogen activated protein kinase 
MEFs, murine embryonic fibroblasts 
MEK, mitogen activated protein kinase kinase 
MEKK , mitogen activated protein kinase kinase kinase 
mESCs, mouse embryonic stem cells 
miRNA, micro RNA 
MLC, myosin II regulatory chain  
MLCK, myosin light chain kinase 
MLCPPase, myosin light chain phosphatase 
MPP+, methyl-4-phenylpyridinium 
mSOD1, mutant superoxide dismutase 1 
MTOB, 4-methylthio-2-oxobutyric 
NADH, nicotinamide adenine dinucleotide 
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NGF, nerve growth factor 
NMJ, neuromuscular junction 
NS, not significant 
NSC, NCS23766 
NT-3, neurotrophic-3  
NWASP, neuronal Wiskott-Aldrich-syndrome protein 
O.D., optical density 
PaGE, paw grip endurance 
PAK, p21-activated kinase 
pAkt, phosphorylated Akt 
pan-JI, pan-JAK inhibitor 
PARP, poly-(ADP-ribose) polymerase 
pBAD, phosphorylated Bad 
PBS, phosphate-buffered saline 
PBS-T, PBS containing 0.1% Tween 20 
PCR, polymerase chain reaction 
pERK, phosphorylated ERK 
PH, Pleckstrin homology 
PI3K, phosphatidylinositol 3-kinase  
pMEK, phosphorylated MEK  
pP90rsk, phosphorylated p90rsk 
pPAK, phosphorylated PAK 
pri-miRNA, primary miRNA 
pSTAT, phosphorylated STAT 
PTEN, phosphatase and tension homolog  
Purv, purvalanol A 
PVDF, polyvinylidene difluoride 
rCasp3, recombinant caspase-3 
RGNEF, Rho guanine nucleotide exchange factor 
ROCK, Rho kinase 
ROS, reactive oxygen species 
Rosc, roscovitine 
RSS, RNA silencing suppressor 
Rux, ruxolitinib 
SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel el ctrophoresis 
SHH, sonic hedgehog 
SNP, sodium nitroprusside 
SOCS, suppressors of cytokine signaling 
SOD1, superoxide dismutase 1 
STAT, signal transducer and activator of transcription 
STS, staurosporine 
tBid, truncated Bid 
Tof, tofacitinib 
ToxB, C. difficile toxin B 
TUNEL, Tdt-mediated dUTP–biotin nick end labeling 
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VAChT, vesicular acetylcholine transporter 
WASP, Wiskott-Aldrich-syndrome protein 
WCL, whole cell lysate 
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